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Abstract 
 
The number of drugs with solubility limitations under development has been increasing. 
Limited aqueous solubility is a major challenge in the development of oral-dosage forms, as it 
may impact oral bioavailability. To circumvent this issue various solubilization strategies have 
been developed. Two of these strategies are the generation of amorphous solid dispersions and 
pharmaceutical cocrystals. Amorphous solid dispersions are today one of the most popular 
solubilization strategies to improve solubility. In contrast, pharmaceutical cocrystals are an 
emerging technology, but whose acceptance has been increasing in the last years. 
In this thesis, new computational screening methods to predict drug-polymer kinetic 
miscibility and in vivo performance were developed to support the early formulation design of 
amorphous solid dispersions.  
Regarding the computational tool to predict kinetic miscibility, this consisted on the 
implementation of a mathematical model that combined thermodynamic, kinetic and process 
considerations. The novelty of this model is related with its potential to evaluate a ternary 
system made of drug, polymer and solvent, as well as, the consideration of time dependent 
phenomena, such as components’ diffusion and solvent evaporation. For considering the 
evaporation of the solvent, the practical utility of this tool was demonstrated for the early 
development of amorphous dispersions produced by spray drying. The results obtained with the 
model not only enabled the ranking of the polymers according to their miscibility capacity with 
the drug, but also the narrowing of an optimal drug load range within which drug-polymer 
miscibility is guaranteed. In what accounts the computational tool to predict amorphous solid 
dispersions in vivo performance, this consisted on a statistical model having as input several 
molecular descriptors of the drug and the polymer, and as output in vivo pharmacokinetic data 
such as the area under the curve (AUC) and the maximum concentration (Cmax) achieved in the 
pharmacokinetic profile. The novelty of this model is related to the fact that the experimental 
in vivo data were obtained from the literature. The results produced generalized performance 
trends, as well as identified the molecular descriptors with higher influence for the in vivo 
performance. 
New and alternative manufacturing methods were also explored in this thesis, for the 
generation of amorphous solid dispersions and pharmaceutical cocrystals. New technologies 
that allow the control of the particle size at the nano-scale while maintaining the amorphous 
state, or technologies with reduced footprint that allow the particle engineering of cocrystals 
are scarce in the literature.   
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A novel solvent controlled precipitation process based on microfluidization was 
assessed to produce nano-sized amorphous solid dispersions. Moreover, an experimental design 
was conducted to study the effect of different formulation variables (viz. polymer type, drug 
load, and feed solid’s concentration) on the particle size and morphology, drug’s solid state and 
drug’s molecular distribution within the carrier of the co-precipitated materials produced. Nano-
composite aggregated particles were produced after isolation using spray drying. According to 
the results obtained it was possible to conclude that the particle size of the spray-dried 
aggregates was dependent on the feed solids’ concentration, while the level of aggregation 
between nanoparticles was dependent on the drug-polymer ratio. Depending on the type of 
polymeric stabilizer and the drug load in formulation, amorphous nano-solid dispersions or 
crystalline nano-solid dispersions could be produced. The small particle size at the nano-scale, 
i.e. the high surface area, was found to be a more important factor than the amorphization of 
the drug, to enhance the dissolution-rate and in vivo bioavailability of a model drug whose 
absorption is dissolution-rate limited.  
Spray congealing was the technology evaluated for the production of cocrystals. The 
work considered a feasibility study, followed by an experimental design to assess the impact of 
varying atomization and cooling-related process parameters on cocrystals formation, purity, 
particle size and shape, and bulk powder flow properties. It was demonstrated that spray 
congealing could be used to produce cocrystals particles. These were compact and spherical 
particles consisting of aggregates of individual cocrystals fused or adhered to each other. 
Varying the process parameters did not influence cocrystals formation, but had an impact on 
cocrystals purity. Moreover, it was demonstrated that cocrystals particle properties can be 
adjusted in a single process step, by varying the atomization and cooling efficiency, in order to 
produce particles more suited for incorporation in the final dosage forms.   
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Resumo 
 
O número de fármacos com solubilidade limitada em desenvolvimento tem vindo a 
aumentar. A baixa solubilidade é um dos grandes desafios no desenvolvimento de formas 
farmacêuticas orais, pois pode afetar a biodisponibilidade. De modo a ultrapassar este 
problema, várias estratégias de solubilização têm sido desenvolvidas. Duas destas estratégias 
são a produção de dispersões sólidas amorfas e cocristais farmacêuticos. As dispersões sólidas 
amorfas são hoje em dia uma das estratégias de solubilização mais divulgadas para melhorar a 
solubilidade. Por oposição, os cocristais farmacêuticos são uma tecnologia emergente, mas cuja 
aceitação tem vindo a crescer nos últimos anos.   
Nesta tese, novos métodos de rastreio de natureza computacional foram desenvolvidos 
para prever a miscibilidade cinética e o desempenho in vivo de uma dada combinação fármaco-
polímero, tendo como objetivo último apoiar o processo de formulação de novas dispersões 
sólidas amorfas.  
A ferramenta computacional para prever a miscibilidade cinética, consistiu na 
implementação de um modelo matemático que combina parâmetros termodinâmicos, cinéticos 
e de produção de dispersões sólidas. A novidade deste modelo relaciona-se com o seu potencial 
para avaliar sistemas ternários compostos por fármaco-polímero-solvente, bem como a 
consideração de fenómenos dependentes do tempo, tais como a difusão dos componentes da 
formulação e a evaporação do solvente. Por considerar a evaporação do solvente, a utilidade 
prática desta ferramenta foi demonstrada para o desenvolvimento de dispersões amorfas 
produzidas por secagem por aspersão. Os resultados obtidos com o modelo não só permitiram 
hierarquizar os polímeros de acordo com a sua miscibilidade com o fármaco, mas também 
reduzir a gama de concentrações de fármaco para uma gama ótima, dentro da qual a 
miscibilidade fármaco-polímero está garantida. No que toca à ferramenta computacional para 
prever o desempenho in vivo das dispersões sólidas amorfas, esta consistiu no desenvolvimento 
de um modelo estatístico, tendo como variáveis independentes descritores moleculares do 
fármaco e do polímero, e como variáveis dependentes dados farmacocinéticos como a área sob 
a curva e a concentração plasmática máxima atingida. A novidade deste modelo relaciona-se 
com o facto de considerar dados experimentais in vivo obtidos a partir da literatura. Os 
resultados obtidos permitiram identificar tendências generalizadas ao nível do desempenho que 
foram transversais a diferentes classes de fármacos e polímeros, bem como a identificação dos 
descritores moleculares com maior influência no desempenho in vivo de uma dispersão sólida 
amorfa.     
 vi 
Métodos de produção alternativos, robustos, economicamente eficientes e facilmente 
escaláveis do laboratório para a escala industrial, também foram explorados nesta tese, mais 
especificamente para a produção de dispersões sólidas amorfas e cocristais farmacêuticos. 
Tecnologias que permitam o controlo do tamanho de partícula à nano-escala bem como a 
manutenção do estado amorfo, ou tecnologias com baixo impacto no ambiente e que permitam 
a engenharia de partículas de cocristais, são escassas de acordo com o estado da arte.   
Assim, um novo processo de precipitação controlada por solvente tendo por base a 
microfluidização foi avaliado para produzir dispersões sólidas amorfas à escala nano. 
Adicionalmente, foi considerado um desenho experimental para estudar o efeito de variáveis 
independentes de formulação - tipo de polímero, concentração de fármaco, e concentração de 
sólidos na solução inicial – nas propriedades finais dos produtos co-precipitados, tais como o 
tamanho das partículas e sua morfologia, estado sólido do fármaco e distribuição deste último 
no polímero. O estudo de viabilidade foi demonstrado com sucesso, sendo que partículas 
agregadas e nano-compósitas foram obtidas após isolamento por secagem por aspersão. De 
acordo com os resultados obtidos foi possível concluir-se que o tamanho de partícula dos 
agregados obtidos após secagem foi dependente da concentração de sólidos na solução inicial, 
enquanto que o nível de agregação entre nanopartículas foi dependente do rácio fármaco-
polímero. Dependendo do tipo de polímero e da concentração de fármaco na formulação, para 
além de nano dispersões sólidas amorfas, foi também possível obter-se nano dispersões sólidas 
cristalinas. Observou-se que a redução do tamanho de partícula à nano-escala foi um fator mais 
importante do que a amorfização do fármaco para melhorar a velocidade de dissolução e a 
biodisponibilidade in vivo de um fármaco cuja absorção é limitada pela sua velocidade de 
dissolução.  
O congelamento por aspersão foi a tecnologia avaliada para a produção de cocristais. O 
trabalho incluiu um estudo de viabilidade, seguido de um desenho experimental de modo a 
avaliar o efeito de variáveis independentes de processo, relacionadas com a atomização e o 
arrefecimento, nas propriedades finais, tais como a formação e pureza do cocristal, tamanho de 
partícula e morfologia e propriedades do pó. Demonstrou-se que o congelamento por aspersão 
pode ser usado para produzir cocristais. Obtiveram-se partículas compactas e esféricas, 
consistindo em agregados de cocristais individuais. A variação dos valores dos parâmetros de 
processo não influenciaram a formação do cocristal, mas afetaram a sua pureza. Demonstrou-
se que as propriedades das partículas de cocristal podem ser ajustadas num único passo do 
processo, manipulando a atomização e o arrefecimento, de modo a otimizar as partículas e 
facilitar a sua incorporação em formas farmacêuticas orais.  
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Introduction 
 
3 
1 Introduction 
 
Among the various routes of drug administration, oral delivery is invariably the most 
preferred, due to the ease of use, convenience to patients and clinicians, and general lower 
manufacturing costs. According to the Food and Drug Administration (FDA), 53% of the new 
drug approvals in 2015 were solid oral dosage forms, such as tablets or capsules [1]. Moreover, 
oral drug delivery today represents the largest share of the pharmaceutical market (around 
60%), and this position is expected to be maintained in the future [2,3].    
One of the most important parameters used to measure oral drug formulation 
performance is bioavailability. Oral bioavailability can be defined as the percentage of active 
drug (or metabolite) that enters the systemic circulation and reaches the site of action [4]. 
Attaining adequate and consistent systemic exposure or bioavailability is important for 
improving drug’s therapeutic efficacy [5]. 
Upon ingestion and disintegration of the dosage form in the gastrointestinal (GI) tract, 
there are four main pharmacokinetic stages that characterize a drug’s journey through the body 
– absorption, distribution, metabolism, and excretion (ADME). In particular, absorption, or the 
fraction of drug absorbed in the GI tract, highly influences bioavailability. Ideally, a drug should 
present high solubility in the aqueous GI fluids, and high permeability across biological 
membranes, either via passive diffusion or active transport. According to the Biopharmaceutical 
Classification System (BCS) these are considered Class I compounds (Figure 1.1 A). BCS Class 
I compounds are the best candidates to work with for formulation scientists, as there are no 
physicochemical limitations to their absorption. However, today there are few BCS Class I 
compounds both in development and market (Figure 1.1 B).  
Indeed, current pharmaceutical pipelines are highly populated with new drug candidates 
belonging to BCS Class II or Class IV, thus presenting low solubility and high permeability, or 
low solubility and low permeability, respectively. It is estimated that around 70-90% of the new 
molecules in the pharmaceutical pipeline present at least solubility constraints. 
The reasons behind this growing trend of poorly water-soluble drugs are two-fold and 
include the current drug-receptor targets being addressed and the current drug discovery 
methodologies. Combinatorial chemistry, in silico modelling and high throughput screening 
techniques started to be routinely used in drug discovery. These methods tend to select drug 
candidates with certain physicochemical properties that are not compatible with high solubility 
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and high permeability. New chemical entities (NCEs) are becoming structurally more complex, 
with high molecular weight and more lipophilic.  
 
A 
B  
 
Figure 1.1. Biopharmaceutical Classification System (BCS, A) and approximate BCS distribution of 
the new chemical entities (NCEs) and marketed products (B) (adapted from [6]). 
 
Limited aqueous solubility has been one of the major hurdles in the development of 
oral-dosage forms, mainly because poor solubility hinders oral bioavailability. Thus, to 
circumvent this issue and to continue to provide new therapies for patients, in the last decades, 
scientists and engineers have explored different formulation strategies with the ability to further 
increase aqueous drug’s solubility and bioavailability. Considering the BCS (Figure 1.1 A), the 
ultimate goal is to move Class II, Class III and Class IV compounds towards Class I, considered 
as the best-case scenario in terms of water solubility and permeability properties. Some 
examples of well-established solubilization technologies are particle-size reduction (such as the 
production of nanocrystals), complexation with cyclodextrines, lipid-based techniques [such as 
self-emulsifying drug delivery systems (SEDDS)], and production of solid dispersions (either 
crystalline or amorphous). Table 1.1 shows some marketed pharmaceutical products obtained 
by these techniques. 
Among the emerging formulation strategies, pharmaceutical cocrystallization became 
known as an alternative crystal-engineering platform to improve the physicochemical 
properties of challenging crystalline APIs, and is today an emerging technology for improving 
the low solubility of modern compounds. 
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Table 1.1. Examples of medicines (oral-dosage forms) according to different solubilization techniques 
commonly used to circumvent poor water solubility limitations [7-10]. 
Product Drug (BCS Class) Company Year of approval 
 
Nanocrystals 
 
Rapamune® Sirolimus (II) Wyeth 2000 
Emend® Aprepitant (IV) Merck 2003 
TriCor® Fenofibrate (II) Abbott 2003 
Triglide® Fenofibrate (II) Shionogi 2005 
Megace® ES Megestrol acetate Par Pharm 2005 
 
Cyclodextrin complexes 
 
Ulgut® Benexate Shionogi 1987 
Pansporin T® Cefotiam hydrochloride Takeda 1990 
Brexin® Piroxicam (II) Chiesi 1993 
Meiact® Cefditoren (IV) Meiji Seika Pharma 2006 
 
SEDDS 
 
Sandimmune® Cyclosporin A (IV) Novartis 1990 
Neoral® Cyclosporin (II) Novartis 1995 
Norvir® Ritonavir (IV) Abbott 1996 
Gengraf® Cyclosporin A (IV) Abbott 2000 
Aptivus® Tipranavir (II) Boehringer Ingelheim 2005 
 
Solid Dispersions 
 
Gris-PEG® Griseofulvin (II) Pedinol 1975 
Sporanox® Itraconazole (II) Janssen 1992 
Kaletra™ Liponavir/Ritonavir (II/IV) Abbott 2005 
Cesamet® Nabilone (II) Valeant 2006 
Certican® Everolimus Novartis 2010 
 
1.1 Amorphous solid dispersions 
 
1.1.1 General considerations 
The production of the amorphous form of the drug is, in certain cases, enough to 
overcome its solubility issues. Since the amorphous state is a metastable state and because the 
amorphous materials lack of long-range order, the typical energetic barriers that need to be 
overcome during the dissolution of crystalline materials (i.e. crystal lattice disruption, solvent’s 
cavitation, hydration of drug molecules) are easily surpassed [11]. This is the reason why 
amorphous materials are more soluble than the crystalline counterparts. However, due to the 
inherent thermodynamic instability of the amorphous state, this approach is often hindered by 
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recrystallization of the drug over time. The use of polymeric matrices in order to improve 
amorphous drug physical stability is an apparently simple alternative that has been attracting 
formulators’ interest. Miscible drug-polymer blends are more resistant to drug crystallization 
than the amorphous drug alone because the chemical potential of the drug is reduced and the 
kinetic barrier or activation energy to crystallization increases, as can be seen in Figure 1.2 [12]. 
 
 
 
Figure 1.2. Representation of the activation energies (Ea) and kinetic barriers that an amorphous drug 
alone or dispersed in a carrier (i.e. amorphous solid dispersion) need to overcome for recrystallization 
to take place. The chemical potential (μ) of the amorphous drug in both situations with respect to the 
crystalline drug is also schematically represented (adapted from [12]). 
 
Indeed, amorphous solid dispersions (ASDs) are today one of the most important 
solubilization strategies to overcome the limited bioavailability of BSC Class II compounds. 
Their efficiency and popularity is not only reflected in the increasing percentage of ASDs 
demonstrating improved bioavailability when compared with the reference products [13], but 
also in the significant number of amorphous-based medicines reaching the market since its 
appearance in the early 90’s (Table 1.2). 
The distinctive advantage of ASDs is that, once the formulation components start to 
dissolve in the gastro-intestinal fluids, a supersaturated state is obtained and drug concentration 
in solution may reach values well above its intrinsic solubility. With a higher amount of drug 
in solution, more drug is available to be absorbed and this will ultimately improve 
bioavailability. Amorphous formulations presenting up to 100-fold enhancement in 
bioavailability comparing with the crystalline formulation have been reported in the literature 
[7,13]. 
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Table 1.2. Examples of marketed ASDs-based medicines [7,8,10,17,18]. 
Product Drug (BCS Class) Company Technology 
Year of 
approval 
Sporanox® Itraconazole (II) Janssen Spray Layeringa 1992 
Prograf® Tacrolimus (II) Astellas Spray Drying 1994 
Rezulin® b Troglitazone Pfizer - 1997 
Kaletra™ Lopinavir (II) / Ritonavir (IV) Abbott Hot Melt Extrusion 2005 
Cesamet® Nabilone (II) Valeant - 2006 
Fenoglide™ Fenofibrate (II) LifeCycle Pharm Hot Melt Extrusion 2007 
Intelence™ Etravirine (IV) Janssen Spray Drying 2008 
Norvir® Ritonavir (IV) Abbott Hot Melt Extrusion 2010 
Onmel™ Itraconazole (II) Merz Pharm Hot Melt Extrusion 2010 
Certican® Everolimus Novartis Spray Drying 2010 
Incivek® b Telaprevir (II) Vertex Spray Drying 2011 
Zelboraf™ Vemurafenib (IV) Roche Co-precipitation 2011 
Kalydeco™ Ivacaftor (II or IV) Vertex Spray Drying 2012 
Noxafil® Posaconazole (II) Merck Hot Melt Extrusion 2013 
Belsomra® Suvorexant Merck - 2014 
Viekira™ 
Ombitasvir/Paritaprevir/ 
Ritonavir/Dasabuvir 
Abbott Hot Melt Extrusion 2014 
Harvoni® Ledipasvir/Sofosbuvir Gilead - 2014 
Orkambi® Lumacaftor/Ivacaftor Vertex Spray Drying 2015 
     a i.e. spray drying on sugar beads; b marketed discontinued. 
 
Supersaturation can be explained by the so called “spring” and “parachute” effect [14]. 
The “spring” effect is the instantaneous peak when the concentration of drug is well above its 
saturation limit (Figure 1.3). However, the drug in solution will tend to precipitate over time, 
eventually losing the advantages acquired. The key aspect is to maintain the supersaturated state 
as long as possible, in order to extend the ”parachute” effect, as shown in the blue curve in 
Figure 1.3. 
To retard drug’s precipitation, the presence of stabilizing polymers is crucial. Polymers 
are capable of hindering drug nucleation and crystal growth in solution either by interacting 
with the drug via hydrogen bonding and other ionic interactions and/or through the formation 
of different drug-polymer assemblies, such as nano and micellar structures, where the drug is 
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safe against recrystallization [15]. The high viscosity of certain polymer grades may also 
contribute for retarding drug nucleation and crystal growth, by reducing drug’s molecular 
diffusion and molecular collision in solution [16]. 
 
 
 
Figure 1.3. The supersaturation state: the “spring” and “parachute” effect. 
 
The use of polymeric excipients is also important in the immobilization of the drug 
molecules in the solid state or during the shelf-life of the product, keeping the latter separate 
from each other, and thus preventing the formation of amorphous clusters, nucleation and 
growing of crystalline material. It has been suggested that the shelf life of the final drug product 
should be at least two years at 25ºC [19]. In order to take the maximum advantage of the 
stabilization effect of the polymer the drug should be irregularly, preferably molecularly, 
dispersed within the carrier forming a one-phase system. This not only promotes drug 
solubilization within the carrier and physical stability during preparation and storage, but also 
improves wettability and dispersability of the drug when exposed to aqueous media. It is 
noteworthy that in this situation the drug particle size is reduced to nearly its absolute minimum 
(i.e. molecular level), which also promotes rapid dissolution.  
That said, the requirements for the successful development of an ASD from any 
therapeutic small-molecule, especially those belonging to BCS Classes II/IV, are related with 
in vivo performance and chemical/physical stability aspects. In what regards the performance 
requirements, an amorphous dispersion formulation should present an improved dissolution 
profile compared with the crystalline reference and should be capable of sustaining drug 
supersaturation in solution for a longer time. Both parameters will contribute to an increased 
amount of drug available for absorption. In what accounts chemical/physical stability, 
maintaining the integrity of the amorphous drug during solid dispersion preparation, 
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manipulation and long-term storage must be guaranteed; otherwise, upon administration, the 
therapeutic effect may be compromised. 
 
1.1.2 Early formulation design 
 
The development of an ASD with the desirable physical stability and performance is a 
challenging process, due to the wide number of formulation and process variables that influence 
both physical and chemical properties of the product (e.g. several existing polymeric stabilizers, 
surfactants, different drug-polymer ratios, solvents, preparation methods, temperature, etc). For 
a long time, the selection of the best formulations was simply based on trial and error 
experiments, together with the own experience of researchers. Some known polymers were 
selected and combined with the drug, a wide range of drug-polymer ratios were studied, and a 
significant number of prototypes were produced using low-throughput laboratory-scale 
equipment [20-23].  In the end of formulation development a few grams of API were spent and 
only a few drug-polymer combinations were tested. Therefore, this empirical approach soon 
demonstrated to be too costly, time-consuming and API demanding.  
 At a time, in which the competition among the pharmaceutical industry demands for fast 
turnaround times, lower costs and to reduce the risks associated with the development of new 
drugs, it became critical the development of new screening methodologies and screening 
programs for narrowing the scope of formulations and to rapidly identify suitable systems for 
subsequent pre-clinical evaluation. Today, several screening methodologies are reported in the 
literature. Some methodologies have been developed to determine (or predict) drug-polymer 
physical stability (i.e. solubility, miscibility) [24], while others to determine drug-polymer 
performance in solution (i.e. supersaturation) [25]. The nature of the reported methodologies 
varies between medium to high-throughput small-scale experimentation in 96-well plates, 
and/or computational modeling, making use of theoretical models. The great advantage of these 
methodologies is the low amount of API needed (in the order of milligrams) and the possibility 
of running several tests at the same time. This not only allows to save time and resources 
(manpower), but also to study different drug-polymers combinations, at different drug loads, 
different solvents, temperatures and even the evaluation of adding a third component, such as 
surfactants. A more detailed analysis of these methodologies will be made in the following 
sections.  
 These methodologies may then be combined to produce full screening programs, in which 
the best drug-polymer formulations are selected based on a “funnel” approach. This means that 
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the less promising formulations are successively eliminated along the screening program, and 
only the best ones - those having acceptable properties in terms of physical stability and/or 
performance - will follow through the next stages of product development. A significant number 
of screening programs have also been disclosed in the literature. Some programs focus on the 
assessment of drug-polymer performance and supersaturation potential of the polymer, while 
others already attempted to establish broader approaches by combining methodologies that 
allow them to select the best amorphous formulations based not only on maximum performance 
but also highest physical stability. Table 1.3 summarizes some of the screening programs that 
have been reported. Most of them have been purely based on small-scale experimentation, 
where a wide range of variables can be evaluated at a time, and with minimal API requirements. 
More recently, some proposed screening programs include a computational screening stage 
prior to the bench screening [26,27]. It is often beneficial to obtain an early insight into drug-
polymer mixture properties by a computational approach. The advantage of computational tools 
is that there is no consumption of raw materials, and typically only the chemical structure of 
the components under study needs to be known. In cases where the amount API available is 
reduced the computational stage can be highly advantageous.   
  The screening methodologies that have been developed and used in the state of the art to 
predict both physical stability and performance of ASDs will be described. 
 
1.1.2.1 Predicting physical stability 
 
Two critical parameters that influence the physical stability of an ASD are the selection 
of the polymeric carrier and definition of the drug load. Regarding the polymer, this should 
present a high glass transition temperature (Tg), potential hydrogen bonding sites and an 
acceptable miscibility capacity with the drug [26]. Regarding the drug load, typically, scientists 
attempt to maximize the drug fraction in the formulation aiming the development of final oral-
dosage forms (i.e. tablets or capsules) with reduced size [11]. However, apart from drug 
potency, dose and solubility requirements, the optimal drug loading in the formulation should 
also take into account the maintenance of the physical state of the ASD.  
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Table 1.3. Examples of full screening programs reported in the literature. 
Reference Brief description  Throughput  Pros/Cons 
      
Dai et al.  
[28,29] 
Automated and miniaturized solvent-
casting (SC) in 96-well plates, followed by 
kinetic solubility evaluation.  
 >10 excipients were screen.  Drug load, 
polymers, dilution ratio and media were 
variables studied. The leading formulation 
was identified with < 10 mg of API, within 
1-2 days. 
 Pros: wide design space studied; API 
sparing; fast method / Cons: No physical 
evaluation of the casted films formed, 
before the solubility evaluation. In certain 
cases, SC may result in heterogeneities.  
      
 
Barillaro et al.  
[30] 
 
Automated SC in 10 mL vials format, 
followed by dissolution testing.  
 12 excipients (7 polymers and 5 
surfactants) and 3 drug loads were studied. 
108 formulations (triplicates) were 
evaluated in 1 day, with a minimum 
amount of materials.  
 Pros: wide design space studied; API 
sparing; fast method / Cons: No physical 
evaluation of the casted films formed, 
before the solubility evaluation. In certain 
cases, SC may result in heterogeneities. 
      
Shanbhag et al. 
[31] 
 
Automated and miniaturized SC in 96-well 
plates. Casted films are held at room 
temperature overnight prior to dissolution. 
Next, a melt-press method is applied as an 
additional “confirmatory step” to identify 
suitable formulations for HME. Films 
follow for dissolution testing.   
 For the SC step, 14 binary and 48 ternary 
formulations were studied (6 polymers and 
8 surfactants). 60 μg compound per 
sample. For the melt-press step, 13 ternary 
formulations were tested. 10 mg compound 
per sample. 
 Pros: an aging step was added to the 
program in order to give the most unstable 
formulations an opportunity to begin to 
recrystallize / Cons: Longer storage times 
or accelerated storage conditions should be 
used to promote aging. 
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Wyttenbach et al.  
[16]  
 
Two-step screening: (1) miniaturized SC in 
96-well plates, followed by dissolution; (2) 
A. miniaturized SC in 100 μL DSC pans, 
followed by spectroscopy (FTIR); B. melt-
quenched films on glass slides, followed 
by imaging (AFM) 
  
28 different binary combinations studied. 
API requirement ~500 mg, within ~2 
weeks. 
  
Pros: detailed analysis of molecular 
interactions, molecular homogeneity and 
stability / Cons: No physical evaluation of 
the casted films formed, before dissolution 
evaluation. In certain cases, SC may result 
in heterogeneities. 
 
      
Chiang et al.  
[32] 
Miniaturized SC in 96-well plates 
(duplicated plates). One plate follows for 
physical stability assessment (XPRD) and 
the other plate is used for solubility 
measurement. The plates are transferred 
for stability ovens for long-term storage 
evaluation under stress conditions.  
 Minimal compound requirement to 
evaluate optimal drug load in 3 different 
polymers. The first results are obtained 
within 1-2 days. The time for complete 
screening is dependent on the number of 
time-points for the long-term stability. 
 
 Pros: physical stability and kinetic 
solubility assessment are run in parallel; 
long-term physical stability is evaluated / 
Cons: using the 96-well plate format, a 
dissolution profile is not possible to be 
obtained due to volume constraints.   
      
Hu et al. [33]  
 
Miniaturized co-precipitation screening in 
1 mL glass vials in a 96 position insert. 
Suspensions are filtered on 96-well filter 
plates (duplicated plates), then the wet-
solids washed and dried. One plate follows 
for physical stability assessment (XPRD 
and Raman) and the other plate is used for 
kinetic solubility measurement.  
 In one 96-well plate, it can evaluate 96 
experimental conditions using only 200 mg 
of material. Within 1 week, it can select the 
best performing polymer, drug loading and 
solvent/anti-solvent ratio.  
 
 Pros: efficient screening tool to guide 
formulation development of amorphous 
formulations using co-precipitation; 
physical stability and kinetic solubility 
assessment are run in parallel / Cons: the 
residual solvent/anti-solvent content after 
drying may impact amorphous physical 
stability. 
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In this respect, the determination of the equilibrium crystalline drug solubility in the 
polymer and the drug-polymer amorphous miscibility is of great importance [34]. 
From a theoretical point of view, an ASD should be prepared, preferably, at a drug 
concentration below the equilibrium solid solubility of its crystalline form in the polymer in 
order to prevent supersaturation of the system and recrystallization. According to the 
hypothetical drug-polymer thermodynamic phase diagram represented in Figure 1.4, this 
equilibrium solubility of drug crystals in the polymer is represented by the solid-liquid curve. 
The area above this curve represents the temperature-composition region where the crystalline 
drug is dissolved in the polymer and both form an unsaturated solution, while the area below 
means that the drug is supersaturated in relation to the polymer [35]. 
Several screening methodologies have been proposed to predict the solid-liquid curve 
or the solubility of the crystalline drug in polymers at room temperature, which represents the 
typical storage temperature during the shelf-life of the product [36-41]. Some predictive 
methods are based on the determination of the solubility of the drug in a liquid monomer of the 
polymer [36,37] or polymer solution [41], on the determination of drug’s melting point 
depression in drug-polymer physical mixtures [36,38,39], or on the determination of the 
demixing kinetics of a supersaturated drug-polymer amorphous dispersion [40]. However, the 
equilibrium crystalline drug concentration in polymer is typically quite low - in the range of    
2-8% [42,43]- and thus incompatible with the production of tablets and/or capsules with an 
acceptable size to be ingested. This is the reason why, in most of the cases, formulators work 
above the equilibrium of drug solubility. 
Now, when quench-cooling a melt composed of a drug and a polymer to a temperature 
below the solid-liquid curve, amorphous (liquid-liquid) phase separation may take place when 
entering the two-phase metastable/unstable regions, as represented in Figure 1.4 [35]. The same 
situation applies with the rapid evaporation of the solvent(s) from a solution containing the drug 
and polymer e.g. during a spray drying process. So, it is important to obtain information on the 
drug-polymer miscibility limits in order to prevent the formation of drug- and polymer-rich 
amorphous phases in the solid dispersion once produced, otherwise any subsequent perturbation 
will further cause recrystallization of the drug. Another important variable, still related to the 
latter, is the kinetic miscibility limit. In real terms, most ASDs are kinetically “stabilized” in a 
non-equilibrium state, not only due to polymeric hindrance, but also due to the process and 
dynamic factors related to the typical energy-intensive methods of preparation (e.g. hot-melt 
extrusion or spray drying) [44]. This is the reason why the market is crowded with amorphous 
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formulations composed of drug loads typically above the thermodynamic solubility and 
miscibility limits. 
 
 
 
Figure 1.4. Hypothetical thermodynamic phase diagram for an API-polymer system. The black solid 
line represents the solid-liquid equilibrium curve or the maximum solubility of crystalline API in the 
polymer. The colored curves represent the API-polymer demixing or two-phase amorphous regions. The 
dashed line represents the glass transition temperature of hypothetically homogenous API-polymer 
mixtures. 
 
 Current literature describes different screening methods to predict drug-polymer 
miscibility. The screening strategies developed can vary between the simple implementation of 
theoretical models (e.g. solubility parameters, Flory-Huggins model) [45,46], the combination 
of the latter with some experimentation in order to obtain the input variables (e.g. melting point 
depression) [36,37], or the use of small-scale experimentation associated with the use of 
advance analytical techniques (e.g. DSC, Raman, AFM) [47,48].  
 Regarding the use of theoretical models to assess drug/polymer miscibility, the analysis 
of the Hildebrand and Hansen Solubility Parameters (HHSP) is one of the oldest methods 
considered [45,46]. Drug-polymer miscibility can be assessed qualitatively through the 
difference in the solubility parameters of two materials. Materials with similar values are likely 
to be miscible. Typically, differences ≤ 7.0 (MPa)1/2 is an indication of miscibility [45]. As the 
difference in the solubility parameters between the drug and the polymer increases, the tendency 
for immiscibility also increases. This method, however, possess some limitations and recent 
studies suggested poor correlation between the HHSP and experimental miscibility [36,46]. 
Nevertheless, this method is still used for an initial and rapid estimation of drug-polymer 
miscibility. The implementation of the Flory-Huggins lattice model has also shown utility on 
Introduction 
 
15 
the quantitative assessment of the thermodynamics of drug-polymer mixing and miscibility. 
The Flory-Huggins theory was initially developed to describe the phase behavior of polymer 
solutions but today is being widely used to study drug-polymer systems [36]. With the use of 
Flory-Huggins interaction parameter (χ), the temperature-composition phase diagram, as 
represented in Figure 1.4, can be obtained. Several authors have reported the construction of 
the phase diagrams as a guide for polymer ranking, selection of initial drug-polymer ratios, 
evaluation of manufacturing-ability and definition of storage temperatures [35,49-53]. The 
Flory-Huggins interaction parameter, at room temperature, is typically estimated using the 
Hildebrand solubility parameters, or at higher temperatures, using the experimental melting 
point depression method [36,37]. Both methods for estimating the interaction parameter also 
present limitations, which can impact the predicted drug-polymer miscibility [54]. The Flory-
Huggins theory itself also fails for not considering specific drug-polymer molecular 
interactions, such as hydrogen bonding or ionic interactions [37]. Recently, more advanced 
thermodynamic models, such as the Perturbed-Chain Statistical Associating Fluid Theory (PC-
SAFT), have been reported in order to give a step forward when it comes to predicting drug-
polymer miscibility [55]. 
 For the determination of the real or kinetic miscibility during screening, the traditional 
analytical techniques that are routinely used to characterize ASDs have been used. The main 
difference is that, during screening, these are applied in solvent-casted [47,56] or quench-cooled 
films [48], in order to spend less of API and obtain preliminary information on miscibility and 
stabilization in less time. The gold standard tests for evaluating amorphous miscibility are 
differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). DSC is 
typically used for detecting amorphous formation and amorphous phase separation based on 
the detection one or two glass transition temperatures (Tg). It is generally accepted, that the 
presence of two Tg’s is indicative of phase separation, whereas a single Tg is often taken as an 
evidence of the formation of a one-phase homogenous blend. The limitation of this technique 
is its inability to discriminate phase-separation at the nano-scale (amorphous domains < 30 nm), 
and for being a thermal method it can alter miscibility during heating [57]. The XRPD 
complements the DSC analysis and it is used for detecting crystalline material in amorphous 
samples, based on the detection of the sharp crystalline peaks. The XRPD of a general 
amorphous material shows a broad halo characteristic of materials lacking of long-range order, 
but still presenting some short-range order. This technique is however unable to detect phase 
separation, and due to this, it is now being used in combination with computational methods 
such as the pair-distribution function (PDF) in order to better assess the miscibility of drug-
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polymer mixtures [58]. Another limitation of the XRPD techniques is its low level of detection 
for trace crystallinity. The limitations of these techniques are even more pronounced when 
dealing with small samples, as commonly obtained during miniaturized screening (in the order 
of a few milligrams of material). Alternative analytical techniques that have been used to 
discriminate between the formation of one-phase or two-phase drug-polymers systems are 
Raman and Atomic Force Microscopy (AFM). Both provide information on the spatial 
molecular structure of drug-polymers mixtures, phase homogeneity, and surface properties on 
the micrometer to nanometer scales [48]. The use of solid-state NMR (ssNMR) has also been 
recently explored to evaluate miscibility at the nano-scale [59,60]. This analysis is based on the 
measurement of the relaxation times in the solid state reflecting the mobility in the sample. For 
example, if a single relaxation time is obtained for the sample it means that drug-polymer are 
completely miscible [59]. 
 
1.1.2.2 Predicting performance  
 
The ultimate goal when developing an ASD is to provide a clinical benefit to the patient, 
by increasing drug’s bioavailability. The in vivo performance of an ASD will greatly depend 
on the stability of the drug’s supersaturated state and on the kinetics of precipitation in solution. 
As long as supersaturation is maintained at high levels, more time is given for the drug to be 
absorbed, and this will ultimately improve bioavailability. 
One of the critical parameters that highly influences the supersaturated state is the 
selection of the polymeric excipient. By selecting the right polymer the formulator can modulate 
the creation and maintenance of the supersaturated state. Thus, during the screening stage, it is 
of interest to evaluate different polymers in terms of their supersaturation potential and 
precipitation inhibition capacity.  
Commonly used strategies to early assess the performance of ASDs consist in the 
implementation of medium to high-throughput bench screening experiments, using smaller 
volumes apparatus, typically in the 96-well plate format, and wherein the API requirements are 
reduced to the minimum. There are experimental methods based on the induction of 
supersaturation in solution, such as the solvent-shift [61-64] and pH-shift assays [65,66], or 
methods based on the dissolution of amorphous casted films [30,31,16], where supersaturation 
is not induced, but should be an inherent characteristic of the system (Figure 1.5). In the end, 
the degree of supersaturation is measured or evaluated as a kinetic solubility time profile that 
works as a surrogate of in vivo performance. 
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Figure 1.5. Representation of the experimental screening methodologies applied to evaluate 
supersaturation: the solvent- or pH-shift method, and the amorphous film dissolution method. The 
hypothetical kinetic solubility time profiles obtained for different drug-polymer combinations are also 
represented. 
 
Briefly, in the solvent-shift method, the drug is first dissolved in a highly polar water-
miscible organic solvent, such as dimethylacetamide (DMA) [61] or dimethylformamide 
(DMF) [64], to form a concentrated stock solution. A small aliquot of this latter solution is then 
transferred and dispersed in the aqueous-based medium to induce supersaturation. The medium 
can vary between a simple buffer [64] or biorelevant fluid [63] to improve predictability, and 
already contains the polymer dissolved at a pre-defined concentration. The pH-shift assay 
follows the same methodology, but instead of inducing supersaturation via a shift in solvent, is 
via a shift in pH, by reducing drug’s ionization in the receptor medium. This method is typically 
used for ionizable drugs. Typical analytical methods used to measure drug concentration over 
time include turbidimetry [62], UV spectroscopy [61] or liquid chromatography [63]. Reported 
limitations of this method are related with the use of the organic solvent, which may act as a 
co-solvent and may interfere with the kinetics of precipitation, and the fact that supersaturation 
creation and maintenance is highly dependent on the drug and polymer initial concentrations.  
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Alternatively, in the cast film dissolution method, different drug-polymer films, at 
different drug loads, are prepared by solvent casting in 96-well plates. A small-volume of the 
dissolution medium is then transferred to each well, and drug concentration is measured over 
time. Typical analytical methods used include UV spectroscopy [31] or liquid chromatography 
[30]. The limitations of this method are related with the heterogeneity that can be formed during 
solvent casting, thus a prior assessment of the physical stability of the films should be made. 
In terms of the use of computational tools for the prediction of the in vivo performance 
of ASDs, the existing physiologically-based pharmacokinetic (PBPK) models, such as 
GastroPlus™ or Simcyp®, have been successfully used [25]. However, these models need to be 
combined with accurate in vitro/in vivo dissolution experiments as input data, only typically 
obtained at advanced stages of formulation development. Thus, from an early screening 
perspective, there are few works reported in the literature demonstrating a theoretical rationale 
for the selection of the best polymers with precipitation inhibition effect. One of these works, 
if not the only one reported in the literature so far, was the work developed by of Warren et al. 
[62]. Warren and co-workers first used a solvent-shift method combined with turbidity 
measurements to monitor the precipitation kinetics of 9 model drugs in presence of various 
polymers, from 42 different polymeric classes. Then, using multivariate data analysis tools such 
as principal components analysis (PCA) applied to the results generated together with a series 
of physicochemical descriptors of the polymers, the authors identified interesting performance 
trends, such as that cellulose-based polymers provide robust precipitation inhibition across 
different drug classes [62]. However, the authors did not attempt to establish any correlations 
with in vivo data. 
 
1.1.3 Overview of the technologies used to prepare ASDs 
 
Among the existing production methods to obtain ASDs, spray drying (SD) and hot melt 
extrusion (HME) are the most widely used. Both are mature and well-established techniques in 
the pharmaceutical industry. They are also compatible with continuous manufacturing 
processes, which is an important aspect, given the recent efforts of regulators in promoting this 
initiative aimed at increasing productivity and reducing costs [67]. 
 At the moment of selecting the best manufacturing technique several aspects should be 
taken into consideration. For example, SD allows particle engineering during processing, 
enabling the control of product attributes such as particle size and density, and supports a broad 
variety of applications [68]. By opposition, when selecting HME, the downstream processing 
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of amorphous extrudates typically requires an additional milling or pelletization step, which 
can affect drug product physical stability [69]. In terms of processing time and costs, these are 
typically higher in SD due to the larger processing equipment footprint and the need for a 
secondary drying step to remove residual solvents. In this regard HME is economically more 
advantageous and environmentally friendly because it is a solvent-free production method. 
Simple physicochemical properties of the drug under development, such as the solubility in 
organic solvents and melting temperature, may also determine the selection of a given technique 
to the detriment of the other, as shown in Figure 1.6. 
For instance, due to the operating principles of HME, this technique is not suitable for 
processing drugs that present high melting points (≥200ºC) due to thermal instability, or drugs 
that are shear sensitive. Even in the cases where the drug is dissolved by the polymer at lower 
temperatures, the drug may not be resistant to heat and/or may not dissolve completely in the 
excipient. For such compounds, SD is certainly a better option for operating at moderate 
temperatures and relatively short residence times. However, one of the prerequisites for the 
production of spray dried ASDs is that the drug should be sufficiently stable and soluble in 
volatile organic solvents; otherwise the final chemical and physical stability of the drug product 
may be compromised [71]. 
 
 
 
Figure 1.6. Selection of the manufacturing technology based on the drug’s melting point and drug’s 
solubility in organic solvent (adapted from [70]). 
 
A particular type of poorly water-soluble compounds whose incidence in 
pharmaceutical development has been increasing, are those that neither have adequate solubility 
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in volatile organic solvents nor a melting temperature below 200ºC. These difficult-to-
formulate compounds are often designated as “brick dust”, and their conversion to the 
amorphous form may be too risky or even impossible when using the traditional techniques. 
Motivated by the need of solving this problem, the solvent controlled precipitation (SCP) 
process has recently come into play associated with the development of an ASD of 
vemurafenib, that ended up being converted into a successful commercial product for the 
treatment of late-stage melanoma (Zelboraf®, Roche) [42]. SCP is a scalable technology, readily 
adaptable from batch to continuous processing. In general terms it consists in the mixing of an 
organic homogenous solution containing the drug and the stabilizer (i.e. polymer or surfactant) 
with an anti-solvent. Due to the insolubility of the pharmaceutical components in the anti-
solvent, when both streams interact, supersaturation is generated inducing rapid precipitation 
of amorphous particles [72]. One of the advantages of this technology when compared with SD 
is that polar solvents with high boiling points, such as DMA or DMF, can be used to dissolve 
such “brick dust” molecules as far as their chemical stability is not compromised. Another 
advantage relates to the fact that it is not necessary to dissolve both pharmaceutical components 
in the same solvent or solvent system, as the stabilizer can be dissolved in the anti-solvent. 
These can significantly improve the process throughput and the drug load in the formulation. 
When compared with HME, SCP is a low temperature process suitable for thermolabile 
compounds, not only because the anti-solvent is cooled to reduce solubility and improve 
precipitation, but also the final suspension passes through a heat exchanger for heat removal 
[71].  
In large-scale production, SCP has been conducted in high volume stirred reactors 
preferably using high shear mixing to promote effective contact between the organic solution 
and the anti-solvent. The final properties of the co-precipitated particles are highly dependent 
on the operational conditions (i.e. shear rate, temperature, mixing time) and formulation 
variables (i.e. properties of the drug, the polymer, drug-polymer interactions, solvent-anti-
solvent ratio and interactions). For example, the amorphous microparticles of vemurafenib 
produced by SCP using high shear mixing are highly porous, due to the “extraction” or 
“substitution” process of the organic solution by the antisolvent that occurs during particle 
precipitation [73]. Consequently, these microparticles present the advantage of having a very 
high specific surface area with improved wetting properties and enhanced dissolution rate when 
compared with spray-dried particles or melt extrudates. 
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1.2 Pharmaceutical cocrystals 
 
1.2.1 General considerations 
 
Pharmaceutical cocrystals are an emerging crystal-engineering strategy, used with 
success by chemists and formulators to enhance the poor physicochemical properties of modern 
APIs. The rapid acceptance of this strategy was noticed since the early 2000s, as evidenced by 
the increasing number of annual citations in CAS SciFinder containing the search term 
“pharmaceutical cocrystals”. These results demonstrate the general interest of bringing 
cocrystals to the same level of typically used formulation platforms, such as ASDs.  
Cocrystals are multicomponent crystals of, at least, two molecules combined in a 
stoichiometric ratio in which one is the active API and the other the coformer. The coformer 
can be another API or a pharmaceutical excipient, vitamin, amino acid, but is generally limited 
to compounds in the Generally Regarded as Safe (GRAS) list [74]. API and coformer form a 
stable molecular complex typically interacting via hydrogen bonding, Van der Waals forces or 
π-stacking [75]. Cocrystals have shown efficacy on improving the aqueous solubility, and thus 
bioavailability, hygroscopicity, stability, taste, and downstream processing capacity [76-79]. 
They also represent a business opportunity for intellectual property and lifecycle management 
[80]. 
Up to date, there is no final drug product in the market that has been intentionally 
developed as a cocrystal. The one that is indicated in Figure 1.7 is an antidepressant product 
from Lundbeck (Cipralex®, 2002) that was developed and filled as a salt, but it is now known 
that it is actually a cocrystal from a salt of an API [81]. Nevertheless, there are already a few 
cocrystal formulations in advanced stages of drug product development, such as Esteve’s 
cocrystal of tramadol and celecoxib (Phase II) [82]. 
The entrance of cocrystal products into the market has also been somehow hindered by 
an uncertain regulatory framework and lack of consensus regarding nomenclature. It was only 
in April 2013, that the FDA released a guidance for industry on the regulatory classification of 
pharmaceutical cocrystals for new drug applications (NDAs) and abbreviated drug applications 
(ANDAs) [83]. According to the FDA’s guidance, pharmaceutical cocrystals are classified as 
a drug product intermediate, similarly to ASDs. By opposition, for the European Medicines 
Agency (EMA) cocrystals should be classified as drug substances, even though any definitive 
regulatory framework has not been issued yet [84]. 
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Figure 1.7. Number of product programs with respect to small molecule, pharmaceutical cocrystals 
(adapted from Pharmacircle.com) 
 
The lack of harmonization between regulatory agencies increases the perceived risk 
associated with developing new cocrystal-based products. Nevertheless, the FDA first step on 
the release of a guidance for industry on pharmaceutical cocrystals has already contributed to a 
better definition of the current regulatory framework, bringing hope to those who (1) need to 
improve poor physicochemical properties of potential therapeutic APIs when alternatives 
formulation platforms have failed, (2) whose market position is the development of generic 
products or (3) pharmaceutical companies seeking for life cycle management opportunities. For 
example, a new cocrystal comprising an API of a brand product can lead to the possibility of 
filling an ANDA, rather than the NDA, which is mandatory for new cocrystals of new APIs. 
This is an advantage for generic companies because it will expedite market entrance and gain 
advantage over competitors. In life cycle management, patenting and intellectual property 
protection are major concerns for extending market position as much as possible. 
Circumventing the original patent with a cocrystal that has the same API as the brand product 
is challenging, but patenting a cocrystal with improved properties is an opportunity and 
typically easier to make it possible. Additional benefits of the current FDA guidance are the 
potential regulatory acceptance of cocrystallization between excipients, in opposition to the 
conventional API-based cocrystals, thus leading to the development of novel functional 
excipients. 
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1.2.2 Overview of the technologies used to prepare cocrystals  
 
Pharmaceutical cocrystals have been prepared by different manufacturing methods, 
briefly summarized in Figure 1.8. Classical approaches for the production of cocrystals include 
solution-based methods (e.g. reaction, recrystallization via slow evaporation, cooling or anti-
solvent addition) and mechano-chemical methods (e.g. neat and liquid-assisted grinding). These 
are by far the most commonly used techniques. By opposition, cocrystallization from slurry 
conversion, sublimation, or crystallization from the undercooled melt are less used [85]. 
Although the majority of these methods have shown to be useful in the production and 
screening of cocrystals at a small-scale (milligrams to grams), the scale-up is in most cases 
difficult or even impossible, due to the inherent limitations of the techniques. For example, in 
solution crystallization approaches the API and the coformer may undergo undesired 
interactions with organic solvents that may be incorporated into the crystal lattice with the 
possibility of solvate/hydrate formation [86]. With the grinding methods the intensive energy 
input may generate some degree of amorphization and/or cocrystal defects, limiting the 
formation of the cocrystal [87].  
 
 
 
 
Figure 1.8. Most common manufacturing methods to produce cocrystals (adapted from [44]). 
 
Currently, with the intensive research and fast development observed in this area, the 
assessment of manufacturing techniques that allow the direct scale-up of cocrystals, in a 
reproducible and cost-effective way has been encouraged. In fact, progress in this field has 
already been made. For example, the use of High Pressure Homogenization (HPH) or Hot Melt 
Extrusion (HME) allows the scale-up of cocrystals in a continuous mode [88,89]. The 
advantage of using HPH when compared with HME is that it enables the particle engineering 
of cocrystals in the particulate form, which facilitates their incorporation in the final dosage 
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forms (e.g. capsules or tablets). Using HME, downstream processing of cocrystal extrudates 
usually requires additional steps such as milling, granulation or pelletization. Currently, the 
development of scalable processes that allow for particle engineering during processing are of 
utmost importance to minimize downstream operations. Particle engineering is not usually 
associated to greener processes, however, the delivery of material with the target properties 
such as particle size without additional downstream processes allows for a significant reduction 
in development costs and waste treatment. The major disadvantage of HPH is the fact that is a 
solvent-based process and an additional drying step is required to isolate the powder from the 
suspension obtained. In this regard HME is more advantageous and environmentally friendly 
because it is a solvent-free production method, which may provide real cost benefits.  
Other methods that have been assessed for the production of cocrystals are Spray Drying 
(SD) and Supercritical Fluid CO2-based methods (SCF) [90-92]. Both methods offer the 
possibility of controlling cocrystal particle’s properties (e.g. particle size, shape or density). 
Although SD is a common technology in industrial pharmaceutical facilities, it should not be 
neglected the fact that SD has associated the limitations of a common solvent-based method 
(i.e. process time, costs, environmental impact). In this respect SCF is considered a more 
environmental friendly process due to the use of “green” solvents, however is still limited due 
to the often poor solubility of pharmaceutical compounds in supercritical CO2, and/or the 
existing challenges of processing feeds with gases at high pressures. In the case of SCF methods 
where supercritical CO2 is used as the anti-solvent, further limitations include the need of using 
organic solvent(s) to dissolve the pharmaceutical compounds, and said solvent(s) should be 
miscible with supercritical CO2, thus limiting the solvents’ selection. 
 
 
1.3 Motivations and objectives of the project 
 
The development of new ASDs to address the current solubility/bioavailability 
challenges is increasing at a fast pace. Considering the high number of variables that influence 
the production of an amorphous dispersion with optimized stability and performance, the 
implementation of screening methodologies from the early beginning of formulation 
development is of critical importance. These strategies help to “build quality into the product”, 
thereby reducing empiricism, development time, risk and costs. Few screening programs have 
been reported combining computational modeling and experimental miniaturization for 
evaluating drug-polymer physical stability and in vivo performance. The use of computational 
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tools contributes for the reduction in API consumption and can serve as a first level screen in 
terms of polymer selection and drug load definition.  
Regarding the prediction of drug-polymer miscibility, currently applied computational 
methods include the analysis of the HHSPs and the use of the Flory-Huggins thermodynamic 
model. One of the limitations of these models is their inability to predict miscibility for drug-
polymer mixtures forming highly directional interactions, such as hydrogen bonding and ionic 
interactions. Moreover, these models do not take into account the influence of the preparation 
methods nor the process parameters (e.g. evaporation rate, mixing effect) on drug-polymer 
kinetic miscibility. This may impact drug load optimization during screening, as one may not 
be taking full advantage of the amount of drug that the polymer can really “dissolve” or 
“incorporate”. Thus, for a more accurate estimation of kinetic miscibility during screening, new 
theoretical models capable of describing both kinetic (typically process related factors) and 
thermodynamic considerations on the phase separation of a drug-polymer system should be 
developed.  
Regarding the prediction of in vivo performance of ASDs, current screening 
methodologies are essentially based on experimentation at a small-scale level. The development 
of computational tools that accurately predict oral absorption is a challenging task, due to the 
complexity of in vivo drug behavior. Existing PBPK mathematical models to predict in vivo 
absorption have been successfully used, however these models require accurate in vitro and/or 
in vivo input data typically obtained at advanced stages of formulation development. Thus, the 
state of the art would benefit from the development of computational screening methodologies 
for guiding the selection of polymers with appropriate supersaturation potential and 
precipitation inhibition capacity. Moreover, it would also be interesting to assess any 
relationships between the properties of the API, the polymer and the final amorphous dispersion 
in vivo performance. 
After the screening stage, the most promising amorphous formulations in terms of 
physical stability and performance are identified. Typically only a small group of formulations 
follow for the production at the laboratory-scale, in order to obtain a few grams of the product 
for further evaluation and characterization. At this stage, an adequate selection of the 
preparation method is also important for the success of the program. Traditional methods for 
producing ASDs vary between SD and HME. However, with the recent approval of the first co-
precipitated amorphous product in the market, a lot of attention has turned to the SCP process. 
SCP enables the production of ASDs with unique properties, especially in terms of surface area, 
a property with a big impact on the dissolution rate. In the context of large-scale production, 
Chapter 1 
 
26 
SCP has been limited to stirred reactors together with high shear mixing. The number of 
reproducible and cost-effective co-precipitation processes to produce ASDs is still scarce in the 
state of the art.  
Regarding the use of pharmaceutical cocrystals, their understanding is increasing at a 
fast pace. On one hand, the knowledge and interest on pharmaceutical cocrystals is increasing 
thanks to solid-state chemists and pharmaceutical scientists who have been actively working in 
this field, but on the other hand, there are still some important legal and scientific issues that 
are hampering the extensive use of cocrystals by the pharmaceutical industry. The legal issues 
are related with the current regulatory scheme and uncertainties when dealing with a relatively 
new technology and crystal form. Among the scientific issues is the scarcity of suitable large-
scale production methods and lack of robust and cost-effective processes. 
 
Given the present research problems in state of the art, the following general goals were 
defined for this thesis:  
 
 To evaluate the applicability of a new computational tool that relies on fundamental 
thermodynamic and kinetic equations and manufacturing considerations to describe 
the influence of formulation and process conditions on drug-polymer miscibility; 
 
 To develop a statistically-based model for predicting the in vivo performance of 
ASDs based on reported information and past history and to find correlations 
between the molecular descriptors of the APIs, the polymer and the in vivo 
pharmacokinetic parameters;   
 
 To investigate a novel solvent-controlled precipitation process that uses 
microfluidization to produce amorphous dispersions, as well as, to study the effect of 
common formulation variables on typical critical quality attributes of ASDs, namely 
particle size/morphology, physical stability, in vitro and in vivo performance;  
 
 To evaluate the use of the spray congealing technology to produce pharmaceutical 
cocrystals, as well as, to study the effect of critical process variables on cocrystal 
formation, purity, particle size, shape and powder flow properties. 
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1.4 Hypothesis and thesis layout 
 
Hypothesis: The physical stability and in vivo performance of amorphous solid 
dispersions can be described by mechanistic and statistical screening methodologies. 
Amorphous solid dispersions and pharmaceutical cocrystals presenting unique characteristics 
can be manufactured by novel production methods.     
 
In order to meet the objectives proposed, this thesis is organized in six chapters. The 
contents and goals of each chapter can be briefly summarized, as follows: 
 
Chapter 1: Consists on a general literature review on amorphous solid dispersions and 
pharmaceutical cocrystals, with emphasis on the existent screening methods to accelerate the 
formulation development of amorphous dispersions and current preparation methods to produce 
both amorphous dispersions and cocrystals.    
  
Chapter 2: Describes the implementation and validation of a mechanistically-based 
computational screening method to predict amorphous physical stability, intended to be used in 
the early development of spray-dried amorphous solid dispersions.  
 
Research question: Can a model that combines thermodynamic, kinetic and 
manufacturing considerations be used to obtain estimates of the miscibility and phase behavior 
of spray-dried ASDs?   
 
Chapter 3: Describes the development of a statistically-based computational screening 
method to predict amorphous in vivo performance, intended to be used in the early development 
of amorphous solid dispersions. 
 
Research question: Can the in vivo performance of ASDs based on molecular 
descriptors and statistical analysis be predicted?  
 
Chapter 4: Describes and assesses an alternative solvent controlled-precipitation 
process to obtain amorphous solid dispersions, together with the analysis of the influence of 
formulation variables on critical quality attributes of co-precipitated ASDs. The in vitro and in 
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vivo performances of the co-precipitated materials produced were compared with an amorphous 
dispersion manufactured by spray drying.   
 
Research question: How formulation variables influence typical critical quality 
attributes of co-precipitated ASDs? In terms of in vivo performance, how is a co-precipitated 
amorphous product compared with a spray dried amorphous dispersion? 
 
Chapter 5: Describes the assessment of the spray-congealing process to obtain 
pharmaceutical cocrystals, together with the analysis of the influence of process variables on 
quality attributes of cocrystals.  
 
Research question: Is it possible to obtain cocrystals using spray congealing? How 
process variables influence the quality attributes of cocrystals? Is it possible to fine tune 
process variables in order to manipulate particle properties? 
 
Chapter 6: Presents the conclusions and complementary perspectives on the subject. 
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2 Screening methodologies for the development of spray-dried amorphous 
solid dispersions 
 
2.1 Introduction 
The study presented proposes a new screening methodology intended to be used in the 
early development of ASDs. This part of the work consists on the implementation of a 
computational tool, based on diffuse interface theories, to guide rationale polymer selection and 
narrow the drug load range with potential to form homogenous amorphous systems. The most 
significant difference over other approaches (e.g. the use of the F-H theory alone) is the 
potential to evaluate a ternary system made of a drug, polymer and solvent, by comparison with 
the traditional two-component system and the consideration of time-dependent phenomena, 
such as components mass diffusion and solvent evaporation. For assessing the effect of 
Thermodynamics, Kinetics and Evaporation (i.e. process variables) on the phase behavior of 
drug-polymer amorphous systems, this model (hereafter named TKE) was regarded as a pre-
formulation tool in the development of amorphous dispersions using spray drying. To assess 
the applicability of this tool and have experimental evidence of the kinetic miscibility estimates, 
solid dispersions of a BCS Class II model drug - itraconazole (ITZ) - and structurally different 
polymers, known for having different compatibilities with ITZ, were produced using different 
solvent-based methods of solvent casting and spray drying.  
 
2.2 Materials and Methods 
 
2.2.1 Materials  
Crystalline ITZ was obtained from Chongqing Huapont Pharm.Co., Ltd (Chongqing, 
China). Three commercially available polymers with different chemical and physical properties 
were selected: polyvinylpyrrolidone-vinyl acetate copolymer (PVP/VA 64, BASF, 
Ludwigshafen, Germany), dimethylaminoethyl methacrylate, butyl methacrylate, and methyl 
methacrylate co-polymer (Eudragit® EPO, Evonik Röhm GmbH, Darmstadt, Germany), and 
hydroxypropylmethylcellulose acetate succinate (HPMCAS grade MG, AQOAT®, Shin-Etsu 
Chemical Co., Ltd., Tokyo, Japan). The solvents used were methylene dichloride (DCM) and 
methanol (MeOH), both of analytical grade. 
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2.2.2 Methods 
 
2.2.2.1 Theoretical considerations  
This section summarizes the underlying theory and mathematical formalism of the 
model presented in this work. For more details on the derivation of the model, readers are 
referred to the work of Saylor et al. [1,2]. 
TKE model is a system of partial differential equations (PDEs) based on diffuse 
interface theories (i.e., Cahn-Hilliard and Allen-Cahn) to describe drug-polymer microstructure 
evolution. The physical basis of the model relies on fundamental thermodynamic, kinetic, 
evaporation equations to describe the influence of process conditions during microstructure 
formation. 
Accounting for the thermodynamic contribution to microstructure evolution, the latter 
is related with the free energy density (i.e., free energy per volume). The free energy (ΔG) is 
then modeled based on the F-H theory equation for a ternary system and is given by: 
 
 
 
∆𝐺
𝑛𝑅𝑇
=𝜙𝑑  𝑙𝑛 𝜙𝑑+𝜙𝑠 𝑙𝑛 𝜙𝑠+
 𝜙𝑝
 𝑚𝑝
 𝑙𝑛 𝜙𝑝+𝜒𝑑𝑠  𝜙𝑑  𝜙𝑠+𝜒𝑠𝑝  𝜙𝑠 𝜙𝑝+𝜒𝑑𝑝  𝜙𝑑  𝜙𝑝 
 
Equation 2.1 
 
 
where, n is total number of mole, R is the ideal gas constant, T is the absolute temperature, ϕ is 
the volume fraction of each of the components in the mixture (drug, polymer and solvent), mp 
is the degree of polymerization and 𝜒𝑖𝑗 is the F-H interaction parameter which accounts for the 
enthalpy of mixing.  
Kinetic contributions are expressed by means of the diffusivities of the components, 
which are related with the implementation of the classic Fick’s second law of diffusion: 
 
 
 
𝜕𝜙𝑖
𝜕𝑡
= ∇ ∙ 𝐷𝑖𝑗∇𝜙𝑗 
 
Equation 2.2 
 
 
where, t is the time and Dij is the concentration-dependent diffusion coefficient of each of the 
components in the mixture. To comply with classical Fickian diffusion theory, two assumptions 
had to be considered, namely ideal mixing and interfaces were absent. The latter assumption 
implies that the systems are completely amorphous during microstructure formation. To 
complete the derivation of this model, the following evaporation model was implemented: 
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𝜕ℎ
𝜕𝑡
= 𝑘𝑒  𝜙𝑠 
 
Equation 2.3 
 
 
where, h is the height of the solution film, ke is the evaporation rate coefficient and ϕs is the 
volume fraction of the solvent. The evaporation of the solvent is homogenous across the liquid-
vapor boundary and the solvent removal is described by a first-order rate coefficient. 
Gathering all the equations together the system’s microstructure evolution is governed 
by iteratively solving the PDEs, while aiming the minimization of the free energy of the system 
as a function of time. The simulations can be run in one or two-dimensions (1D or 2D, 
respectively) using a PDE solver software, such as FiPy version 3.1 (NIST, Gaithersburg, 
Maryland, USA) [3].    
 
2.2.2.2 Implementation of the TKE model 
The application of the TKE model within the formulation field of new ASDs is 
anticipated to support the early identification of the theoretical kinetic miscibility region in 
which the amorphous system is homogenously mixed.  
A representation demonstrating a proposed flowchart for the application of the model, 
as a pre-formulation tool for the early development of ASDs is shown in Figure 2.1. 
To run a simulation one must start with the definition of the input variables that are 
dependent upon the drug-polymer-solvent(s) system under study. These variables include 
thermodynamic and kinetic material-properties and process parameters. The material-properties 
are the F-H interaction parameters (χij), the molar volume (Vmi) and the diffusion coefficient of 
each component (Di). To calculate these properties it is necessary to have information on the 
molecular structure of the formulation constituents. The process variables are the evaporation 
rate coefficient (ke) of the spray drying process and the initial volume fraction of each 
component in the solution (ϕi). All of these input parameters were calculated using the 
correlations described in the following sections.  
Then, 1D simulations are run at the beginning of the process to screen the different 
systems and/or variables considered. In order to fine-tune the output or to improve clarity about 
phase-separation, 2D simulations should be considered. The latter are in general more time-
consuming than the former. 
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Figure 2.1. Representation showing the application of the TKE model as a screening tool for the 
development of amorphous systems. 
 
Whether in one or two dimensions, once the computational simulation starts, the solvent 
evaporates across the liquid surface and the drug-polymer microstructure begins to evolve by 
diffusion, according to the molecular affinity between the ingredients. The final 1D 
microstructures are represented on a x-y plot, where the y-axis represents the final volume 
fraction of drug, polymer and solvent (0< ϕi <1) along the film’s height, hfilm (x-axis). On the 
contrary, the final 2D microstructures can be described as a matrix of volume fractions (drug, 
polymer or solvent) or composition map, where the y-x axes correspond to height and width 
(Lfilm) of the liquid film, respectively. In 1D simulations, homogeneity after solvent evaporation 
is characterized by relatively constant bulk volume fractions (drug and polymer) along the film 
height, while heterogeneity or phase-separation is indicated by abrupt shifts of the drug and 
polymer volume fraction curves along the x-axis. In case of 2D simulations, a homogenous 
system is represented as a composition map depicting a uniform color correspondent to a single 
final volume fraction, whereas different structures at sharp variations in colors correspond to 
the formation of different amorphous regions with different levels of drug concentration. 
After conducting a computational simulation, if a homogenous amorphous mixture is 
obtained, such drug-polymer system can be considered a good starting point for further 
formulation development. Conversely, if the simulation indicates a phase-separated system 
with two distinct amorphous domains, the drug-polymer system may be considered physically 
unstable and alternative combinations (e.g. polymer, drug-polymer ratio, solvent composition) 
or changes of the process conditions should be considered (e.g. solution concentration, 
temperature).   
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2.2.2.3 Obtaining the input variables of the model  
 
2.2.2.3.1 F-H interaction parameters  
Three different F-H interaction parameters per system should be determined to apply 
the TKE model. These are the interaction parameters for the drug-polymer (χdp), drug-solvent 
(χds) and polymer-solvent (χps) pairs.  
The interaction parameters can be calculated according to the following equation, using 
the Hildebrand solubility parameters: 
 
 
 
𝜒𝑖𝑗 =
𝑉𝑚
𝑖
𝑅𝑇
(𝛿𝑖 − 𝛿𝑗)
2 
 
Equation 2.4 
 
 
where, Vim is the molar volume of the smaller component within the ij pair and δ is the 
Hildebrand solubility parameter.  
In this work, χds and χps were calculated using Equation 2.4 with the data provided in 
Table 2.1. When the solubility parameters are estimated using group contribution values, the 
respective interaction parameter obtained is an estimative at 298 K [26]. Due to this, it was 
decided to calculate χdp at the spray drying outlet temperature. This value will be more 
representative of the thermodynamic affinity during the formation of the microstructure.  
To calculate an interaction parameter at non-ambient conditions, it is necessary to obtain 
the dependence of 𝜒 with temperature. According to the F-H theory and for polymer blends 
showing an upper critical solution temperature (UCST) behavior, it is accepted the following 
𝜒-T relation [5,6]: 
 
 
𝜒𝑖𝑗 = 𝐴 +
𝐵
𝑇
 
 
Equation 2.5 
 
 
where, A and B are fitting parameters that need to be determined in order to obtain χij at any 
temperature. 
Assuming that drug-polymer systems also exhibit an UCST, the temperature 
dependence of χdp can be described by Equation 2.5. The parameters A and B were determined 
by fitting a linear regression between two χdp’s obtained at two different temperatures. These 
temperatures were around the melting point of the drug (T1), and at room temperature or 298 K 
(T2). To obtain χ (T1) the melting point depression method was used for being a simple 
experimental method to obtain the interaction parameter at higher temperatures [7], while χ (T2) 
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was obtained using the Hildebrand solubility parameters (Table 2.1). The experimental protocol 
for the melting point depression studies and associated results are presented in Supplementary 
Information A. 
 
2.2.2.3.2 Diffusivity of the components  
The diffusivity of the solutes in the solvent was approximated to the diffusivity of the 
smaller component (i.e. drug) at 298 K, since its molecular mobility is much higher when 
compared with the mobility of the polymer [8].  
The drug’s diffusivity was estimated using the Wilke-Chang equation [9]: 
 
 
𝐷𝑑𝑠 =
7.4 × 10−8 ∙ 𝑇 ∙ √𝛼𝑠 ∙ 𝑀𝑊𝑠
𝜂𝑠 ∙ 𝑉𝑚,𝑑
0.6  
 
Equation 2.6 
 
 
where, Dds is the diffusivity of the drug in the solvent, αs is the association coefficient of the 
solvent and ηs  the viscosity of the solvent. 
 
2.2.2.3.3 Evaporation rate coefficient  
The evaporation rate on the spray dryer was estimated according to the correlation for 
the drying of a single droplet in still air, according to Equation 2.7 [10]: 
 
 
𝑑𝑊
𝑑𝑡
=
𝑘𝑑  𝐴 𝑀𝑊𝑠
𝑅𝑇
(𝑃𝑤𝑏 − 𝑝𝑤) 
 
Equation 2.7 
 
 
where, kd is the mass transfer coefficient, A is the droplet’s surface area, T the drying 
temperature, Pwb is the vapor pressure of the solvent at the wet bulb temperature and pw 
corresponds to the partial pressure of the solvent in the surrounding drying gas. 
Equation 2.8 describes the mass transfer correlation for a spherical droplet in still air: 
 
 
𝑆ℎ =
𝑘𝑑 𝑑
𝐷𝑠𝑔
= 2 
 
Equation 2.8 
 
 
where, d is the droplet diameter, which was considered to be 30 μm [11], and Dsg is the 
diffusivity of the solvent vapor in the drying gas, which was estimated using the Fuller et al. 
Correlation [12]. 
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Regarding the estimation of Pwb and pw, the former was calculated using Antoine’s 
equation [12], and the latter was considered to be 10% of Pwb. The wet bulb temperature was 
estimated according to reference [13]. 
In the case of a solvent mixture, the evaporation rate was considered to be the 
evaporation rate of the solvent with the lowest vaporization enthalpy. 
 
2.2.2.3.4 Volume fraction  
The initial volume fraction of each component in the solution can be calculated from 
the respective weight fraction (wi) and the true density (ρi), based on Equation 2.9: 
 
 
𝜙𝑖 =
𝑤𝑖
𝜌𝑖⁄
𝑤𝑖
𝜌𝑖⁄ +
𝑤𝑗
𝜌𝑗⁄ +
𝑤𝑧
𝜌𝑧⁄
 
 
Equation 2.9 
 
 
 
 
2.2.2.4 Solvent casting (SC) 
Cast films of ITZ and each polymer were obtained from solutions with 10, 15, 35, 45, 
65 and 85% (w/w) ITZ. The total solids fraction was constant at 10% (w/w). The system 
ITZ:HPMCAS-MG was dissolved in a mixture of DCM:MeOH in a proportion of 80:20 (wt.%), 
whereas ITZ:PVP/VA and ITZ:Eudragit® EPO were dissolved in pure DCM. 
A volume of approximately 40μL of each stock solution was pipetted to a DSC 
aluminum pan to expedite direct analysis. At least three replicates of each drug-polymer system, 
at each drug fraction, were prepared. The sample holder was placed in a tray dryer oven at 40ºC 
for 1h, under vacuum to promote the rapid evaporation of the solvent. The goal was to design 
a SC experimental method as close as possible in terms of evaporation rate, to the subsequent 
spray drying process. The aluminum pans were sealed with the respective lids (pinholed) and 
directly placed in the sample tray of the calorimeter to be analyzed for the physical stability and 
experimental or kinetic drug-polymer miscibility capacity. 
 
2.2.2.5 Spray drying (SD) 
Spray-dried prototypes of ITZ were produced at 45% and 65% (w/w) load with 
HPMCAS-MG, 45%, 65% and 85% (w/w) drug load with PVP/VA 64, and 15% and 35% 
(w/w) ITZ with Eudragit® EPO. Solutions of ITZ and each of the polymers were prepared with 
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10% w/w concentration of solids. The solvents used in the SD experiments were the same as 
those used in the SC tests.  
Spray dried dispersions (SDDs) were produced in a laboratory scale spray dryer 
(BÜCHI Mini Spray Drier B-290, Switzerland). The spray drying unit was operated with 
nitrogen in single pass mode, i.e. without recirculation of the drying nitrogen. The drying gas 
fan was set at 100% of its capacity (flow rate at maximum capacity is approximately 40 kg/h). 
A flow rate of 0.76 kg/h was set for the atomization with nitrogen. The feed flow rate was set 
to 30% in the peristaltic pump (about 12mL/min of liquid feed). The inlet temperature was 
adjusted to achieve an outlet temperature of 40ºC. The SDDs were subjected to a post-drying 
step in a tray dryer oven with a temperature of 40°C for approximately 12 h, under vacuum. 
At the end of the process, SDD powders were sampled and DSC pinholed aluminum 
pans were prepared. The products were analyzed for their physical stability and kinetic 
miscibility, according to the DSC analysis protocol described below. Powders were also 
analyzed by polarized light microscopy (PLM) to evaluate the presence of crystalline material. 
 
2.2.2.6 Differential Scanning Calorimetry (DSC) 
Conventional and modulated DSC (mDSC) experiments were performed in a TA Q1000 
(TA Instruments, New Castle, Delaware, USA) equipped with a Refrigerated Cooling System 
(RCS). The enthalpy response was calibrated using indium. Three replicates of each sample, 
weighing between 5 and 10 mg were analyzed under continuous dry nitrogen purge (50 
mL/min). Data was analyzed and processed using the TA Universal Analysis 2000 Software. 
The glass transition temperature was taken as the inflection point in the heat capacity change 
(ΔCp) observed in the reversible heat flow, while exothermic and endothermic peaks were 
identified in the total heat flow.  
Pure raw materials (ITZ and polymers) were analyzed using a modulated heating ramp 
from -10°C to 250°C at a heating rate of 5°C/min using a period of 60s and amplitude of 0.8°C. 
It should be pointed out that crystalline ITZ had to be first subjected to a heat-cool-heat cycle 
(conventional DSC) to render the product amorphous, before applying the modulation cycle. 
Cast films and spray dried dispersions (SDDs) were analyzed using mDSC, while for the latter 
the modulation conditions were the same as the ones used for the pure components, the 
amplitude used for the cast films was 1.6ºC (i.e., two times 0.8ºC) in order to increase 
sensitivity.  
DSC was applied to detect key indicators of homogeneity and phase separation of the 
cast films and SDDs. The number of amorphous phases present in the mixtures was defined 
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based on the following generally accepted rules in the literature [14-16]. If a single Tg value 
between the Tg’s of the pure components is detected in the reversible heat flow, then one can 
consider that drug and polymer are homogenously mixed and a true amorphous solid solution 
(i.e. glass solution) was formed. Conversely, if two distinct Tg’s corresponding to the pure 
components were detected, one can consider that amorphous-amorphous phase separation had 
occurred and an amorphous (or glass) suspension with polymer and drug rich phases was 
produced. For systems with higher drug loading is also common to detect other thermal events 
characteristic of phase-separation, namely recrystallization and melting during heating of the 
sample. Such events may correspond to the presence of crystalline material in the raw sample 
or may have been triggered by heating during the DSC run. 
In this work, the detection of amorphous-amorphous phase separation can be facilitated 
by the fact that the molecule (ITZ) presents a mesophase (i.e. two endothermic peaks in the 
reversible heat flow around 69.6±1.0ºC and 84.7±1.0ºC) [17]. 
 
2.2.2.7 Polarized Light Microscopy (PLM) 
The SDDs powders were analyzed in a Nikon Labophot-2 Polarizing Microscope 
(Nikon, Japan) in order to detect crystalline material in the samples, by the presence of 
birefringence. Micrographs were taken using a TCA-9.0 Color Camera (Tucsen Imaging 
Technology Co. Ltd, China). Images were taken using the TSview 6.2.2.6 software. 
 
2.3 Results  
 
2.3.1 F-H interaction parameter calculation using solubility parameters 
 
The F-H interaction parameter (𝜒𝑖𝑗) accounts for the enthalpic contribution for the Gibbs 
free energy of mixing (ΔG) and is a measure of the cohesive (intramolecular) and adhesive 
(intermolecular) interactions within the ij pair. Table 2.1 compiles important physicochemical 
properties of the solid compounds and solvents used in this work, to calculate the three F-H 
interactions parameters - drug-polymer (𝜒𝑑𝑝), drug-solvent (𝜒𝑑𝑠) and polymer-solvent (𝜒𝑝𝑠) 
pairs.  
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Table 2.1. Physicochemical properties of the raw materials considered in this project. 
Substance MW [gmol-1] ρ [gcm-3] Vm  [cm3mol-1] a δ [(MPa)1/2] b Tg [ºC] c 
ITZ 706 1.27 d 556 24.77 59.2±0.3 
HPMCAS-MG 18,000 e 1.29 e 13,846 23.49 120.3±0.7 
PVP/VA 64 55,000 e 1.2 e 45,833 22.92 107.9±0.3 
Eudragit® EPO 47,000 e 1.1 f 42,727 19.62 55.8±2.1 
DCM 
MeOH 
85 
32 
1.33 
0.79 
64 
40 
20.2 
29.7 
- 
- 
 
MW: Molecular weight; ρ: True density; Vm: Molar volume; δ: Hildebrand solubility parameter;  
Tg: Glass transition temperature. 
a Calculated dividing the molecular weight by the true density; 
b Drug and Polymers: estimated at according to [18]; Solvents: taken from reference [19]; 
c Obtained by mDSC – Mean± s.d., n=3; 
d From reference [20];  
e Supplier Information;  
f From reference [21]. 
 
 
2.3.2 Drug-polymer kinetic miscibility predictions 
 
The phase behavior of the simulated systems will depend on the strength of the 
interaction between species and the process variables. The latter will dictate the formation of a 
homogenous and molecularly mixed ASD (i.e. amorphous solid solution), or on the other hand, 
an amorphous system showing phase separation of a drug- and polymer rich region (i.e. an 
amorphous suspension). The formation of two distinct amorphous regions is an indication of 
physical instability, and recrystallization may be observed when producing the respective 
dispersion [16]. Thus, the model will only return one of two possible outcomes: 
homogeneity/heterogeneity, one-phase system/two-phase system or miscibility/immiscibility. 
Figure 2.2 presents the sequence of 1D simulations for the drug-polymer systems in this 
study. A comparison of the kinetic miscibility predictions among the three pharmaceutical 
mixtures shows differences in drug-polymer phase behavior at the drying temperature. 
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Figure 2.2. Results from 1D simulations showing the expected final phase behavior of ITZ:HPMCAS-
MG, ITZ:PVPVA/64 and ITZ:Eudragit® EPO systems with increasing drug concentration (from left to 
right). The 1D simulations show the final drug (blue), polymer (green) and solvent (red) volume fraction 
curves along the film height (horizontal axis). 
 
In the case of the ITZ:HPMCAS-MG system, after solvent evaporation, both 
components remained homogenously mixed up to 85% ITZ. The drug and polymer volume 
fraction curves in the 1D ITZ:HPMCAS-MG figures remained almost constant and parallel 
along the film height. No additional simulations were run for drug loads above 85% ITZ. 
In the case of the ITZ:PVP/VA 64 system, the drug and polymer remained 
homogenously mixed up to 45% ITZ. For 35% ITZ load the results suggest a potential for the 
system to separate into two phases, with the drug and polymer volume fraction curves showing 
an abrupt change in trend along the film height when compared to lower drug loads. With an 
ITZ concentration higher than 65%, the system was considered to be phase-separated, which 
was indicated by the formation of drug and polymer-rich amorphous regions along the film 
height. 
Considering the results obtained, it can be said that the ITZ:PVP/VA 64 system was 
partial or locally miscible at the drying temperature and showed a miscibility discontinuity with 
increased drug loading. At this point, this miscibility discontinuity could be seen as a set of ITZ 
loads comprehended between 45% and 65%  drug fraction, which contained the maximum drug 
concentration from which the miscibility-immiscibility transition was observed.  
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Among the different drug-polymer systems studied, the pair ITZ:Eudragit®EPO 
presented the lowest drug-polymer kinetic miscibility, taking into account that the phase-
separation was observed at the lowest drug load tested – 10% ITZ. In this case, it can be 
postulated that a miscibility discontinuity exists for drug loads lower than 10% ITZ. Drug loads 
lower than 10% were considered to be below those used in practice, thus no further simulation 
was carried out for this system. By opposition, the reasons for not having run additional 
computational simulations for drug loads above 10% ITZ:Eudragit® EPO were different. For 
drug-polymer systems presenting a miscibility behavior with a UCST (one of the assumptions 
considered in this work), above the critical temperature (Tc) drug and polymer form a 
homogenous system, while below Tc the drug-polymer system phase-separates. Analyzing the 
drug-polymer phase-diagrams reported in the literature by different authors, one can observe 
that they are highly asymmetric and shifted towards high drug loads [5,6,15,22, 23]. The critical 
compositions (ϕc) are generally above 80% (volume or weigh fraction) and the critical 
temperatures (Tc) are well above temperatures of interest with respect to spray drying 
processing (>100ºC). These assume that for the drug-polymer systems under study and 
considering the temperature at which the kinetic miscibility predictions were run (Tdrying=40ºC), 
once the formation of a two-phase system occurred, heterogeneity was continuous up to 85% 
drug load, or another predefined upper bound by the user. The results from the 1D simulations 
of the ITZ:PVP/VA 64 corroborated the latter statement, showing drug-polymer phase 
separation above 65% ITZ.  
 
2.3.2.1 Optimization of drug load – ITZ:PVP/VA 64 Case-study  
In this section the drug load of the ITZ:PVP/VA 64 system was optimized within the 
miscibility transition range determined in the 1D simulations (45% to 65% w/w).  
The first row in Figure 2.3 shows the final 1D microstructures obtained after the 
evaporation of the solvent, while the second row corresponds to the final 2D microstructures 
with respect to the volume fraction of one of the components of the system, which in this 
specific case is the volume fraction of the drug (ϕd). The 2D microstructures respecting the 
volume fraction of polymer and solvent (ϕp and ϕs, respectively) are not shown for sake of 
simplicity. The final polymer composition is the inverse of the drug, i.e. (1- ϕd), while the 
solvent fraction is ≈0 in the whole domain. 
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Figure 2.3. Results from 1D and 2D simulations showing the phase composition of ITZ:PVPVA/64 
system with increasing drug load within the kinetic miscibility discontinuity boundary (from 45% to 
65% ITZ w/w).  
 
Increments of 5% ITZ were simulated in one- and two-dimensions starting with the 50% 
up to 60% ITZ:PVP/VA 64 systems. The 1D and 2D figures obtained for 45% and 65% loads 
were also included in Figure 2.3 for comparison purposes.  
The analysis of the 1D simulations in Figure 2.3, indicates that phase-separation would 
occur above 50% ITZ due to the formation of different layers or amorphous domains along the 
film thickness. However, the analysis of the respective 2D simulations has shown that, although 
apparent different amorphous regions have been formed in the 1D calculations, the 50% ITZ 
system could be considered as a one-phase homogenous system in the 2D simulation, for 
presenting an overall constant volume fraction of drug around 0.4-0.5 along the film. This 
specific case illustrates well the importance and usefulness of 2D simulations if drug load 
optimization is desired. 
At this point, the miscibility discontinuity or the drug load interval that contains the 
maximum theoretical drug load expected for the ITZ:PVP/VA 64 system was comprehended in 
the range between 50-55% ITZ, and it could have been further narrowed down by executing an 
additional simulation at 52.5% ITZ  (Figure 2.4). 
Comparing the 1D simulations at 50% and 52.5% ITZ, the final microstructures formed 
were fairly similar. According to the 2D simulations at 52.5% ITZ, phase-separation with a 
clear segregation of two amorphous regions was more obvious, with one phase enriched in drug 
and the other in polymer. The drug load window from 50% to 52.5% ITZ was now narrowed 
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down so that one can infer that the theoretical maximum drug load the system can admit without 
compromising miscibility was ≈ 50% ITZ. 
 
   
 
Figure 2.4. Results from 1D and 2D simulations presenting the final phase behavior of ITZ:PVPVA/64 
system at 52.5% (w/w) ITZ. 
 
2.3.3 Solvent casting and spray drying experiments 
 
To assess the validity of the TKE model and to produce experimental evidence of the 
kinetic miscibility estimates, SC experiments were performed. The cast films produced were 
analyzed using mDSC to define the level of ITZ that could be added to the ASD before signs 
of phase-separation appear (either amorphous-amorphous or recrystallization). The drug load 
range between the maximum drug load added to the mixture before phase separation occurred, 
and the minimum drug load tested that exhibited signs of phase separation was defined as the 
SC miscibility discontinuity. Subsequently to the SC screening phase, SD prototypes were also 
produced. Drug-polymer spray drying experiments were undertaken according to the limits of 
the SC miscibility discontinuity. Only an additional ITZ:PVP/VA 64 SDD system was 
produced due to the detection of a false-negative result. This will be explained in more detail 
later in the text.  
The DSC heat flow curves correspondent to the thermal analysis of the cast films and 
spray dried materials with drug loads equal to the SC miscibility discontinuity limits are 
presented in Figure 2.5, Figure 2.6 and Figure 2.7, for the systems ITZ:HPMCAS-MG, 
ITZ:PVP/VA 64 and ITZ:Eudragit® EPO, respectively. More detailed information (i.e. 
temperatures and micrographs) regarding the analytical characterization of the casted films and 
spray dried powders produced is presented as Supplementary Information A. 
Screening methodologies for amorphous solid dispersions 
 
55 
Figure 2.5 shows the mDSC profiles for the 45% and 65% ITZ mixtures with HPMCAS-
MG prepared by solvent casting and subsequent spray drying. In what regards the cast films, at 
45% ITZ the product presented a single glass transition temperature (Tg) in the reversible heat 
flow (shown by an arrow) and a single relaxation endotherm in the non-reversible heat flow 
(not shown). No signs of amorphous-amorphous phase separation or crystallization were 
observed in the thermograms. Profiles for the 10, 15 and 35% ITZ loading cast films were 
identical to the 45% ITZ. 
The results suggest that ITZ was homogenously mixed and molecularly dispersed within 
HPMCAS-MG up to 45% drug load. In the case of 65% ITZ:HPMCAS-MG cast films, the only 
change in heat capacity detected in the reversible heat flow profile was around 26.7±4.2ºC, a 
temperature significantly below from the one expected, considering the Tg of the pure 
components or even considering the mixed Tg value decay due to increasing ITZ loading, 
according to the Gordon-Taylor equation [24]. No phase-separation or recrystallization events 
were detected during heating, but an endothermic peak at 151.6 ±1.2ºC was observed. This 
endothermic peak might correspond to the melting of ITZ (Tm= 162.6±0.2ºC). The melting 
point depression observed was due to the presence of the polymer that lowered the chemical 
potential of the drug and led to a decrease of its melting temperature [25,26]. 
The existence of an endothermic event without the observation of a prior exothermic 
recrystallization also presupposes the presence of a starting crystalline material in the sample. 
This observation could be related to the absence of a mixed Tg, thus with the formation of 
heterogeneities along the cast film due to e.g. poor drying conditions, inefficient process of 
amorphization or residual solvent plasticizing the product. The 85%  ITZ:HPMCAS-MG casted 
films showed a single Tg value near the Tg of pure ITZ, but considering that neither the drug 
mesophase nor the Tg of the polymer were detected, a homogenous amorphous system might 
have been formed. However, the system evolved into recrystallization followed by melting of 
the drug, during the heating cycle. Recrystallization triggered by heating is a consequence of 
increased molecular mobility and molecular rearrangement in amorphous systems with high 
drug load and insufficient polymeric stabilization [27]. Such systems are considered less stable 
and are more prone to phase-separation and drug crystallization triggered by external variables 
(e.g. temperature, humidity) [28,29].  
Both the thermograms of the 45% ITZ cast film and the SDD presented a single Tg in 
the reversible heat flow without signs of amorphous-amorphous phase separation or 
recrystallization, suggesting the formation of an amorphous solid solution. Moreover, no 
birefringence was observed in the sample. The thermogram of 65% ITZ SDD has shown that 
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the heterogeneities formed during SC disappeared and gave place to a clear mixed Tg with the 
respective relaxation endotherm in the non-reversible heat flow (not shown). 
 
          
Figure 2.5. Reversible heat flow thermograms for the 45 and 65% (w/w) ITZ:HPMCAS-MG cast films 
(SC) and spray-dried materials (SD). Arrows indicate the Tg’s. 
 
The absence of birefringence by microscopy also indicated the formation of a 
homogenous ASD. However, this system like the one with 85% ITZ cast film was not stable on 
heating; the drug recrystallized prior to melting (Figure 2.5, insert). Although SD promoted a 
more efficient amorphization process with a faster entrapment of the components of the 
solution, the high drug load in formulation may present a higher risk of structure destabilization 
and physical instability.     
Figure 2.6 presents the mDSC thermograms for the ITZ:PVP/VA 64 binary mixtures 
manufactured by the solvent casting and spray drying processes. For casted films with 45% ITZ 
no recrystallization or melting endotherms were detected and only a single mixed Tg was 
observed. On the other hand, for lower drug loads (10, 15 and 35% drug load) no conclusion 
regarding the physical-state of these systems can be drawn by the analysis of the thermograms. 
In the three replicates, unexpected endothermic events appeared at 80ºC and 150ºC in the total 
heat flow. Janssens et al. also observed endothermic events in the range of 40ºC and 100ºC in 
the mDSC thermograms of ternary systems made up of 10, 20 and 40% ITZ load in 25/75 (w/w) 
TPGS 1000/PVPVA 64 [30]. These authors justified the appearance of such events as relaxation 
enthalpy peaks correspondent to the formation of amorphous inhomogeneities in the samples. 
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To validate this hypothesis, they performed a heat-cool-heat cycle with those materials in the 
calorimeter, and the endothermic peaks disappeared in the second heating run. This second 
heating eliminated the thermal history of the samples and potential amorphous phases present 
in the raw material disappeared [14]. 
In this work, amorphous inhomogeneities may have also been formed in the cast films. 
Although additional tests could have been performed, the indication of the production of an 
amorphous and homogenous system containing a higher drug load [i.e. 45% (w/w)] was 
sufficient to move forward with the screening method. 
Increasing the ITZ potency to 65% and 85%, the cast films presented a single Tg and 
considering the absence of a drug mesophase or second Tg in both systems, this was a strong 
indication that the drug was homogenously mixed with the polymer. Still, upon increasing the 
drug loading to 65%, a slight melting endotherm was detected, while increasing the ITZ potency 
to 85% caused a large melting endotherm. Both compositions have shown a recrystallization 
exotherm when analyzing the total heat flows.  
The SD results from the respective SDDs with 45% and 65% ITZ exerted a single mixed 
Tg and no signs of amorphous-amorphous phase separation or crystallization, which suggests 
that amorphous solid solutions were formed. Consequently, one can refer that the cast film with 
65% ITZ was a false-negative result. This observation reinforces the fact that although solvent 
casting can provide useful preliminary information on kinetic miscibility and physical stability, 
premature conclusions should not be drawn from the analytical results of the cast films; again, 
one may be neglecting the real solubilization capacity offered by the polymer. This shows the 
importance of confirming the SC results with the production of the respective SDDs.  
In order to determine the experimental kinetic miscibility limit of the ITZ:PVP/VA 64 
mixture, an additional SD experiment at 85% ITZ was performed. Upon increasing the ITZ 
loading, despite the detection of a mixed Tg, a recrystallization peak followed by melting was 
observed. No glassy ITZ clusters were detected, but according to the PLM results, ITZ 
crystallites were present. The results obtained indicate that at 85% ITZ, even using such drying 
process conditions, the drug cannot be completely stabilized by the polymer. Comparing with 
the 85% ITZ:PVP/VA 64 cast film, the thermal results were similar. 
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Figure 2.6. Reversible heat flow thermograms obtained for the 45, 65 and 85% (w/w) ITZ:PVP/VA 64 
cast films (SC) and respective spray-dried materials (SD). Arrows indicate the Tg’s. 
 
Finally, Figure 2.7 shows the thermal results for the 15% and 35% ITZ:Eudragit® EPO 
cast films and respective spray dried powders. Amorphous solid solutions without the detection 
of key indicators of physical instability were produced via SC, up to and including 15% drug 
load. Contrarily, when increasing the ITZ load to 35% two single Tg’s and the ITZ mesophase 
were detected in the reversible heat flow. The zoom in Figure 2.7 shows the relaxation 
endotherms correspondent to the phase-separation event. The 45% cast films also present signs 
of amorphous segregation within the same temperature range. It is difficult to conclude with 
certainty if these two Tg’s correspond to the complete segregation of two phases or to the 
formation of amorphous clusters of ITZ, still with a certain percentage of drug molecularly 
dispersed within the polymer (glass suspension/solution) [31,32]. It was also noted that, while 
the 35% ITZ cast films remained kinetically stable as phase-separated systems and any 
additional events were detected during heating, the 45% system presented drug recrystallization 
and melting. For the 65% and 85% cast films, the formation of drug amorphous clusters was 
observed (detection of mesophase), however only one Tg was detected. For those cases, the 
detection of two single Tg’s may be hidden by the detection of a broad Tg value.  
The results obtained for the spray-dried materials produced were consistent with the 
respective SC profiles. At 15% ITZ load a single-phased amorphous system was obtained with 
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no observation of further events during heating, while at 35%, though the SDD presented one 
single Tg it has evolved into crystallization of the drug during the heating cycle. 
 
         c 
 
Figure 2.7. Reversible heat flow thermograms obtained for the 15 and 35 (wt.%) ITZ:Eudragit® EPO 
cast films (SC) and respective spray-dried materials (SD). Arrows indicate the Tg’s. 
 
2.4 Discussion 
 
Over the last few years, there was a growing interest by the pharmaceutical industry, in 
the implementation of screening methodologies to support the development of ASDs. The basis 
for this change might be related to the application of Quality by Design (QbD) principles and 
concepts, where one of the main goals is to build quality into the product, thereby reducing 
empiricism, development time, risk and costs [33]. 
Screening methodologies should include, but not be limited to, the assessment of the 
thermodynamic drug solubility in the polymer and drug-polymer kinetic amorphous miscibility. 
Effective screening tools should provide the answer to key questions, such as, what are the most 
suitable polymers and process variables that allow the manufacturing of high-dose formulations 
showing improved physical stability during product development and long-term storage. 
The study presented proposes a new screening methodology intended to be used in the 
early development of ASD produced by spray drying. The novelty of this work is the 
implementation of a computational tool to guide rationale polymer selection and the narrowing 
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of drug load ranges with the potential to form miscible binary systems. The major differences 
of the TKE model implemented from commonly applied methodologies to predict the solubility 
and miscibility of a drug in a polymeric carrier are the assessment of the thermodynamics of 
mixing of a drug-polymer-solvent system, the inclusion of kinetic material properties and 
process variables (i.e., components diffusion and evaporation rate, respectively). The use of this 
model allows the definition of the kinetic drug-polymer system phase boundaries, as it will also 
provide detailed information regarding the influence of important process variables (e.g. 
selection of the solvent, concentration of solids in the solvent, drying temperature) on the limits 
of this miscibility region.  
As a first assessment of the validity of the TKE model, three amorphous pharmaceutical 
systems composed of ITZ and PVP/VA-64, HPMCAS-MG and Eudragit® EPO were tested. 1D 
computational simulations were run, and in order to have an experimental evidence of the 
kinetic miscibility estimates a SC experimental protocol was developed. Cast films were 
produced with the same drug-polymer systems, at the same drug loads and process conditions 
(i.e. drying temperature) as the computational simulations tested. Then, the scale-up of the 
systems correspondent to the limits of the SC miscibility discontinuity using spray drying 
further confirmed the validity of the model and the screening methodology as a whole.  
In order to analyze the results obtained together, Figure 2.8 compiles in a single 
schematic representation the theoretical predictions provided by the TKE model and the 
analytical results obtained for the casted films and spray dried products for the different ITZ 
amorphous systems studied. 
The results are depicted by means of continuous bars, which represent the kinetic 
miscibility behavior as a function of drug loading for each ITZ system studied. According to 
the results that have already been described in previous sections, grey bars were extended up to 
the maximum drug load tested that each polymer could stabilize without the existence of signs 
of physical instability. By opposition, black bars were extended from the minimum drug load 
tested with the detection of two amorphous regions (A-A) or the presence of crystalline material 
suspended in the amorphous matrix (C-A). The presence of crystalline drug in the product may 
have origin from incomplete amorphization, or recrystallization during the DSC heating run. 
The uncertain region bars correspond to what was defined as the miscibility 
discontinuity or the region that includes the drug loading from which phase separation is 
observed or inferred from the results. 
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Figure 2.8. Theoretical miscibility predictions given by the TKE model and analytical results obtained 
for the solvent casting films and spray drying products, as a function of drug load. 
 
It should be noted that the representation of the bars are supported on discrete 
experimental points, bearing in mind that a lower number of tests were performed for the 
representation of the spray drying bars. It is assumed that these miscibility interpolations can 
be considered and that these are valid within the assumption that drug-polymer pharmaceutical 
systems in general present a typical temperature-composition phase diagram, i.e. the 
asymmetrical “inverted U” presenting only an UCST, shifted for higher drug loads 
[5,6,15,22,23]. 
 
2.4.1 Validation of the TKE model and screening methodology 
Analyzing Figure 2.8 and comparing the miscibility estimates and the experimental 
results of the casted films and spray-dried products of each drug-polymer system, it can be seen 
that the TKE is able to globally describe the amorphous drug-polymer compatibility and phase 
behavior. For example, the drug-polymer pairs which exhibited a higher experimental 
miscibility capacity, i.e. around 45% for the ITZ:HPMCAS-MG and 65% for the ITZ:PVP/VA 
64 system, were those which  simulations indicated the formation of a homogenous amorphous 
systems for higher drug loads [85% and 50% (w/w) TZ, respectively]. In a similar way, the 
drug-polymer mixture which presented its maximum of experimental miscibility at lower drug 
loads, i.e. around 15% for the ITZ:Eudragit® EPO system, was the one where the model 
predicted phase-separation for lower drug loads [10% (w/w) ITZ]. 
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These results suggest that the TKE model can be used successfully to rank the best 
polymers for amorphous drug stabilization. In this study, the following ranking would be 
obtained by ascending order of kinetic miscibility capacity for the ITZ systems tested: 
Eudragit® EPO<< PVP/VA 64 < HPMCAS-MG.  
As far as the maximum miscibility values obtained are concerned, some differences 
were identified for the predicted and observed results. Despite including the influence of 
thermodynamic, kinetic and dynamic factors on the final phase behavior of ASDs, TKE may 
not fully capture the complexity of drug-polymer particle formation. The causes that contribute 
for these differences may be seen from a three level perspective, i.e. starting from the global 
design and structure of the computational tool taking into account the objectives for which the 
model was originally developed, considering simultaneously the limitations and assumptions 
of the models applied, especially in what regards the F-H theory and the evaporation model, 
and finally the simple experimental methods and correlations used to estimate part of the 
system-dependent input parameters. Thus, the accuracy of the predictions should be analyzed 
in light of the limitations and assumptions of the computational system.  
Although validation from a quantitative standpoint should not be made at this point of 
the work, it is still possible to use the kinetic miscibility estimates obtained from the model to 
create some guidelines to define a narrow drug load range to be tested using solvent casting or 
spray drying. Moreover, we can use all the information gathered (TKE+SC) to improve the 
experimental design with reduction of the experimental work [15,34]. For instance, for systems 
partially miscible up to a proper relevant drug dose (e.g. ITZ:PVP/VA 64), a small number of 
solvent casting experiments with solutions containing a concentration of drug around the 
maximum value before phase-separation is detected, could be sufficient to provide useful 
information on experimental miscibility and ASD stabilization. Conversely, for systems that 
experience spontaneous phase-separation already at low drug loads (e.g. ITZ:Eudragit® EPO), 
it would probably be a poor decision to experimentally test systems with drug loads well above 
the minimum tested, due to the high probability of drug-polymer immiscibility. Finally, 
estimates such as the ones obtained for the ITZ:HPMCAS-MG system, where the model 
predicted total miscibility for the entire drug load range, should not be over interpreted because 
a formulation with 85% (w/w) drug concentration may present a higher risk of drug 
recrystallization, as observed for ITZ. 
Based on these results, it can be verified that optimal spray dried ASDs can be produced 
using less time and resources, owing to the early implementation of screening methodologies 
that work as important decision-making elements for the rationale design of new amorphous 
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products. Through a correct validation of the proposed methodology, it can be used not only to 
rank the best polymers and define a safe drug load/miscibility window, but also to study the 
influence of changing the solvent(s), solution composition and drying temperature on the final 
phase behavior of ASDs. A workflow demonstrating the implementation of the screening 
program developed in this work is shown in Figure 2.9. 
 
 
 
Figure 2.9. Workflow for the early development of a new spray dried amorphous solid dispersion. 
 
2.5 Conclusions 
 
In this work, a screening methodology was developed to support the early development 
of spray dried amorphous solid dispersions. One of the main improvements in relation with 
other screening methodologies is the application of a computational tool based on diffuse 
interface theories for studying drug-polymer microstructure evolution.   
Simulations were run for three ITZ-based systems (at increasing drug loading), with the 
Thermodynamic, Kinetic and Evaporation (TKE) model being able to globally describe the 
amorphous drug-polymer compatibility and phase behavior on the basis of the computational 
predictions and experimental results obtained through solvent casting and spray drying. The 
polymer ranking by ascending order of physical stability as determined by the model - 
Eudragit® EPO<< PVP/VA 64 < HPMCAS-MG – was consistent with the experimental data. 
The miscibility of ITZ in PVP/VA 64 was higher than HPMCAS-MG, or Eudragit® EPO. 
Despite differences observed in the absolute maximum miscibility values obtained, it is still 
possible to use the information given by the TKE model to create guidelines to define a narrow 
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drug load range to be tested in the following stages of process development, thus saving time 
and resources. 
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3 Predicting the in vivo performance of amorphous solid dispersions based 
on molecular descriptors and statistical analysis  
 
3.1 Introduction 
 
Computational tools based on molecular descriptors and statistical analysis have been 
used for predicting drug’s oral absorption and bioavailability [1], drug’s solubility in 
biorelevant fluids [2], drug’s glass forming ability and crystallization tendency [3,4], the 
solubility advantage of amorphous drugs [5] or the potential to form a solid dispersion [6], to 
mention some applications. The strategy of using multivariate methods to correlate molecular 
properties with specific responses is based on quantitative structure activity/property 
relationships (respectively, QSAR/QSPR) methods.  
With the growing interest in the development of new ASDs, there is a significant number 
of research papers in the literature demonstrating the improved in vivo bioavailability of ASDs 
when compared with the reference products (e.g. crystalline drug, drug-polymer physical 
mixture, current commercial product). Taking advantage of amorphous dispersions past history, 
the purpose of this work was to develop a statistical model, based on multivariate data analysis 
tools - principal components analysis (PCA) and partial least squares method (PLS) - that could 
help on guiding ASD formulation design to obtain the desired in vivo performance. The goal of 
this work was not to develop reliable models for the prediction of oral bioavailability of ASDs, 
but rather to assess if there are any trends and/or correlations between the molecular descriptors 
of the APIs and the polymers (POLs) and in vivo pharmacokinetic parameters. This work does 
not intend to rule out the pre-clinical in vivo testing in advanced stages of product development. 
A database considering 37 ASDs (or observations) and 35 XY variables was 
constructed. The X variables included molecular descriptors that described the APIs, the POLs 
and interactions thereof, while the Y variables corresponded to experimental data obtained from 
the literature, more specifically in vivo pharmacokinetic (PK) parameters, such as the area under 
the (in vivo) concentration-time curve (AUC), the peak plasma drug level or maximal plasma 
drug concentration (Cmax) and the time to obtain Cmax (tmax). 
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3.2 Methodology 
 
The work developed consisted on the following steps: (1) select from the literature a 
reasonable number of articles with in vivo bioavailability data of ASDs (section 3.2.1);  
(2) definition of molecular descriptors that describe the API, POLs and interactions thereof 
(section 3.2.2); (3) creation of the database or dataset; (4) overview of the dataset and outliers 
identification using PCA (section 3.2.3); (5) development of PLS models between molecular 
descriptors (X-variables) and in vivo PK parameters (Y-variables) (section 3.2.3); (6) testing 
the PLS models on a test set of compounds and identification of correlations. 
 
3.2.1 Database 
A database with 37 observations (rows) and 35 variables (columns) was created, as 
schematically shown in Figure 3.1, corresponding to ASDs described in 20 scientific reports 
found in the literature [7-26]. The variables included simple molecular descriptors for the APIs, 
the polymeric excipients (POLs) and interactions thereof (see section 2.2.), together with 
experimental data obtained from the selected articles, namely formulation-related variables and 
the typically reported in vivo pharmacokinetic parameters. 
 
 
 
Figure 3.1. Representation of the database. A database with 37 observations (N) and 35 variables (K), 
in total, divided into K1 molecular descriptors to describe the APIs, K2 the molecular descriptors to 
describe the polymers (POLs), K3 API-POL interaction variables based on the individual molecular 
descriptors of the APIs and POLs, and K4 experimental variables. 
 
The selection of data from the literature to support the creation of this database was 
based on the following criteria: (1) availability of in vivo PK data both for the ASD and a 
reference product (e.g. pure crystalline drug, drug-polymer physical mixture or commercial 
product), in order to obtain “gaining-factors” in relation to AUC, Cmax and tmax; (2) only binary 
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ASDs composed of an API and one excipient were considered, in order to reduce the complexity 
of the system and the in vivo phenomena involved; (3) only polymeric ASDs were considered, 
due to the fact that polymers are the mostly used carriers to stabilize amorphous drugs and 
enhance drug’s dissolution; (4) the selection of the ASDs was independent from the 
amorphization method and the animal model selected to assess the in vivo performance.  
Overall the database included 21 different APIs, with different ionization behaviors, and 
13 different polymers across the major polymeric classes, such as those based on cellulose [viz.  
hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate 
(HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl cellulose 
(HPC)], polyvinylpyrrolidone (viz. PVP, Kollidon®) and polyvinylpyrrolidone/vinyl acetate 
(Kollidon® VA 64), methacrylic acid and methyl methacrylate [e.g. dimethylaminoethyl 
methacrylate, butyl methacrylate, and methyl methacrylate co-polymer or Eudragit® E100], and 
a graft copolymer composed of polyethylene glycol (PEG), polyvinylcaprolactam (PVCL), and 
polyvinylacetate (PVA) (i.e. Soluplus®). Table 3.1 describes the ASDs considered with the 
respective abbreviations used along the text and references. 
 
3.2.2 Molecular descriptors and experimental data  
To describe the APIs and the POLs, 15 and 8 molecular descriptors were considered, 
respectively. These were mostly molecular descriptors that could be easily computed from the 
molecular formula/structure, thus avoiding the dependence on complex and time-consuming 
computational tools.  
Common structural properties to both APIs and POLs included parameters like 
molecular weight (MW), molar volume (MV), glass transition temperature (Tg), the total 
solubility parameter (SP), number of hydrogen-bond acceptor groups (#H-A), number of 
hydrogen-bond donor groups (#H-D), total number of hydrogen-bond groups (#H-total) and a 
derived parameter in an attempt to represent all possible hydrogen bonds of the API-API and 
the POL monomer-monomer self-association [#H-A×#H-D, or #H(A×D)]. 
Additional structural parameters used to describe the APIs included the octanol-water 
partition coefficient (log P, for neutral molecules), the pH-dependent octanol-water distribution 
coefficient (log D, at pH=5.5 and pH=7.4, for ionizable molecules), melting point (TM), reduced 
glass transition temperature (Trg), molecular polar surface area (PSA) and the number of 
rotatable bonds (#rotbonds). Whenever the molecular descriptors for the APIs were reported in 
the respective reference, those values were used in the database.  
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Table 3.1. ASDs considered as observations, with respective abbreviations and references. 
# Obs. API-Polymer Amorphous Dispersion Abbreviation Ref. 
1 ER-34122 – HPMC (TC5RW) ER-HPMC (TC5RW) [7] 
2 Torcetrapib – HPMCAS M TCB-HPMCAS M [8] 
3 Torcetrapib – HPMCAS M * TCB-HPMCAS M * [8] 
4 Compound 2 – HPMCAS M C2-HPMCAS M [8] 
5 Compound 6 – HPMCAS L C6-HPMCAS L [8] 
6 Tacrolimus – HPMC E5 TCL-HPMC E5 [9] 
7 BMS-488043 – PVP K-29/30 BMS-K29/30 [10] 
8 BMS-488043 – PVP K-29/30 * BMS-K29/30 * [10] 
9 Danazol – PVP K-15 DNZ-K15 [11] 
10 HO-221 – Kollidon® 30 HO-K30 [12] 
11 HO-221 – Kollidon® VA 64 HO-KVA64 [12] 
12 HO-221 – Kollidon® VA 64 * HO-KVA64 * [12] 
13 HO-221 – HPMCP 55 HO-HPMCP 55 [12] 
14 Fenofibrate – Eudragit® E100 FEN-E E100 [13] 
15 AMG-517 – HPMCAS M AMG-HPMCAS M [14] 
16 Compound I – Kollidon® 30 CI-K30 [15] 
17 Compound I – Kollidon® 30 * CI-K30 * [15] 
18 MFB-1041 – HPMC (60SH-50) MFB-HPMC (60SH-50) [16] 
19 MFB-1041 – HPMCP 55 MFB-HPMCP 55 [16] 
20 MFB-1041 – HPMCP 55 * MFB-HPMCP 55 * [16] 
21 Nobiletin – HPC SSL NBT-HPC SSL [17] 
22 Probucol – PVP K-30 PBC-K30 [18] 
23 Probucol – PVP K-30 * PBC-K30 * [18] 
24 Probucol – PVP K-30 * PBC-K30 * [18] 
25 Probucol – PVP K-30 * PBC-K30 * [18] 
26 Tolbutamide – PVP K-30 TBT-K30 [19] 
27 Lonidamine – PVP K-29/32 LDM-K29/32 [20] 
28 Fenofibrate – Soluplus® FEN-SOL [21] 
29 Itraconazole – Soluplus® ITZ-SOL [21] 
30 Raloxifene – Kollidon® 30 RXF-K30 [22] 
31 Griseofulvin – HPMCAS M GRS-HPMCAS M [23] 
32 Dutasteride – Eudragit® E100 DTT-E E100 [24] 
33 Dutasteride – HPMC DTT-HPMC [24] 
34 Dutasteride – HPC SL DTT-HPC SL [24] 
35 Compound 1 – HPMCP 55 C1-HPMCP 55 [25] 
36 Fenofibrate – HPMC E5 FEN-HPMC E5 [26] 
37 Fenofibrate – HPMCAS L FEN-HPMCAS L [26] 
 
The * aims to differentiate among ASDs, from the same API-POL system; means that the API load and/or    
the in vivo animal model and/or the in vivo dose tested was different. 
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Alternatively, chemical databases and software tools available online, such as 
ChemSpider [27] and Molinspiration [28], were used to obtain the missing molecular 
descriptors for the APIs.The molecular descriptors for the POLs were mostly obtained through 
information provided by the suppliers and from the literature. There were other parameters 
common to the APIs and POLs, such as the total SPs that were estimated using the Fedors group 
contribution [29]. The number of #H-A and #H-D for the POLs were determined per monomer 
unit and then normalized to 100 MW [30].  
Regarding the interaction parameters, these were included to evaluate whether the 
combined effect of a variable of the API and the POL correlate with the in vivo performance of 
ASDs. The interaction parameters considered were: 
- the ratio between the MV of the POL and MV of the API (MVPOL/MVAPI); 
- the ratio above but considering the number of moles (#mol) of each of the components, 
while considering the drug load in formulation [(MVPOL/MVAPI)*(#molPOL/#molAPI)];  
- the difference between the total solubility parameters of the API and the POL  
(Delta SP); 
- the number of all possible hydrogen bonds between the #H-A of the API and #H-D of 
the POL (API#H-A*POL#H-D); 
- the number of all possible hydrogen bonds between the #H-D of the API and #H-A of 
the POL (API#H-D* POL#H-A); 
- the sum of the latter interactions [(API#H-A*POL#H-D)+(API#H-D* POL#H-A)]; 
- the number of all possible hydrogen bonds between the API and the POL together with 
all possible hydrogen bonds of the API-API and the POL monomer-monomer self-
association [[API #H(A*D)]* [POL #H(A*D)]].  
The experimental data consisted of parameters gathered from the literature on ASDs, 
namely the API drug load in formulation, the dose of API given to the animal model to perform 
the in vivo studies, and in vivo PK parameters, such as AUC, Cmax and tmax. To perform the 
analysis with “gaining-factors” the PK parameters were normalized by calculating the ratio 
between AUCASD, Cmax, ASD and tmax, ASD obtained for the ASD and AUCref, Cmax, ref, tmax, ref 
obtained for the reference product (e.g. pure crystalline drug, drug-polymer physical mixture 
or commercial product). These values were further converted into a logarithmic scale, due to 
the large variance observed among observations. In the cases where the PK parameters were 
not tabulated in the respective references, these had to be taken from graphical data, using the 
Engauge Digitizer software [31]. There were also a few cases where a graphic was not available 
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and only the AUC values were reported. As such Cmax and tmax were considered as missing 
values. 
 
3.2.3 Statistical analysis  
In order to extract correlations from the large dataset constructed, multivariate data 
analysis tools were used. The principal components analysis (PCA) and the partial least squares 
(PLS) method enable the reduction in size of the dataset, by creating new variables, known as 
principal components (PCs), which consist in linear combinations of the original variables. 
PCA and PLS models were developed using SIMCA-P+ 13.0 software (Umetrics, Sweden). All 
variables from the dataset were mean centered and scaled to unit variance before the effective 
analysis, in order to give variables equal weight.  
A PCA was first performed in order to get an overview of the dataset. This overview 
helps to visualize whether the observations were well distributed or grouped together, to 
evaluate preliminary correlations between observations and variables, and to identify potential 
outliers. Outliers typically show up outside the 95% confidence interval/ellipse represented in 
the score plot [32]. The dataset included all molecular descriptors and experimental data, as 
PCA does not make any differentiation between independent and dependent variables.  
Figure 3.1 serves as good schematic representation of the dataset considered for the PCA 
analysis. 
As a second stage of the analysis, PLS models were developed to find correlations 
between the molecular descriptors (independent variables or X-variables) and the in vivo PK 
parameters, namely log AUCratio, log Cmax, ratio and log tmax, ratio (dependent variables or Y-
variables). The dataset was divided in a training set and a test set. The training set was used to 
calibrate the model, while the test set served to validate the latter. The test set corresponded to 
1/3 of the number of observations [33], and was randomly selected within the range of the 
dataset. To assess the performance of the PLS model, statistical parameters such as the 
coefficient of determination (R2) and the cross-validation parameter (Q2) were considered. Q2 
is obtained from the cross-validation method, specifically the leave-1/7th-out default method of 
SIMCA-P. The optimal number of PCs of the PLS model was determined based on the 
maximization of both R2 and Q2. Variable selection, or the elimination of non-important 
descriptors, was performed to maximize model performance, minimize prediction error, and 
avoid overfitting. 
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3.3 Results and Discussion 
 
3.3.1 Dataset overview by Principal Components Analysis (PCA) 
 
The result of a PCA is typically displayed graphically by means of two plots, i.e. the 
score and the loading plots. Both plots are complementary and should be analyzed 
simultaneously, in order to extract as much information as possible. While the score plot 
represents a summary of the correlations among observations (or ASDs), the loading plot 
displays the correlations among variables (i.e. molecular properties and experimental data) and 
may serve as a means to interpret the patterns in the score plot. The analysis of the score plot is 
also useful for the detection of outliers.  
In a first PCA of the dataset, an outlier was identified. Observation #6 (i.e. TCL-HPMC 
E5) showed up outside the 95% confidence ellipse in the score plot (Figure B.1, in 
Supplementary Information B). The reason for this observation being an outlier was due to the 
API - Tacrolimus - that has certain molecular properties significantly different from the other 
APIs considered. This analysis was made via the contribution plot shown in Figure B.2, in 
Supplementary Information B.  This ASD was then removed from the dataset and a new PCA 
generated. 
The second PCA of the dataset, with two PCs, was capable of describing 44% of the 
total variance (R2) in the dataset. Figure 3.2A shows the respective PCA score plot. As can be 
seen, no additional outliers were observed. The observations were colored according to the type 
of POL used to stabilize the amorphous drug. It can be observed different ASDs groups 
correspondent to the different POL classes. For example, ASDs that considered the 
methacrylate-based polymer Eudragit® E100 were located in the lower right quadrant, together 
with the ASDs based on Soluplus® and some based on PVP polymer. In contrast, in the lower 
left quadrant appeared the ASDs that used PVPVA as the polymer, while the upper left quadrant 
was exclusively populated with cellulose-based polymers.  
Figure 3.2B shows the PCA loading plot that is complementary to the score plot. The 
variables were also colored, in this case according to the type of variable, i.e. molecular 
descriptors for the APIs, POLs, API-POL interactions and experimental variables. 
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A. 
 
B. 
 
 
Figure 3.2. Score plot (A) and loading plot (B) of the two first PCs of the PCA dataset. In the score plot, 
each number identifies an ASD (Table 3.1); the color identifies the POL class, correspondent to the type 
of POL used to produce the ASD; observations identified with a red circle correspond to the ASDs 
identified with an asterisk (*) in Table 3.1. Loading plot: the color identifies the molecular descriptors 
correspondent to the APIs, POLs, APIxPOL interactions and experimental data taken from the literature. 
 
 
Variables contributing with similar information were grouped together, which means 
that they were correlated. For example, the variables API log P and API log D at pH 5.5 and 
7.4 that can be observed in the upper right quadrant, were grouped together for reflecting drug 
lipophilicity. Parameters describing the size of the APIs and POLs, such as MW and MV were 
also correlated. Correlated key parameters representing cohesive energy (e.g. API TM, API SP 
and POL SP) appeared close to parameters representing the number of potential hydrogen 
bonds, namely API and POL #H-A, #H-D, #H-total, API PSA and interactions thereof. Among 
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the experimental variables, the in vivo PK parameters presented, as expected, higher correlation 
between each other, than the correlation with formulation-related parameters such as API load 
or in vivo dose. Moreover, PK parameters seem to be more correlated with API variables, than 
POL variables.  
The distance of a variable (or group of variables) from the plot origin also provides 
insight on the impact of that variable on the PCA analysis. The higher the distance from the 
origin, the stronger the impact of that variable on the PCA. Most of the variables that were 
observed on the peripheral area of the plot were related with the number of possible hydrogen 
bonds and the API descriptors for lipophilicity.  
The loading plot is also useful to understand the patterns shown in the score plot, since 
the position of the variables in the former links to the position of the observations in the latter. 
When comparing the loadings with the scores in Figure 2A, the correlation that stood out was 
that the number of possible hydrogen bonds was highly correlated with cellulose-based ASDs. 
In fact, polymers like HPMC, HPMCAS, HPMCP, are semi-synthetic macromolecules based 
on natural cellulose as the monomer unit, with varying degree of methyl and/or hydroxypropyl, 
acetate and/or succinate, and/or phthalate substitutions, respectively [34]. These groups possess 
high hydrogen bond acceptor and donor capability.  
 
3.3.2 Finding correlations between molecular descriptors and ASDs in vivo performance 
using Partial Least Squares (PLS) modeling 
 
After the preliminary analysis with PCA, from which it was possible to obtain a first 
overview of the dataset and identify outliers, a PLS model was developed in an attempt to 
establish correlations among the molecular descriptors and the in vivo responses (or Y-
variables), namely log AUCratio, log Cmax, ratio and log tmax, ratio. As it was observed that the Y-
variables were relatively close to each other in the PCA loading plot (Figure 3.2A), meaning 
that a certain level of correlation exist among the latter, a PLS model with multiple responses 
was developed. Indeed, the strategy of modeling multiple correlated dependent variables should 
be considered not only because the correlations stabilize the model but also it provides a broader 
and simpler perspective than separate models for each response [32].  
A first PLS model considering the three PK parameters (i.e. log AUCratio, log Cmax, ratio 
and log tmax, ratio) was developed. The PLS yielded a one-component model, but with R
2 and Q2 
values significantly below the recommended guidelines for QSAR modeling, even after 
variable selection. In QSAR modeling, obtaining a R2 and a Q2 around 0.78 and 0.65 
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respectively is considered a good model [35]. Thus, a second PLS model considering only two 
PK parameters (i.e. log AUCratio and log Cmax, ratio) was developed. A two-component model 
with an R2 of 0.7 and Q2 of 0.5 was obtained after the variable selection. The accuracy and 
applicability of a predictive model is highly dependent on the quality of the dataset. Given the 
existing uncontrolled variability in the data - in vivo data obtained from disparate sources and 
different animal models - the PLS model obtained is considered adequate, at least, for 
interpretation purposes.  
To further evaluate the model, Figure 3.3 shows the observed versus predicted plot 
obtained for each dependent variable, together with the predictions obtained for the external 
test set. The use of an independent test set of observations is often referred to as external 
validation as opposed to the internal validation, which corresponds to the method of cross-
validation. 
 
A 
 
B 
 
 
Figure 3.3. Observed data versus predicted data by the PLS model. A – log AUCratio response; B - log 
Cmax, ratio response; training set (red circles); prediction set (blue circles). The numbers identify the ASDs 
(Table 3.1). 
 
Ideally, the data should be close to and symmetrically distributed along the y=x line. A 
higher correlation between the observed and predicted values was observed for the log AUCratio 
response when compared with log Cmax, ratio response. In terms of the error of prediction (i.e. 
RMSEP in log10 units) both models yielded similar values.  
Figure 3.4A shows the loading plot for the two-component PLS model developed, and 
Figure 3.4B shows the variable importance plot (VIP), which shows the variables by descending 
order of influence in the model. The loading plot shows the relationships between the inputs 
and output variables simultaneously. Results from the loading plot can be interpreted as an 
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“optimization” exercise, i.e. we can evaluate which combination of independent variables may 
guide the production of an ASD with both high log Cmax, ratio and high log AUCratio. In this 
respect, all variables projected on the left quadrants of the loading plot should be increased, and 
the ones that appeared diagonally opposite, should be decreased. According to the VIP plot in 
Figure 3.4B, the most important variables for the model included API-related molecular 
descriptors, followed by POL-related molecular descriptors and API-POL interaction variables. 
This result was aligned with the fact that the global in vivo performance of an ASD is 
not only dependent on formulation-related parameters. The presence of the POL and its capacity 
to sustain supersaturation will only influence the drug absorption process. Besides absorption, 
there are other pharmacokinetic stages that highly influence the final performance, such as drug 
distribution and elimination. These processes are highly dependent on the drug 
physicochemical properties.  
As can be seen in Figure 3.4B, API MV, API #rotbonds and API MW resulted as the 
top-3 variables with higher influence on the model. The positive strong correlation observed 
between these parameters and in vivo performance is somehow difficult to understand. On one 
hand, it is known that bioavailability is negatively related to molecular size, as it impacts 
membrane permeability, and on the other hand, reduced molecular flexibility was found to be 
an important predictor of oral bioavailability in rats [36]. Other API variables such as API  
log D and log P, also presented positive influence on the model. Lipophilicity is known to be 
positively correlated with permeability for drugs that are absorbed by passive diffusion [37]. 
However, in this dataset there are certainly APIs whose absorption is not only mediated by 
passive diffusion, but also by active transport. API Trg, API PSA and API TM were the third 
group of API variables that were found to have a positive influence on the model. The API Trg 
variable is related with glass stability and molecular mobility of the amorphous state. This 
variable may be related with in vivo performance in the sense that the higher the stability of the 
amorphous form, the lower the potential for drug precipitation and consequently higher 
exposure. API PSA and API TM are also difficult to explain in the sense that molecules that are 
highly polar and with high lattice energy exhibit solubility- and permeability-limited 
absorption.  
Among the POL variables, the ones that demonstrated higher influence on the model 
included POL #H-A and POL#H-total, followed by POL #H(A*D), POL #H-D, and POL SP 
as the polymer variable with lower influence. 
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Figure 3.4. PLS loading plot (A) and correspondent variable importance plot (B). The color identifies 
the molecular descriptors correspondent to the APIs, POLs, API-POL interactions and dependent 
variables. 
 
This result highlights the big influence of hydrogen bonding on ASDs performance. 
Still, one should not neglect the importance of other type of interactions, such as ionic 
interactions, that are not being captured in any of the molecular descriptors considered. 
Regarding the positive correlation of POL SP with in vivo ASDs performance. The SP gives an 
idea of the cohesive energy of a molecule, and according to Ilevbare et al., the higher the SP of 
a POL the more hydrophilic it is [38]. Ilevbare et al. identified the POL SP as the most important 
variable to inhibit crystal growth of ritonavir in solution. The authors also stated that good 
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polymeric precipitation inhibitors should present a good hydrophilic/hydrophobic balance. 
POLs that are more hydrophilic (high SPs) would be expected to interact more favorably with 
the solvent molecules than with the API, while more hydrophobic polymers (low SPs) would 
have a higher tendency for self-association. This result remains to be fully elucidated. 
Among the interaction variables, the one presenting the highest influence on the model 
was MVPOL/MVAPI. The particularity of this variable was that it was the only one that appeared 
to negatively influence in vivo performance. MVPOL/MVAPI was included as an interaction 
variable as a measure of the relative size of the POL to that of the API, and to evaluate whether 
this discrepancy in sizes would influence the performance. The result indicated that, the higher 
the MV of the POL to that of the API, the worse the in vivo performance. This seem to be 
counter-intuitive in the sense that, at a first glance, the greater the difference of API-POL size, 
the lower diffusion of the former in relation to the latter. Thus, the lower the diffusion of the 
API, higher polymeric stabilization, lower potential to recrystallize and higher in vivo 
performance. Other interaction variables such as API #H-A*POL #H-D and (API #H(A*D))* 
(POL #H(A*D)) presented a positive influence in the model. The former variable further 
emphasized the importance of hydrogen bonding for the optimization of performance, while 
the latter was an attempt to account for API and POL self-association and API-POL interaction 
at the same time. However, the interpretation of this variable is not straightforward.    
Lastly, Figure 3.5 shows two scatter plots of two important variables for the model - 
API #H-A*POL #H-D versus POL SP. The size of each point/observation corresponds to the 
log AUCratio and log Cmax, ratio, which can also be regarded as a “gaining-factor”. The 
observations were colored according to the POL class. The importance of hydrogen bonding 
for improving the in vivo performance of ASDs was in line with the observation that polymers 
with higher solubility parameters also tend to contribute for higher AUCs. In general, cellulose-
based polymers (i.e. HPMCAS, HPMC, HPMCP) seem to provide better precipitation 
inhibition across different classes of APIs, when compared with other polymer families.  
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B. 
 
 
Figure 3.5. Scatter plots of two important variables for the model. The size of the points/observations 
represent the AUC (A) and Cmax (B) gains. The colors represent the different POL classes. 
 
3.4 Conclusions 
 
In this work, multivariate data analysis was applied to assess correlations between 
molecular descriptors of the ASDs formulation ingredients and performance related output 
variables, namely AUCin vivo and Cmax, in vivo. Although the interpretation of some of the 
correlations obtained was not straightforward, it was possible to obtain general performance 
trends. It was found that hydrogen bonding capacity plays a key role in the optimization of 
ASDs performance and that cellulose-based polymers are general good precipitation inhibitors 
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among different APIs classes. Still, the accuracy of a predictive model is highly dependent of 
the size and diversity of the dataset and the quality of the molecular descriptors selected. By 
addressing some of these limitations in the future, it is believed that the model will become a 
useful computational tool for narrowing the polymers to be further explored, in terms of their 
capacity to improve amorphous dispersions in vivo performance. A proposed workflow 
demonstrating the implementation of this methodology is shown in Figure 3.6. 
 
            
 
 
Figure 3.6. Workflow showing the application of the PLS model as a screening tool for development of 
amorphous systems. 
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4 Production of nano-solid dispersions using a novel solvent-controlled 
precipitation process – benchmarking their in vivo performance with an 
amorphous micro-sized solid dispersion produced by spray drying. 
 
4.1 Introduction 
 
The focus of this work was the development of alternative, reproducible and cost-
effective co-precipitation processes, suitable to produce ASDs with unique characteristics. In 
this regard, a novel SCP process that uses microreaction or microfludization to fine control 
supersaturation and precipitation was assessed. This technology involves high shear, 
continuous fluid processing through a fixed geometry microreactor that provides intense and 
uniform micro- to nanomixing [1]. Considering that critical process parameters of the SCP 
process include mixing time and temperature, the micro/nano mixing provided by the micron-
sized channel diameter of the microreactor, not only minimizes diffusion limitations between 
the solvent and anti-solvent streams, thus significantly-reducing mixing times, but also provides 
excellent heat exchange, due to the large surface-to-volume ratio. This system when compared 
with the use of high shear mixers enables the generation of nano to microparticles in a single 
passage through the microreactor, with a greater control over the particle size distribution, as 
well as a greater solid-state stability of the particles produced. The possibility of producing 
nanoparticles by microfluidization leads consequently to an increase of the specific surface 
area, which is also an advantage in terms of dissolution rate. 
This work was divided in two main parts. First, a half-factorial experimental design was 
conducted to study the effect of formulation variables (viz. polymer type, drug load, and feed 
solids’ concentration) on typical critical quality attributes (CQAs) of solid dispersions, namely 
particle size/morphology and drug’s solid state and drug’s molecular distribution within the 
carrier. Six different suspensions were produced using the SCP process presented, following by 
spray drying to isolate the particles from the liquid medium. As the second part of the work, the 
drug-polymer system that demonstrated higher flexibility in terms of its capacity to form both 
amorphous and crystalline solid dispersions, under the formulation and process conditions 
tested, was pursued for in vitro dissolution and in vivo bioavailability evaluation, as well as 
long-term stability evaluation. For benchmarking purposes, an ASD of this exact formulation 
was also produced by spray drying and tested. Carbamazepine (CBZ) was selected as the model 
drug to conduct this feasibility study. CBZ is categorized as BCS Class II or more specifically 
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Class IIa, according to the recent Developability Classification System (DCS) [2]. DCS Class 
IIa compounds present dissolution-rate limited absorption. 
 
4.2 Materials and Methods 
 
4.2.1 Materials 
 
4.2.1.1 Chemicals 
Crystalline carbamazepine (CBZ, anhydrous Form III, purity > 97%) was purchased 
from TCI Co., Ltd. (Tokyo, Japan). Two commercially available polymers with different 
chemical and physical properties were selected: 1:1 methacrylic acid and methyl methacrylate 
co-polymer (Eudragit® L100, Evonik Röhm GmbH, Darmstadt, Germany) and 
hydroxypropylmethylcellulose acetate succinate (HPMCAS grade MG, AQOAT®, Shin-Etsu 
Chemical Co., Ltd., Tokyo, Japan). The solvent and anti-solvent used were methanol (MeOH) 
and deionized water, both of analytical grade. 
 
4.2.1.2 Animals 
Adult CD1 female mice (22-24 g) were purchased from Charles River (Barcelona, 
Spain). Animals were fed with standard laboratory food and water ad libitum. All animal 
experiments were carried with the permission of the local animal ethical committee, and in 
accordance with the Declaration of Helsinki, the EEC Directive (2010/63/UE) and Portuguese 
Law (DL 113/2013, Despacho nº 2880/2015), and all following legislation for usage of animals 
in research. 
 
4.2.2 Methods 
 
4.2.2.1 Design of experiments (DoE) 
A half-factorial design 23-1 plus 2 central points conducted to study the effect of 
formulation variables on critical quality attributes (CQAs) of solid dispersions produced 
through an alternative SCP process are described in Table 4.1 and Figure 4.1. The formulation 
variables and ranges studied were: the type of polymeric stabilizer (Eudragit® L100 or 
HPMCAS-MG), the drug load in the solid dispersion (20 to 60 wt.%), and the feed solids 
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concentration (C_feed, 2 to 8 wt.%). The CQAs evaluated were: solid-state and physical 
stability (upon preparation and 30 and 90 days under stress storage conditions), particle size 
and morphology, in vitro dissolution and in vivo bioavailability. 
 
Table 4.1. Experimental design for the SCP study. 
Exp. 
Number 
Polymer Type 
Drug load 
(wt.%) 
Feed solids’ concentration 
(C_feed / wt.%) 
1 HPMCAS-MG 20 2 
2 HPMCAS-MG 40 5 
3 HPMCAS-MG 60 8 
4 Eudragit® L100 20 8 
5 Eudragit® L100 40 5 
6 Eudragit® L100 60 2 
 
 
Figure 4.1. Representation of the experimental design for the SCP process study. 
 
4.2.2.2 Solvent controlled precipitation (SCP) process 
Six solutions of CBZ and each polymer were prepared in MeOH (solvent) for a total 
weight of solids of 3 g. The weight proportion between the components and the solids 
concentration in solution are described in Table 4.1. As anti-solvent, a mass of deionized water 
corresponding to 10 times that of the solvent was used. The water was acidified until pH=2 
using a 37 wt.% hydrochloric acid solution and its temperature was maintained around 5 ºC, for 
the lowest solubility of both components.  
Solvent controlled precipitation (SCP) experiments were undertaken using PureNano™ 
Microfluidics Reaction Technology (MRT, CR5 Reactor model) whose setup is schematically 
represented in Figure 4.2. The solvent and anti-solvent streams were fed to an intensifier pump 
at individually controlled rates. The intensifying pump was set to impose a pressure of 
approximately 1379 bar (20 kPsi, maximum processing pressure). While the anti-solvent stream 
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was gravity fed, the peristaltic pump of the solvent reservoir was set to maintain a ratio of 1:10 
of solvent and anti-solvent (~ 50 mL of solvent/min). Then, both streams were pressurized in a 
combined stream within the intensifier pump, and delivered to an interaction chamber with 75 
µm diameter reaction channels (F20Y) followed by an auxiliary processing module with 200 
µm diameter reaction channels (H30Z). After the interaction chamber, the suspension passed 
through a heat exchanger (ice water bath). One single passage through the processor was 
considered for all experiments. Following this process step, the suspensions were dried in a lab-
scale spray dryer, for particle collection. 
 
 
 
 
 
 
 
 
 
Figure 4.2. Representation of the solvent/anti-solvent controlled precipitation process, followed by the 
isolation step in a spray dryer. 
 
4.2.2.3 Spray drying 
A laboratory scale spray dryer (BÜCHI Mini Spray Drier B-290, Switzerland), equipped 
with a two fluid nozzle, was used to dry (1) all the suspensions produced by SCP and (2) a 20 
wt.% CBZ: Eudragit® L100 homogenous solution, at 8 wt.% solids concentration. In both 
situations the unit was operated in open cycle mode, i.e. without recirculation of the drying gas. 
Before feeding the suspensions/solution to the nozzle, the spray dryer was stabilized with 
nitrogen to assure stable inlet and outlet temperatures (T_in and T_out, respectively). In the 
case of the suspensions produced by SCP the temperatures were optimized to dry a water 
suspension (T_in=156 ºC, T_out=80 ºC), while for the SD of the solution the temperatures were 
set to dry a methanolic solution (T_in= 65ºC and T_out=40ºC). After stabilization, the 
suspensions/solution were fed to the nozzle by means of a peristaltic pump (F_feed=0.81 kg/h), 
and atomized at the nozzle’s tip (atomization nitrogen, F_atom=1.4 kg/h). The suspensions 
were kept under magnetic stirring, during spray drying. The droplets were then dried in the 
spray drying chamber by a co-current nitrogen stream (F_drying=40 kg/h). The stream 
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containing the dried particles was directed into a cyclone and collected at the bottom.  
The collected powders were post-dried in a tray dryer oven under vacuum at 45 ºC for 
approximately 12 h. 
 
4.2.2.4 Modulated differential scanning calorimetry (mDSC) 
Thermal analysis experiments were performed in a TA Q1000 (TA Instruments, New 
Castle, Delaware, USA) equipped with a refrigerated cooling system after calibration with 
indium. The samples were analyzed in pinholed DSC aluminum pans and under continuous dry 
nitrogen purge (50 mL/min). Samples, weighing between 5 to 10 mg, were analyzed using a 
modulated heating ramp from -10 °C to 250 °C at a heating rate of 2 °C/min using a period of 
60 s and and amplitude of 0.32 °C.  
Data was analyzed and processed using the TA Universal Analysis 2000 Software (TA 
Instruments, New Castle, Delaware, USA). The glass transition temperature (Tg) was taken as 
the inflection point in the heat capacity change (ΔCp) observed in the reversible heat flow, while 
exothermic and endothermic peaks were identified in the non-reversible and total heat flows. 
 
4.2.2.5 X-ray powder diffraction (XRPD) 
XRPD experiments were performed in a D8 Advance Bruker AXS θ/2θ diffractometer 
with a copper radiation source (Cu Kα, wavelength = 1.5406 Å), voltage 40 kV, and filament 
emission 35 mA. The samples were measured over a 2θ interval from 3 to 70º with a step size 
of 0.017º and step time of 50 s.  
 
4.2.2.6 Scanning Electron microscopy (SEM) 
To obtain the micrographs, samples were attached to adhesive carbon tapes (Ted Pella 
Inc., CA, USA), previously fixed to aluminum stubs where the powder in excess was removed 
by a jet of pressurized air. The samples were left in vacuum for 2 hours and then coated with 
gold/palladium (South Bay Technologies, model E5100, San Clement, CA). A JEOL JSM-
7001F/Oxford INCA Energy 250/HKL scanning electron microscope (JEOL, Tokyo, Japan) in 
high vacuum operated at a typical accelerating voltage of 15 – 20kV. Micrographs were taken 
at various magnifications, ranging from 1500x up to 40,000x.  
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4.2.2.7 Particle size  
The particle size of the dried powders, expressed as the mean circular diameter, was 
determined by image analysis using the ImageJ software (National Institute of Health, 
Bethesda, MD, USA) from around 200 randomly selected particles, which demonstrated a 
normal distribution of sizes. The parameter “circular diameter” is the diameter of a circle having 
the same area of the manually selected particle in the SEM image. 
 
4.2.2.8 Surface area determination  
The specific surface area of the samples was determined using an ASAP 2000 
equipment (One Micromeritics Drive, Norcross, GA, USA). A six-point Brunauer-Emmet-
Teller (BET) method from the nitrogen adsorption analysis was performed after degassing the 
samples with helium (purity >99,5%) until a stabilized absolute vaccum below 15 μm of 
mercury at 25ºC was reached. Sample weight after degassing was around 200 mg. The 
adsorbate used was nitrogen (purity >99.9%) and the specific surface area was determined in 
the relative pressure (P/P0) range of 0.05 to 0.30, with an equilibration time of 5 sec, allowing 
the determination of pore diameters between 300 nm to 1.7 nm. 
 
4.2.2.9 Evaluation of the stability of the amorphous powders 
Samples were placed in open Petri dishes at 25ºC/60% RH and 40ºC/75% RH. To create 
these storage conditions, glass desiccators with oversaturated salt solutions were prepared and 
conditioned at the desired temperatures (tray dryer oven and room temperature). Samples were 
removed and analyzed by XRPD after 30 and 90 days after storage. 
 
4.2.2.10 High performance liquid chromatography (HPLC) 
The quantification of CBZ was performed using a Waters HPLC system (model 2695) 
with a dual wavelength absorbance detector (model 2487) (Waters, Milford, MA, USA). The 
column used was a Zorbax® XDB - C18 (4.6 mm × 150 mm, 3.5 µm) and the mobile phase was 
a 60:40 vol.% of methanol and water. The injection volume was 10 µL and the isocratic flow 
rate was maintained constant at 1 mL/min. The CBZ UV absorbance was measured at λ=285 
nm. The temperature of the column was maintained at 25◦C. The chromatographs were 
collected and the areas under the peaks integrated using Empower Version 2.0 (Waters, Milford, 
MA, USA). 
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4.2.2.11 Drug content in solid dispersions 
The drug content in the solid dispersions that were considered for in vitro dissolution 
and in vivo bioavailability were assayed according to the HPLC method described in Section 
4.2.2.10. Concentrated stock solutions of the respective solid dispersions in MeOH were 
prepared. Standard solutions with a target CBZ concentration of 10 ug/mL were prepared by 
diluting an aliquot of each concentrated stock solution in MeOH prior to analysis. The 
quantification was performed against a single-point external standard of pure CBZ in MeOH 
(10 µg/mL). 
 
4.2.2.12 In vitro dissolution studies 
Powder dissolution profiles were obtained using a microcentrifuge dissolution method 
[3,4]. The experiments were conducted in 2 mL microcentrifuge tubes in a 37ºC temperature 
water bath. The simulated gastric phase consisted of 0.9 mL of 0.01 N HCl (pH=2) and the 
simulated intestinal phase consisted of an additional volume of 0.9 mL of FaSSIF biorelevent 
media (pH=6.5) (Biorelevant.com, Croydon, Surrey, UK). Both media were degassed and 
preheated to 37 °C prior to use. The dissolution experiments were performed with a target drug 
load of 850 µg of CBZ, which corresponded to approximately 5 and 2 times the concentration 
at equilibrium of CBZ in the gastric and intestinal phases, respectively. Samples were taken at 
various time points (10, 20, 35, 60, 90, 150 and 180 min) with no dissolution medium 
replacement. The pH-shift occurred at the 50-min time point. The preparation of the test tubes 
for sampling consisted of removing the latter from the water bath and centrifuged using a Himac 
Microcentrifuge CT15RE (Hitachi Koki Co, Ltd, Tokyo, Japan) for 1 min at 13,000 rpm. Then, 
25 μL of the supernatant was aliquoted, but only 10 μL was diluted 15-fold in methanol in a 
HPLC vial with low volume insert (150 μL). The solutions remaining in the test tubes were 
vortexed for a few seconds until total redispersion of the sediments was observed. The test tubes 
were placed back in the water bath until the next time point.  
The amount of drug in the samples was measured by HPLC according to the method 
described in Section 4.2.2.10, against a single-point external standard of pure CBZ in 1:15 v/v 
FaSSIF:MeOH (20 μg/mL). 
The area under the dissolution curves (AUCs) for the total dissolution tests was 
calculated by the linear trapezoidal method.  
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4.2.2.13 In vivo pharmacokinetic studies 
On the day of administration, the animals were fasted for approximately 6 h before the 
beginning of the experiments. This period was considered sufficient for the emptying of the 
stomach of mice [5]. The mice were dosed by oral gavage with an equivalent amount of each 
formulation to provide 7.4 mg/kg body weight of CBZ (n=3, except otherwise stated). The 
vehicle was acidified water (0,01N HCl, pH~2) and the concentration of the suspension was 
adjusted in such way that an appropriate dose was present in 0.35 mL of the suspension. By an 
appropriate dose means a dose not too low which will then impact with drug detection, but not 
excessively high in order to have a homogenous suspension for administration. Moreover, being 
the stomach capacity of a mouse approximately 0.4 mL, 0.35 mL was considered an ideal oral 
dosage volume to not overload the stomach capacity and/or avoid reflux into the esophagus [6]. 
The time interval between suspension preparation and dose administration was around 30 s. 
After administration, mice were kept in restraining cages, with free access to water. 
Blood samples (~ 1 mL) were collected from the orbital sinus at 2, 5, 10, 15, 30, 45, 60, 
120 and 180 min post administration. The blood samples were centrifuged, and the serum 
samples were refrigerated until the assay. 
 
4.2.2.14 Bioanalytical method 
The concentration of CBZ in the serum was assayed using an IMMULITE 2000® XPi 
Immunoassay System (Siemens Healthcare Diagnostics, Erlangen, Germany). This system 
combines chemiluminescence and immunoassay reactions (i.e. solid-phase, competitive 
chemiluminescence enzyme immunoassay). The assay is based on the measurement of light 
emission produced by dephosphorylation of a substrate, which is directly conjugated to the 
drug in the sample. Thus, the light produced by the reaction is proportional to the amount of 
drug in the sample.  The lower limit of quantification (LOQ) of the immunoassay method was 
1.25 μg/mL.  
 
4.2.2.15 CBZ extraction of serum samples  
Pre-selected serum samples with an amount of drug below the LOQ of the bioanalytical 
method described above were treated by a liquid-liquid extraction method and assayed by 
HPLC (Section 4.2.2.10).  
Aliquots of serum were transferred to 2 mL microcentrifuge tubes. Methanol in a ratio 
of 1:4 v/v was then added to each tube and vortex mixed for 5 min. White-opaque solutions 
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were formed due to precipitation of water-soluble proteins. The samples were then centrifuged 
using a Himac Microcentrifuge CT15RE (Hitachi Koki Co, Japan) at 2,000 rpm for 5 min. The 
supernatants were extracted and directly transferred to HPLC vials with low volume inserts 
(150 μL). The quantification was performed against a single-point external standard of pure 
CBZ in MeOH (1 μg/mL) that was prepared from dilution of a more concentrated stock standard 
(1 mg/mL of CBZ).  
The average yield of extraction when applying the extraction method to samples with 
CBZ, i.e. samples that were above the LOQ of the immunoassay method, was around 60%. 
 
4.3 Results and Discussion  
 
4.3.1 Part I - Experimental Design 
 
This study proposes an alternative SCP process (Figure 4.2) based on microfluidization 
to produce solid dispersions.  
In the first part of this work, six spray-dried co-precipitated powders were obtained and 
were characterized in terms of particle size and morphology as well as the drug’s solid state and 
molecular distribution within the carrier.   
 
4.3.1.1 Particle size and morphology of the spray-dried co-precipitated particles 
The SEM results obtained for the different spray-dried co-precipitated products 
according to the DoE conducted (Figure 4.1) are present in Figure 4.3.  
Spherical particles were generally obtained among all the formulations tested. These 
results were expected as spray drying was the technology chosen to isolate the particles in 
suspension, after co-precipitation [7,8].  
When analyzing the particles at higher magnifications, the observation of the surface of 
the particles revealed that the latter were aggregates of individual particles, most of them within 
the submicron range and with a mean circular diameter around 100 nm. These results lead us 
to two important conclusions: first, the final suspensions obtained after the SCP process were 
nanosuspensions, that following drying aggregated as nano-composite particles; second, these 
nanoparticles were compact, while e.g. the microparticles of vemurafenib produced via SCP 
using high shear mixing were highly porous, meaning that the thermodynamics of mixing 
Chapter 4 
 
102 
between the components (i.e. drug-polymer-solvent-anti-solvent) and the kinetics of 
precipitation played a major role in the type of particulate structure obtained. 
 
           
 
Figure 4.3. SEM micrographs corresponding to Tests 1, 2, 3 and Tests 4, 5, 6 of the DoE conducted. 
The micrographs on the back were taken at 1500x magnification, while the inserts were taken at 5000x 
magnification. 
 
In fact, and as far as liquid-liquid demixing of polymeric solutions is concerned, whether 
precipitation occurs via nucleation and growth or spinodal decomposition, different co-
precipitated structures can be obtained [9,10]. For example, precipitation path A typically 
results in porous structures (Figure 4.4), due to the nucleation and growth of droplets of 
polymer-poor phase in a polymer-rich phase. By opposition, in case of precipitation path B, 
nucleation and growth of droplets of the polymer-rich phase in a polymer-poor phase occurs. 
Particulate structures are typically obtained when following this path.   
It was also interesting to observe that these submicron particles obtained from the two 
CBZ-based formulations tested presented different shapes which were more pronounced for 
lower drug loads. For instance, when comparing the images of Tests 1 and 4, the former 
demonstrated more filamentous-like particles entangled with spherical particles, while the latter 
showed a higher number of spherical aggregates composed of easily distinguishable 
nanoparticles. Possible reasons for these differences may be related with the different 
precipitation paths followed in the ternary diagram as previously explained and/or the presence 
of crystalline material in the CBZ: HPMCAS-MG samples, according to the solid-state and 
physical stability results, demonstrated in the following Section 4.3.1.2. 
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Figure 4.4. Representation of a hypothetical ternary phase diagram for the system polymer-solvent-anti-
solvent, indicating two possible precipitation paths (A and B) and respective polymeric structures 
obtained. 
 
When increasing the drug load of both formulations, i.e. from 20% to 40% and then  
60% of CBZ, it was observed that particle aggregation between nanoparticles increased from 
Tests 2 and 5 and then Tests 3 and 6, leading to the overall reduction of the surface area-to-
volume ratio of the co-precipitated particles produced. Indeed, aggregation of nanoparticles 
during the isolation step, either using spray drying or freeze-drying, is a major concern reflected 
in the literature [7,11,12]. If nanoparticles form aggregates, this may compromise the 
redispersibility of these powders upon contact with the aqueous medium, thus neglecting the 
dissolution-rate gain and ultimately the enhancement of the bioavailability. The results obtained 
suggested that the level of aggregation was mainly dependent on the drug load in formulation 
or, in other words, in the amount of polymeric stabilizer presented. This again links with the 
mechanisms of nucleation and growth of polymer-poor and polymer-rich phases, as explained 
above. Moreover, this result is aligned with the findings in the literature, which describe as 
important formulation variables to overcome drying induced aggregation the addition of one or 
more stabilizers to the suspension before the drying step [7,13], the type of stabilizer selected 
(i.e. ionic versus non-ionic, leading to electrostatic versus steric stabilization) [7,14], the 
distribution of the stabilizer in the formulation (i.e. surface adsorption versus matrix 
distribution) [15,16], and the concentration of the stabilizers [17,18].  
In this work, no significant differences in the aggregation level were observed among 
the polymers tested, apart from the observation of the filamentous-like particles in the CBZ: 
HPMCAS-MG co-precipitated powders. Both HPMCAS-MG and Eudragit® L100 are ionic 
polymers, so can be suggested that electrostatics contributed to the stabilization of the 
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nanoparticles while in the liquid medium. According to Thorat and Dalvi, in the electrostatic 
stabilization mechanism, charged stabilizers cause repulsion between particles due to similar 
charges on particle surface, thus leading to the prevention of aggregation [19].  
Feed solids’ concentration (C_feed) in solution demonstrated to have no effect on the 
level of aggregation, as when analyzing the results of Tests 1 and 6 and Tests 4 and 3, which 
represent the extreme cases in terms of aggregation, these were run at the same C_feed. 
The mean circular diameter results obtained for the different spray-dried co-precipitated 
products are present in Figure 4.5. The mean circular diameter of the aggregated particles 
ranged between 1.14 and 4.58 μm for all the tests performed. However, differences in particle 
size were observed between Tests 1, 2, 3 and Tests 4, 5, 6. In general, from Test 1 to Test 3 an 
increasing number of particles with a larger diameter was observed, while from Test 4 to  
Test 6 it was observed a progressive increase in the number of particles with a reduced diameter. 
The tendencies of the results obtained demonstrated that the particle size of the spray dried co-
precipitated powders was mainly dependent on the feed solids’ concentration in solution, as 
from Test 1 to Test 3 the C_feed increased from 2% to 8%, and from Test 4 to Test 6 the C_feed 
decreased from 8% to 2%. To our best knowledge, no correlations between the C_feed of the 
initial solution prepared for the co-precipitation process and the particle size of the final spray 
dried aggregates have been made in previous research described in the literature. 
 
             
 
Figure 4.5. Mean circular diameter results correspondent to Tests 1, 2, 3 and Tests 4, 5, 6 of the DoE 
conducted. The bars represent the standard deviation. 
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4.3.1.2 Drug’s solid-state and molecular distribution within the co-precipitated particles 
Regarding the drug’s solid-state and molecular arrangement of the six spray-dried co-
precipitated materials produced, these were characterized by XRPD analysis, to evaluate the 
presence of crystalline material, and by mDSC, to evaluate the glass transition temperature (Tg) 
and phase separation phenomena. Amorphous phase separation was defined based on the 
detection of two Tg’s corresponding to the pure components, whereas the detection of a single 
Tg value between the Tg’s of the pure components corresponded to the formation of an 
amorphous and homogenously mixed system (i.e. glass solution). Figure 4.6 shows the XRPD 
diffractograms obtained for the different spray dried co-precipitated products. The data 
associated with the mDSC analysis is available as Supplementary Information C (Table C.1). 
 
                
 
Figure 4.6. Powder diffractograms correspondent to Tests 1, 2, 3 and Tests 4, 5, 6 of the DoE conducted. 
The arrows indicate crystalline peaks with reduced intensity.  
 
Differences in the drug’s solid state and drug’s molecular arrangement were observed 
between the groups of Tests 1, 2, 3 and Tests 4, 5, 6 correspondent to the two CBZ-based 
systems evaluated, i.e. CBZ:HPMCAS-MG and CBZ:Eudragit® L100, respectively, and within 
each group correspondent to the increase of drug load in the formulation, i.e. from 20%, to  
40% and 60% of CBZ. Regarding the CBZ:HPMCAS-MG formulations, it was observed a 
gradual increase in the relative intensity of the characteristic peaks of crystalline CBZ from  
Test 1 up to Test 3, indicating the formation of crystalline solid dispersions. Consequently, and 
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as expected, it was also observed a gradual decrease in the drug amorphous halo’s intensity 
from Test 1 to Test 3. 
A good alignment was observed by comparing these results with the ones obtained from 
the mDSC analysis. Only the 20% CBZ: HPMCAS-MG formulation presented a single Tg 
around 102ºC, a value that was consistent with the mixed Tg obtained using the Gordon-Taylor 
equation (i.e. 106ºC) [21]. In fact, a significant percentage of this product was still amorphous 
and homogenously mixed, as indicated by the absence of any additional or secondary glass 
transition temperature. The thermal evidence of crystalline material in the CBZ: HPMCAS-MG 
formulations was related with the detection of endothermic events within the temperature 
ranges ~150-16ºC and ~188ºC that were coincident with two endothermic peaks characteristic 
of pure CBZ. Pure CBZ, when heated, first presents a polymorphic transformation at 150ºC, 
followed by the melting of the new phase formed at 186ºC [22]. 
Comparing the CBZ: HMPCAS-MG co-precipitated products with the CBZ: Eudragit® 
L100 counterparts, the latter demonstrated to be capable of forming both amorphous and 
crystalline solid dispersions under the formulations and process conditions tested in the DoE. 
According to the XRPD results, Test 4 showed a halo characteristic of the amorphous form with 
no characteristic peaks of the XRPD profile of pure crystalline CBZ being observed in this co-
precipitated product. In terms of thermal behavior only one single Tg was detected, and no signs 
of amorphous-amorphous phase separation were observed. Similarly to Test 1, the Tg value 
obtained for Test 4 was also in agreement with the respective Gordon-Taylor equation (i.e. 
167ºC versus 166ºC, respectively). Eudragit® L100 apart from providing sufficient stabilization 
of CBZ at 20% drug load, and thus enabling the formation of a true glass solution, its high Tg 
(190ºC) also leveraged the Tg of the final mixture to values well above 75ºC, which is an ideal 
situation from a product shelf-life perspective, but also in terms of processability. Test 5 and 
Test 6, correspondent to the 40% and 60% CBZ:Eudragit® L100  formulations, showed 
identical results to Test 2 and Test 3. These co-precipitated products also resulted in crystalline 
solid dispersions of the drug within the polymer, indicated by the presence of the CBZ 
characteristic peaks either in the XRPD diffractograms and mDSC thermal profiles. During 
thermal analysis, it was also detected a single Tg in the reversible heat flow profile of Test 5, 
which was not observed in Test 6.  
From the results obtained it was concluded that different types of solid dispersions, with 
different levels of drug’s molecular arrangement, were capable of being produced using the 
novel SCP process presented in this work. The possibility of producing nano-sized glass 
solutions is of utmost importance due to the potential dual benefit of the high energy amorphous 
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state, which provides an increase on saturation solubility, together with the particle size 
reduction up to the nanoscale, that it is known for having a greater positive impact on the 
dissolution rate. By opposition, producing crystalline nanoencapsulated particles as crystalline 
nano-solid dispersions/solutions offer the advantage of higher drug loadings in the formulation, 
enabling the possibility of decreasing the number of administrations to patients, which can be 
an advantage, namely on increasing patient compliance. Moreover, working with the crystalline 
state can be an advantage in terms of stability during scale-up and downstream processing. 
As the results in this section showed, the selection of the polymeric carrier or stabilizer 
as well as the drug load in formulation are critical formulation variables that will impact the 
type of solid dispersion obtained. The feed solids’ concentration had no effect on this matter, 
as both amorphous and crystalline nano-solid dispersions where obtained from solutions at low- 
and high-level of C_feed (Tests 1 and 6 and Tests 4 and 3, respectively). 
Regarding the polymer type, when considering the production of crystalline solid 
dispersions, the drug’s physical stability aspect is not a major concern and thus both polymers 
evaluated - HPMCAS-MG or Eudragit® L100 - showed to be a viable option to nanoencapsulate 
crystalline CBZ up to high drug loads (60% minimum). In contrast, if the objective is to obtain 
a glass solution, the maintenance of its physical stability either during processing and long-term 
storage are critical factors that must be taken into consideration when choosing the polymer or 
optimizing the drug load, in order to avoid recrystallization. In this case Eudragit® L100 was 
suggested to be a better stabilizing polymeric agent for CBZ to produce glass solutions, when 
compared to HPMCAS-MG. Possible explanations for this difference might be related, among 
others, with the type and strength of interactions that can be established between the hydrogen 
bond acceptor and donors of CBZ and each of the polymers [16] and/or the different Tg’s of the 
polymers that help to increase the overall stability of the amorphous mixture as explained above 
for the case with Eudragit® L100. On the top of these formulation variables, one should not 
neglect the effect of process variables, namely temperature, working pressure and the type of 
interaction chamber that will define the homogenization conditions, the time between the 
production of the suspensions and the isolation step. These are some critical process variables 
that were maintained constant in this work but are known to affect the incorporation of drug 
within the carrier. For example, according to Sertsou et al. although intense mixing and faster 
precipitation is favorable for the creation of the amorphous, increasing mass transfer may also 
lead to a greater polymer’s plasticization and loss of drug as part of the solid dispersion [23]. 
In terms of the influence of the drug load in formulation, obtaining an amorphous or 
crystalline solid solution/dispersion will depend on the equilibrium crystalline drug solubility 
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in the polymer and the maximum drug-polymer amorphous miscibility. These limits are 
typically evaluated by means of the construction of the thermodynamic phase diagrams of the 
drug and the polymer, which include the plot of the binodal and spinodal curves, as 
schematically shown in Figure 4.7. These curves help to define the maximum limits of drug 
that the polymer can “incorporate”, before nucleation and growth or spinodal decomposition 
takes place. The formulator by knowing in which point of the phase diagram is, can define a 
priori a potential range of drug loads to be further evaluated in advanced stages of product 
development, whether their intention is to obtain an amorphous or crystalline solid dispersion. 
 
                  
 
Figure 4.7. Representation of a hypothetical temperature-composition phase diagram for a general drug-
polymer binary system. 
 
4.3.2 Part II - Benchmarking solid dispersions obtained through SCP and SD processes 
 
Following the experimental design, it was defined that the CBZ-based system that 
demonstrated higher flexibility in terms of its capacity to form both amorphous and crystalline 
nano-solid dispersions, under the formulations and process conditions tested in the DoE, would 
follow to part II of this work. According to the results obtained in Section 4.3.1.2, a comparative 
study was then performed using different formulations of CBZ: Eudragit® L100. For the in vitro 
and in vivo performance evaluation, one of the formulations tested was the nano-sized 
amorphous solid dispersion formulation produced by the SCP process (Test 4), hereafter 
defined as NanoAmorphous. In order to study the effect of different surface area-to-volume 
ratios in the dissolution rate of CBZ, a second formulation of 20% CBZ: Eudragit® L100 micro-
sized amorphous solid dispersion formulation was produced by spray drying 
(MicroAmorphous, Supplementary Information C, Figure C.1). Finally, in order to assess the 
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solubility-gain of the amorphous versus the crystalline drug maintaining identical submicron 
particle size and high surface area, a third system consisting of 60% CBZ: Eudragit® L100 
nano-crystalline solid dispersion formulation was produced by the SCP process (Supplementary 
Information C, Figure C.2). This NanoCrystalline formulation was obtained under the same 
experimental conditions of Test 6, but at 8% feed solids concentration to maintain the particle 
size of the spray-dried aggregates. Pure crystalline CBZ was also used, without further 
processing, in the in vitro and in vivo studies. For the powder stability study, only the 
NanoAmorphous and MicroAmorphous powders were considered, in order to assess their 
resistance to recrystallization under temperature and humidity stress conditions. 
 
4.3.2.1 In vitro dissolution  
In the literature a significant number of research papers exist demonstrating the higher 
dissolution rate of nano-composite aggregates obtained from spray-dried nanosuspensions 
when compared with their micro-sized counterparts [7,11,13,23]. Figure 4.8 shows the powder 
pH-shift dissolution profiles, over 180 minutes, for the different CBZ: Eudragit® L100 
formulations, as described above. 
As can be seen from Figure 4.8, powders showed significantly different CBZ release 
profiles once placed in contact with the acidic aqueous medium. As expected, the crystalline 
CBZ reference product was the one that demonstrated a lower dissolution rate. The drug 
dissolved in the medium from pure CBZ crystalline particles was only around 15% in the first 
10 min of testing, reaching its maximum of 20%, after 35 min. This crystalline powder was 
tested unprocessed, thus presenting the largest particle size among all the formulations tested, 
and was used as received, which means no additional wetting agents were added. When 
comparing this dissolution profile with the ones obtained for the NanoAmorphous, 
NanoCrystalline and MicroAmorphous formulations, these powders demonstrated a 2 to 3-fold 
increase in the dissolution rate for the first 10 min of testing. 
There are two important reasons for this difference. The first is related with the fact that 
these latter powders are all solid dispersions, i.e. regardless the drug’s solid state and molecular 
arrangement, the polymeric carrier, in this case Eudragit® L100, is present in the formulation 
and polymers are known for providing an a priori improvement in the wettability of the drug. 
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Figure 4.8. Powder dissolution profiles correspondent to the formulations NanoAmorphous (20% CBZ: 
Eudragit® L100, squares), NanoCrystalline (60% CBZ: Eudragit® L100 diamonds), MicroAmorphous 
(20% CBZ: Eudragit® L100, triangles), pure crystalline CBZ (circles). The vertical dashed line at the 
50-min time point corresponds to the pH-shift. The bars correspond to the standard deviation from 
triplicates. 
 
 
The second reason, probably the most relevant, is related with the reduced particle size 
of these powders, in the order of a few microns, when compared with pure crystalline CBZ 
particles, which promotes a dissolution boost as soon as they contact the liquid medium. When 
comparing the in vitro releases and performances among the NanoAmorphous, NanoCrystalline 
and MicroAmorphous formulations, these showed differences among each other. The 
NanoAmorphous powder was the one that exhibited the higher dissolution rate, with almost 
45% of CBZ dissolved within the first 10 minutes of test. At the 10 min timepoint, the 
MicroAmorphous and NanoCrystalline powders were only able to reach 30% of drug dissolved 
in the medium. After 20 min, a 10% increase in the amount of drug dissolved was observed for 
the NanoCrystalline formulation.  
To complement this analysis, Figure 4.9 and Table 4.2 show the SEM images and 
surface area measurements, respectively, for the NanoAmorphous, NanoCrystalline and 
MicroAmorphous powders. The NanoAmorphous powder is noticeable for having a 
significantly larger specific surface area, with a value around 4 and 9 times higher than the 
surface area of the NanoCrystalline and MicroAmorphous powders, respectively. The surface 
area of the NanoCrystalline powder with respect to the NanoAmorphous was lower due to the 
higher level of aggregation between nanoparticles promoted by the lower concentration of 
polymeric stabilizer present in the formulation, as explained in the Section 4.3.1.1. 
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Figure 4.9. SEM micrographs corresponding to the NanoAmorphous, MicroAmorphous and 
NanoCrystalline powders, from left to right. 
 
 
Table 4.2. Results for the surface area for the NanoAmorphous, MicroAmorphous and NanoCrystalline 
powders. 
 
 NanoAmorphous MicroAmorphous NanoCrystalline 
Surface Area (m2/g) 81.7 9.1 19.7 
 
 
Still, the surface area of this crystalline nano-sized formulation is around 2 times higher 
the surface area of the MicroAmorphous powder. The surface area enhancement factor obtained 
when comparing the NanoAmorphous with the MicroAmorphous powder was aligned with the 
general observed 10-fold increase in surface area when reducing from micron to nanoparticles, 
as reported by Shah et al. [24]. However, when comparing with the highly porous amorphous 
microparticles of vemurafenib produced by SCP using high shear mixing, the surface area 
enhancement factor of the NanoAmorphous powder reduces to about 4 times, a similar gain 
relatively to the NanoCrystalline powder [25].   
When analyzing the SEM micrographs in Figure 4.9, both nano-composite particles 
obtained by the SCP process – the NanoAmorphous and NanoCrystalline – presented a 
completely different structure when compared with a spray-dried powder. The spray-dried 
particles showed similar particle size in the micron range when compared with the co-
precipitated aggregates, but in terms of particle shape corresponded to the typically one-phased 
composite and hollow particles with smooth surface, and in this case with a shriveled 
morphology. The spray dried co-precipitated powders obtained by SCP for presenting a much 
more reticular structure consequently present a significantly higher specific surface area.  
As described by the Noyes-Whitney equation, the dissolution rate is directly 
proportional to the diffusion coefficient of the drug, the surface area of the particle and the 
difference between the saturation solubility of the drug in the boundary layer and its 
concentration in the bulk liquid medium, and is inversely proportional to the thickness of the 
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diffusion layer [26]. Therefore, as the particle size decreases, the surface area increases, which 
results in the enhancement of the dissolution rate of the drug. Moreover, particles with reduced 
size also present reduced diffusion layers, which further contributes for a positive effect on the 
dissolution rate. Another factor that can ultimately increase the dissolution rate is the increase 
of the saturation solubility of the drug if the particle size is reduced below 100 nm [24]. The 
surface area results were completely aligned with the differences in the dissolution rate 
observed for the different powders. The NanoAmorphous powder for being the one that 
presented a lower level of aggregation, and thus the highest specific surface area, was the one 
that presented a higher dissolution rate, followed by the NanoCrystalline and the 
MicroAmorphous powders that presented almost identical dissolution profiles. The 
NanoCrystalline powder for being more aggregated, presented a reduced surface area and a 
slower dissolution rate at the 10 min timepoint, when compared with the NanoAmorphous 
powder that was less aggregated. Kumar et al. observed the same results when evaluating the 
impact of particle’s aggregation on the dissolution rate of spray dried crystalline nanoparticles 
obtained from nanosuspensions [17]. These results also suggested that, in fact, a synergistic 
effect from the amorphous state together with the particle size reduction may promote a 
significant increase in the dissolution rate and absorption of BCS/DCS Class IIa compounds.  
The rationale of performing a pH-shift dissolution test was to evaluate the capacity of 
the formulations to maintain CBZ supersaturation in solution after changing from acid to basic 
conditions, and to enable better in vitro-in vivo correlations. Supersaturation is a 
thermodynamically unstable state, and if the drug is not sufficiently stabilized in solution, it 
will tend to recrystallize, eventually losing the solubility advantages generated. As long as 
supersaturation is maintained in the gastro-intestinal tract more time is given for drug 
absorption to occur, thereby promoting an increase in the bioavailability. The presence of the 
polymeric stabilizer has a key role in the prevention of drug’s recrystallization and maintenance 
of the drug’s supersaturation e.g. by interacting with the drug via hydrogen bonding and other 
ionic interactions and/or by creating nano and micellar structures where the drug in incorporated 
and safe from recrystallization. Ionic polymers, for example, such as methacrylate copolymers 
(i.e. Eudragit® L100) can create complexes with the drug and thus maintain its supersaturation 
[27].  
As expected, pure crystalline CBZ presented the lower area under the dissolution curve 
(AUCd) over the 180 min period of testing (433 mg.h/L). Both the NanoAmorphous and 
MicroAmorphous formulations were capable of maintaining their levels of CBZ supersaturation 
in acid conditions until medium transfer. The NanoCrystalline formulation, in turn, precipitated 
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from the 20 min timepoint onwards and CBZ concentration decreased gradually, and after 60 
min, the dissolution profile of the NanoCrystalline formulation intersected the dissolution 
profile of the MicroAmorphous powder, leading to the second lowest AUC observed (844 
mg.h/L). Upon medium transfer, a slight decrease in the CBZ release was observed for the 
NanoAmorphous and MicroAmorphous formulations, but this was maintained constant until the 
end of the test. The MicroAmorphous powder showed a progressive increase in the percentage 
of CBZ dissolved as approaching the 180 min timepoint, which should be related with the 
successive centrifuge cycles of the dissolution test method developed that promoted further 
hydration/wetting of the powder. Non-formulated amorphous spray dried powders typically 
present poor wetting properties and often need additional dispersion steps to allow a good 
hydration of the powder. Spray dried co-precipitated aggregates, by opposition, readily 
disintegrated and formed fine suspensions.  
Therefore, the formulation performance ranking by ascending order of potential to 
improve CBZ in vivo exposure was the following: pure crystalline CBZ < NanoCrystalline < 
MicroAmorphous (AUCd ~962 mg.h/L) < NanoAmorphous (AUCd ~ 1.1 g.h/L).  
 
4.3.2.2 In vivo pharmacokinetics 
In order to provide a deeper understanding of the particle size effect in the absorption 
and bioavailability of BCS/DCS Class IIa drugs, pharmacokinetic (PK) studies with the 
NanoAmorphous, NanoCrystalline and MicroAmorphous formulations, as well as pure 
crystalline CBZ particles, were performed in mice in the fasted state. The fasted state was 
selected because in certain cases the presence of food may interact (either increasing or 
decreasing) the dissolution performance, especially of micro-sized formulations [24].  
Figure 4.10 shows the pharmacokinetic profiles, obtained over 180 min, for the different  
CBZ: Eudragit® L100 formulations. 
The NanoAmorphous and the NanoCrystalline formulations were the ones that exhibited 
higher in vivo dissolution rates.  When compared with the MicroAmorphous powder or pure 
crystalline CBZ particles, drug levels in serum samples of mice dosed with the nano-solid 
dispersions were distinctively superior. The amount of drug dissolved, and consequently 
absorbed, from both the MicroAmorphous and pure crystalline formulations was well below 
1.25 mg/L, and even when assuming a yield of 60% for the liquid-liquid extraction process, 
drug levels would still be well below the LOQ of the method, and consequently far away from 
the performance of the nano-sized systems. 
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Figure 4.10. Pharmacokinetic profiles, correspondent to the formulations NanoAmorphous  
(20% CBZ:Eudragit® L100, squares), NanoCrystalline (60% CBZ:Eudragit® L100, diamonds), 
MicroAmorphous (20% CBZ:Eudragit® L100, triangles), pure crystalline CBZ (circles). The dashed line 
corresponds to the limit of quantification (LOQ) of the immunoassay method, which is 1.25 mg/L. The 
broken-dashed line corresponds to the maximum of drug concentration obtainable in the serum samples, 
if a 60% yield is considered for the extraction process. The bars correspond to the standard deviation 
from n=3. When no bars are shown data points are from n≤2 animals. 
 
 
From the results obtained it can be concluded that the observed differences are clearly 
related to the difference in particle sizes and surface areas between the formulations. The high 
specific surface area of the nano-solid dispersions, both the NanoAmorphous and the 
NanoCrystalline, when exposed to the gastro-intestinal fluids led to very rapid dissolution rates, 
which in turn contributed to a greater amount of CBZ in solution. Since the absorption of CBZ 
is not limited by permeability, if more drug is present in solution, a higher amount can 
potentially be absorbed both by passive and/or active mechanisms and can reach the systemic 
circulation. The concentration of CBZ that reaches the blood will consequently be quantified in 
the blood serum. Neither the MicroAmorphous nor the pure crystalline powders were able to 
dissolve sufficiently fast in the gastro-intestinal fluids, due to their larger particle size and lower 
surface area. A lower quantity of drug in solution, led to lower absorption resulting in a lower 
bioavailability, as observed. The results obtained were in line with the works reported by  
Kumar et al. [13] and Angi et al. [18], who also evaluated the in vivo dissolution rate and 
bioavailability of nano-sized amorphous formulations obtained by co-precipitation followed by 
spray drying, against the respective micro-sized formulations. According to Shah et al. [24], 
apart from particle size reduction, other factors that may contribute for the increase in 
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bioavailability is the mucoadhesion behavior of nanoparticles in the gastric and intestinal 
mucosa, similarly to an extended-release formulation. 
In terms of the total drug exposure or AUC both NanoAmorphous and NanoCrystalline 
formulations were considered identical. No clear distinction or ranking could be established 
between these two systems due to the high variability observed between mice of the same group. 
The same issue was encountered when attempting to obtain other pharmacokinetic parameters, 
such as the time and the value of the maximum concentration (i.e. tmax and Cmax). These results 
somehow contradicted our initial expectations, in the sense that, the a priori dual benefit for 
bioavailability of having the drug in the amorphous state and the particle size of the solid 
dispersion reduced to the nano-range was not clearly verified. Indeed, the results suggested that 
for CBZ the effect of the reduction of particle size is more important than having the drug in its 
amorphous state. Further research and validation would be needed to verify whether this 
hypothesis could be extended to all BCS/DCS Class IIa compounds. Nevertheless, and taking 
into consideration that amorphization apparently does not bring any additional advantage to this 
system, formulation development can focus on the optimization of crystalline nano-solid 
dispersions. As already mentioned in Section 4.3.1.2, crystalline nanoparticles offer not only 
the stability advantage (storage and processability stability) but also the possibility of obtaining 
formulations with higher drug loads. A final-dosage form with a higher drug load can be 
delivered at a lower dose to maintain the same therapeutic effect. 
From the PK profiles shown in Figure 4.10, the information gained for the 
NanoAmorphous and NanoCrystalline systems, was that tmax was most likely achieved within 
the first 30 min, and Cmax had a value between a minimum and a maximum of 1.73-2.38 mg/L 
and 1.42-3.47 mg/L, for the former and latter formulations respectively. When comparing these 
values with the PK parameters obtained after administration of rats, the closest animal model 
to mice, with an oral solution of CBZ in PEG-400 at 25 mg/kg (tmax= 90 min, Cmax= 2.29 mg/L) 
it can be concluded that nano-solid dispersions presented a significant reduction in tmax, and for 
a lower dose (7.4 mg/kg in this work) the Cmax was identical [28]. This further confirms that the 
high dissolution rate of the nanoparticles led to the supersaturation of the drug in the GI fluids 
promoting the absorption of CBZ, thus improving its bioavailability. 
Comparing the AUCs of the nano-sized formulations with those obtained for the 
MicroAmorphous and pure crystalline CBZ samples, these were approximately 5 and 50 times 
higher, respectively. According to Shah et al., the overall bioavailability of nanoparticles was 
reported to be a 3-fold increase when compared with micronized particles and a 9-fold increase 
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when compared with coarse powder [24]. Thus, the results obtained in this work are in 
agreement with the data found in the literature.  
Finally, in what regards the PK parameters obtained for the MicroAmorphous 
formulation, there was one mouse that presented a concentration marginally above 1.25 mg/L 
in its serum, at the 30 min timepoint. Similarly, and despite the mice variability observed, when 
comparing this result with the in vivo profiles of the nano-sized samples, these values were most 
likely related with the Cmax and tmax achieved for this formulation.        
Comparing the in vivo with the in vitro results, these were generally aligned with each 
other, although a change in the ranking between the NanoCrystalline and MicroAmorphous 
formulations was observed. One should not neglect the fact that in vivo powder dissolution and 
absorption are much more complex and dynamic processes when compared with what happen 
in vitro. 
 
4.3.2.3 Amorphous powder stability 
For the powder stability study, only the amorphous powders, either produced by SCP 
and SD, were considered in order to assess their potential for recrystallization under temperature 
and humidity stress conditions. Figure 4.11 shows the XRPD diffractograms of the 
NanoAmorphous and MicroAmorphous powders obtained after 90 days in open Petri dishes 
conditioned inside glass dessicators at 25 ºC/65% RH and 40 ºC/75% RH conditions. It should 
be pointed out, that although the results obtained after 30 days of storage were omitted for 
simplicity, but the conclusions remained the same. 
As can be seen, both powders exhibited the typical halo characteristic of the amorphous 
state and no peaks of pure CBZ were detected under both stress conditions and up to 90 days 
of storage. Both amorphous powders showed identical long-term storage physical stability, and 
acceptable resistance to recrystallization. 
The assurance of long-term storage physical stability is the ultimate goal when 
developing an amorphous formulation. The formulation should be capable of maintaining its 
solid state and physical stability during the shelf life of the product. In this respect, (1) the 
selection of the right polymeric stabilizer, (2) the respective drug-polymer miscibility and (3) 
the method of amorphization or method of production are fundamental variables that may affect 
the physical stability of an amorphous formulation. 
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Figure 4.11. Powder diffractograms correspondent to the NanoAmorphous and MicroAmorphous 
formulations after 90 days of storage at 25ºC/65% RH (A and B, respectively) and 45ºC/75% RH (A.1 
and B.1, respectively). 
 
 
In the case of this work, and as regards to the polymeric stabilizer, Eudragit® L100 
possess certain characteristics that most probably contributed for the high physical stability of 
these powders. As already explained in Sections 4.3.1.2 and 4.3.2.1 Eudragit® L100 has a 
relatively high Tg by comparison to other polymeric carriers and it is an ionic polymer. In what 
concerns drug-polymer miscibility, as the drug load in formulation increases the propensity for 
phase separation and recrystallization also increases. Indeed, the miscibility of the amorphous 
drug within the carrier was limited. The amorphous formulations produced in this work and 
tested for long-term storage stability have a 20% CBZ load. This is a relatively low drug fraction 
that typically provides completely amorphous and homogenous ASDs. Finally, both the SCP 
and SD allowed sufficiently fast precipitation to form homogenous and physically stable 
amorphous formulations up to 20% CBZ load. 
 
4.4 Conclusions  
 
In this work, an alternative SCP process based on microfludization was evaluated to 
produce solid dispersions. Six different suspensions were produced by co-precipitation and 
were dried using spray drying. Spray-dried nano-composite microparticles were obtained, 
meaning that the final suspensions produced by co-precipitation were in fact nanosuspensions. 
The nano solid dispersions were non-porous and presented a mean circular diameter around 100 
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nm. The level of aggregation of the nanoparticles was shown to be dependent on the drug-
polymer ratio, while the feed solids’ concentration in solution defined the particle size of the 
micro-sized aggregates. Both amorphous and crystalline nano-solid dispersions were produced, 
which showed to be dependent on the type of stabilizing polymer used and drug load in 
formulation.  
 The nano-solid dispersions (either amorphous or crystalline) presented faster 
dissolution rates and improved bioavailability when compared with a spray dried amorphous 
solid dispersion. The effect of particle size and surface area showed to be more important than 
the amorphization of the drug, for improving the bioavailability of CBZ, a BCS/DCS Class IIa 
compound. Further validation is needed to evaluate whether this result can be extrapolated to 
other compounds that present dissolution-rate limited absorption. In case this hypothesis is 
verified means that formulation development can focus on the optimization of crystalline nano-
solid dispersions, which offer stability advantages and higher drug loads in formulation. 
Still, the long-term storage physical stability of the amorphous nano-solid dispersion 
produced by SCP was comparable to the amorphous micro-solid dispersion produced by SD. 
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5 Green production of cocrystals using a new solvent-free approach by 
spray congealing 
 
5.1 Introduction 
 
Despite the potential of cocrystals, their application in the pharmaceutical field is still 
limited due, in part, to the scarcity of suitable large-scale production methods and lack of robust 
and cost-effective processes. In order to address some of these challenges a novel solvent-free 
approach by spray-congealing (SCG) was evaluated in this work to produce pharmaceutical 
cocrystals.  
SCG is a well-established manufacturing technology in the food and pharmaceutical 
industries for the production of microencapsulates, taste masked and controlled release products 
[1-3]. SCG can be described as a hybrid technology between SD and HME, comprising the best 
of particle’s engineering and green chemistry/pharmacy fields.  
As schematically presented in Figure 5.1, SCG consists of feeding a molten mixture to 
an atomizer (1), which then breaks the liquid feed into small droplets (2), and those droplets are 
cooled and solidified in a co-current stream of cooling gas that removes thermal energy from 
the droplets (3). The particles are then separated from the cooling gas in a cyclone (4) and 
collected in a container.  
 
                 
 
Figure 5.1. Representation of the spray congealing process. 
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The major advantage of cocrystallization by SCG when compared with traditional 
solvent-based methods, such as HPH or SD, is the fact that it is a solvent-free technique. 
Cocrystallization via SCG complies with green chemistry and sustainable pharmacy principles, 
allows cost reduction and avoids the formation of solvates. Moreover, when compared with 
similar processes such as HME the major asset of SCG is that it allows the particle engineering 
of cocrystals in situ, avoiding additional downstream processing steps. Because the unit 
operation can be conducted in a modified spray drying apparatus the scale-up is relatively 
straightforward [4]. This can be considered as an advantage over the SCF-based methods that 
require more specific equipment design. Finally, because SCG only implies the melting of the 
pharmaceutical components, additional concerns such as limited solubility in organic solvents 
or supercritical fluids, are discarded.    
The main limitation of the SCG process is the heating of the pharmaceutical components 
to obtain the molten mixture, which according to the physicochemical properties of the API and 
coformers, can occur at high temperatures and thus attention should be paid with heat labile 
compounds in order to avoid degradation. 
This work was divided in two main parts. In the first part, a feasibility study of SCG 
applied to cocrystallization was conducted. This was performed with two cocrystals that were 
already characterized in the literature - Caffeine:Salicylic Acid (CAF:SAL, Figure 5.2A) and 
Carbamazepine:Nicotinamide (CBZ:NIC, Figure 5.2B), both at 1:1 molar ratio.  
Both caffeine (CAF) and carbamazepine (CBZ) are typical API model compounds in 
pharmaceutical cocrystallization studies. CAF is considered a BCS Class I compound (high 
solubility/high permeability), whereas CBZ belongs to Class II (low solubility/high 
permeability). Both are low molecular weight organic molecules, easily crystallizable from the 
undercooled melt according to Baird et al. [5].  
The 1:1 CAF:SAL cocrystal was first obtained by Lu et al. [6] presumably using the 
slurry method according to Zhang et al. [7,8]. The 1:1 CBZ:NIC cocrystal has already been 
obtained from solution and slurry crystallization [6,9,10], neat grinding [11] and melt method 
[12]. At least two polymorphic forms of 1:1 CBZ:NIC cocrystal are known in the literature, 
form I and II, being the latter identified from the melt during a calorimetric study [13,14].  
In the second part of this work, a design of experiments (DoE) with 2 parameters at 2 
levels plus 1 central point was conducted with another CAF-based cocrystal also well described 
in the literature, to further evaluate the applicability of SCG. The cocrystal selected was the 1:1 
Caffeine:Glutaric Acid (CAF:GLU, Figure 5.2C) that was previously produced using liquid-
assisted grinding [15], slurry conversion [7], spray-drying [16], cooling crystallization [17]. 
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Similarly to the 1:1 CBZ:NIC cocrystal, the 1:1 CAF:GLU also presents two 
polymorphic forms, form I and II, both structurally characterized in the literature [15,18]. 
The goal of performing an experimental design was to assess the effect of two critical 
process variables of the SCG process on cocrystal formation, purity, particle size, shape and 
powder flow properties. The parameters evaluated were atomization and cooling-related 
parameters. 
 
 
 
Figure 5.2. Chemical structures of the APIs and coformers considered in the study. The chemical 
functionalities with potential to form H-bond interactions are identified. 
 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
Caffeine (CAF, β-caffeine anhydrous, purity 99%), glutaric acid (GLU, purity 99%), 
salicylic acid (SAL, purity ≥ 99%) and nicotinamide (NIC, purity ≥ 99%) were purchased from 
Sigma-Aldrich Quimica SA (Alcobendas, Spain). Carbamazepine (CBZ, anhydrous Form III, 
purity > 97%) was purchased from TCI Co., Ltd. (Tokyo, Japan). 
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5.2.2 Methods 
 
5.2.2.1 Cocrystallization by spray congealing 
Stoichiometric mixtures of each API and respective coformers (total mass of ~30 g) 
were physically blended in a laboratory turbula mixer for 10 min. The physical mixture was 
slowly fed into a jacketed beaker and agitated with a magnetic stirrer. A silicone-based heat 
transfer fluid (SYLTHERM XLT, Dow Chemical Co.) circulated inside the jacket of the beaker, 
feed line, and nozzle in order to keep the mixture in a molten state until the atomization point. 
The physical mixture was heated, through small temperature increments, until total melting of 
both API and coformer was observed (TM, mix).  
Spray congealing (SCG) was conducted using a modified lab scale spray dryer (4M8-
TriX ProCepT, Zelzate, Belgium), adapted for spray congealing and operated in open cycle 
mode. The cooling chamber height was set to its maximum (180 cm). Atomization was 
conducted with a jacketed two fluid nozzle (orifice size of 1.20 mm) that was used to atomize 
the melt. Co-current nitrogen was used to promote the solidification of the melt after 
atomization. The congealing gas flow rate (F_gas) was kept constant in all tests at 0.35 m3/min. 
Before feeding the melt to the nozzle, the SCG unit was stabilized with nitrogen to assure stable 
inlet (T_in) and outlet (T_out) temperatures. After stabilization, the liquid/melt was fed by 
pressurizing the beaker using a pressure regulator. The liquid feed rate (F_feed) was kept 
constant and was approximately 5 g/min. The droplets were then cooled and solidified in the 
SCG chamber by the co-current nitrogen stream. The stream containing the product was 
directed to a cyclone to separate the solids from the gas. 
Table 5.1 compiles the formulation and process variables tested in both phases of this 
work (feasibility study and DoE), complementing the above description. 
For the DoE, the two process variables studied were the F_atom and the T_in of the 
congealing gas, represented as ΔT. These two process variables are directly related with the 
atomization and cooling phases of the spray congealing process, which are fundamental steps 
for spray-congealed particle formation. The low-level chosen for the F_atom (11 L/min) was 
related to the “minimum atomization gas volume” to “feed rate” ratio necessary to create a 
homogenous and continuous spray inside the congealing chamber. The high-level of 20 L/min 
was then selected to decrease the droplet size. Varying the ΔT value enabled modulation of the 
cooling efficiency. At ΔT=0ºC the cooling kinetics will be slower, because the molten droplets 
will be cooled and solidified only by means of the decreasing temperature gradient observed 
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inside the congealing chamber, while at ΔT=50ºC the cooling efficiency will theoretically 
improve. 
 
Table 5.1. API/coformer systems tested and process variables defined for each test. 
 
 
5.2.2.2 Modulated Differential Scanning Calorimetry (mDSC) 
Modulated differential scanning calorimetry experiments were performed in a TA 
Q1000 (TA Instruments, New Castle, Delaware, USA) equipped with a Refrigerated Cooling 
System (RCS). The enthalpy response was calibrated using indium. The raw materials, physical 
mixtures and spray-congealed samples were analyzed in pinholed DSC aluminum pans and 
under continuous dry nitrogen purge (50 mL/min). 1:1 CAF:SAL and 1:1 CBZ:NIC samples 
were analyzed using a modulated heating ramp from 25°C to 300°C at a heating rate of 5°C/min 
using a period of 60 s and amplitude of 0.8°C. Respective raw materials and physical mixtures 
were analyzed using the same method. The 1:1 CAF:GLU samples and respective physical 
mixture were analyzed using a heating ramp, from 25°C to 250°C at a heating rate of 10°C/min. 
All samples weighed between 5 to 10 mg. 
Data was analyzed and processed using the TA Universal Analysis 2000 Software (TA 
Instruments, New Castle, Delaware, USA). 
 
5.2.2.3 X-Ray Powder Diffraction (XRPD) 
X-ray powder diffractograms were obtained in a D8 Advance Bruker AXS θ/2θ 
diffractometer with a copper radiation source (Cu Kα, λ= 1.5406 Å), voltage of 40 kV, and 
 API/Coformer system 
Molar 
ratio 
Exp. 
number 
Spray Congealing Process Variables 
TM, mix 
(ºC) 
T_in 
(ºC) 
T_out 
(ºC) 
ΔT=TM, mix-T_in 
(ºC) 
F_atom 
(L/min) 
F
ea
si
b
il
it
y
 
st
u
d
y
 
Caffeine:Salicylic acid 
(CAF:SAL) 
1:1 - 150 100 58 50 9 
Carbamazepine: 
Nicotinamide (CBZ:NIC) 
1:1 - 175 50 36 125 12 
2
2
+
1
 D
es
ig
n
 o
f 
E
x
p
er
im
en
ts
 (
D
o
E
) 
Caffeine:Glutaric acid 
(CAF:GLU) 
1:1 
#1 
140 
140 85 0 11 
#2 90 57 50 11 
#3 140 85 0 20 
#4 90 57 50 20 
#5 115 70 25 16 
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filament emission of 35 mA. For the total scan, the samples were measured over a 2θ interval 
from 3 to 70º with a step size of 0.017º and step time of 50 s. For the slow scan, the samples 
were measured over a 2θ interval from 10 to 14º with a step size of 0.017º and step time  
of 1500 s. 
 
5.2.2.4 Scanning Electron Microscopy (SEM) 
The samples were attached to adhesive carbon tapes (Ted Pella Inc., CA, 
USA), previously fixed to aluminum stubs where the powder in excess was removed by a jet of 
pressurized air. The samples were left under vacuum for 2 h and then coated with 
gold/palladium (South Bay Technologies, model E5100, San Clement, CA). A JEOL JSM-
7001F/Oxford INCA Energy 250/HKL scanning electron microscope (JEOL, Japan) operated 
in high vacuum at an accelerating voltage of 15 kV was used. Micrographs were taken at 
different magnifications from 50x up to 5000x. 
 
5.2.2.5 Particle size analysis 
The particle size of the 1:1 CAF:SAL and 1:1 CBZ:NIC samples, expressed as the mean 
circular diameter, was determined by image analysis using the ImageJ software (National 
Institute of Health, Bethesda, MD, USA) from 400 randomly selected particles, which 
demonstrated a normal distribution of sizes. 
In the case of the 1:1 CAF:GLU samples, the particle size was expressed as the circular 
equivalent diameter (CED) and was analyzed in a Morphologi G2 particle characterization 
system (Malvern Instruments, Worcestershire, UK). CED is the diameter of a circle having the 
same area of the projected particle image. Approximately 10 mg of each sample was dry 
dispersed onto a glass slide using the system sample preparation device (n=3). Sample 
preparation settings were as follows: injection pressure: 2.0 bar; injection time: 200 ms; delay 
time: 2 s. Image analysis was conducted using 10x and 20x magnification lens, with the plate 
tilt compensation enabled. The resolution ranges covered were 3.5 μm to 210 μm and 1.8 μm 
to 100 μm, respectively. The scanning area was a square with approximately 56 mm2, centered 
in the center of the glass slide. Diascopic illumination was used to visualize the particles, and 
light intensity was automatically calibrated prior to the analysis of each sample (80.00 ± 
0.20%). The number of particles counted in each glass slide (n=3, per test) was combined in a 
single result giving a total count of approximately 1000 particles. Number-based CED 
distributions (Dn, 50) were obtained and the then compared. 
Green production of cocrystals 
131 
 
5.2.2.6 Characterization of powder flowability 
The powder flow characteristics of the different 1:1 CAF:GLU samples was analyzed 
using a FT4 powder rheometer (Freeman Technology Ltd., Tewkesbury, UK). Powder 
compressibility and permeability data of the different materials produced were measured 
according to the respective standard test programs. The compressibility and permeability tests 
were performed using the 23.5 mm blade and the 25 mm vessel. 
In the compressibility test, each powder was compressed at different normal stresses, 
from 1 to 15 kPa, with a vented piston to enable release of entrained air. In the permeability 
test, each powder was subjected to the same program sequence of the compressibility test, 
though with the difference that a stream of air at constant velocity (2 mm/s) was continuously 
injected below the powder bed while being compressed. The permeability tests were performed 
first, with fresh samples, followed by the compressibility tests re-using the same materials.  
 
5.3 Results and Discussion 
The first two case-studies that are described in the following section were part of the 
feasibility study of using SCG to produce pharmaceutical cocrystals. 
 
5.3.1 Feasibility study: cocrystals of 1:1 CAF:SAL and 1:1 CBZ:NIC using spray congealing  
 
Figure 5.3A and Figure 5.3B show the total heat flow curves corresponding to the 
thermal analysis of the 1:1 CAF:SAL and 1:1 CBZ:NIC cocrystals, respectively.  The pure 
APIs, coformers and respective physical mixtures (same molar proportion) were also analyzed 
by thermal analysis and are also represented in the respective thermal profiles. Table 5.2 
summarizes the onset temperatures and enthalpy data associated to the principal endothermic 
events detected in the thermal profiles.  
The endothermic events, namely phase transformations and melting peaks, observed for 
the pure components were in agreement with those reported in the literature [6,12]. Pure CAF 
presented two endothermic peaks, one at 139ºC correspondent to the transition of β-caffeine to 
α-caffeine, and the other at 233ºC correspondent to the formation of an isotropic liquid when 
heating the α-anhydrous form. The DSC profile of pure SAL presented a sharp endothermic 
peak at 156ºC attributed to the melting of the material followed by a broad endothermic peak 
that may correspond to degradation. 
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Figure 5.3. Total heat flow profiles of 1:1 CAF:SAL (A) and 1:1 CBZ:NIC (B): a – pure API, b – pure 
coformer, c – respective physical mixture in the same molar proportion, d – cocrystal obtained by spray 
congealing. CAF and CBZ are considered the APIs and the SAL and NIC the coformers. 
 
Pure CBZ first underwent a polymorphic transformation at 150ºC, followed by the 
melting of the new phase formed at 186ºC. Finally, the thermogram of pure NIC presented a 
single endothermic peak at 126ºC attributed to the thermodynamic melting of the material, also 
followed by a broad endothermic peak that may correspond to degradation. 
Starting with the comparison of the thermal profiles of the pure APIs and coformers 
with the respective spray-congealed materials, it was observed that any of the endothermic 
events characteristic of the pure components were present in the thermal profiles of the final 
products produced by SCG. These results were indicative that new crystalline forms were 
produced and thus presented a different thermal behavior when compared with the pure 
precursors. The thermal profiles obtained for the physical mixtures also serve as a confirmatory 
analysis for cocrystal formation. When heating a physical mixture of an API and a coformer in 
a preferred stoichiometric ratio both components typically undergo two different stages, in 
which the first is correspondent to the formation of a eutectic phase and the second to the 
cocrystal melting [6]. This can be confirmed e.g. when analyzing curve c of Figure 5.3A. The 
physical mixture of 1:1 CBZ:NIC (curve c, Figure 5.3B), in this regard, presented another 
endothermic event at 103ºC with a much smaller associated enthalpy (4.0 J/g) preceding the 
eutectic and cocrystal melting peaks.  
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Table 5.2. Onset temperatures and enthalpy values of the endothermic events detected in the thermal 
profiles of the pure components, respective physical mixtures and spray-congealed products. 
 
 
 
Sample (profile ID) 
1st Endothermic Event 2nd Endothermic Event 
 T (ᵒC) ΔH (J/g) T (ᵒC) ΔH (J/g) 
F
ig
u
re
 3
A
 
CAF (a) 139.1 17.3 232.8 109.8 
SAL (b) 156.4 202.1 - - 
Phy. Mix. (c) 119.4 68.6 132.7 30.4 
Cocrystal (d) 136.32 167.4 N.D. N.D. 
F
ig
u
re
 3
B
 
CBZ (a) 149.6 5.1 186.0 94.12 
NIC (b) 126.3 264.9 - - 
Phy. Mix. (c)* 122.0 64.5 155.6 99.6 
Cocrystal (d)* 154.2 137.3 N.D. N.D. 
                        
     N.D. – not detected;  
    * Two small thermal events, one before and the other after, the major peak(s) were detected. 
 
According to Chieng et al., this small peak may correspond to an endo-exothermic event 
associated with a phase transformation [11]. Still, the temperature at which the cocrystal 
melting occurs can be used as a reference of cocrystal formation.In this work, when comparing 
the thermal profiles of the physical mixtures and the respective cocrystals, it was observed that 
the eutectic peaks were absent in the latter but the cocrystal melting peaks appeared within the 
same temperature range - 133-136ºC and 154-156ºC for the 1:1 CAF:SAL and 1:1 CBZ:NIC 
cocrystals, respectively. These results further suggest the high purity of the materials produced 
by spray congealing. 
As mentioned in the Introduction section the 1:1 CBZ:NIC cocrystal presents two 
polymorphic forms, termed as form I and II. According with Seefeldt et al. [13] the thermal 
profile of the form I cocrystal shows a single endothermic event around 158ºC, while form II 
shows an additional first exothermic peak around 83-90ºC correspondent to the phase 
transformation of form II to form I. Given the results obtained, one can concluded that form I 
of the 1:1 CBZ:NIC cocrystal was obtained by SCG. Another event was detected in the thermal 
profiles of the 1:1 CBZ:NIC physical mixture and cocrystal at 227ᵒC (~3.0 J/g). Similarly to 
the thermal event observed at 103ᵒC (4.0 J/g), this peak may be an endo-exothermic event, 
which may be related with a phase transformation or even a small recrystallization. However, 
this event has not been reported by Chieng and co-workers [11]. 
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Finally, the cocrystal melting temperatures were in agreement with the temperatures 
observed for the same cocrystal systems prepared by different techniques [6,11,12]. 
XRPD analyses were conducted to further characterize the materials. Figure 5.4A and 
Figure 5.4B show the XRPD patterns correspondent to the 1:1 CAF:SAL and 1:1 CBZ:NIC 
cocrystals, respectively. The diffractograms of the pure APIs, coformers, physical mixtures and 
respective cocrystals obtained from the Cambridge Structural Database (CSD) are also 
represented [19]. Similarly to the thermal analysis, the XRPD diffractograms for the pure 
components were equivalent to the ones reported in the literature [6,11,12]. 
The XRPD diffractograms obtained for the physical mixtures were, as expected, 
equivalent to the patterns of the pure crystalline starting components. In contrast, when 
comparing the latter results with the diffractograms of the materials produced by SCG the 
appearance of new crystalline peaks and an overall decrease in the peak intensities of the 
characteristic peaks of the pure components was observed. These results corroborated the 
thermal analysis and confirmed that new crystalline forms were produced by SCG. Moreover, 
these diffractograms were in agreement with previously reported as well as with the existing 
data in the CSD.  
 
 
 
Figure 5.4. Powder diffractograms correspondent of 1:1 CAF:SAL (A) and 1:1 CBZ:NIC (B): a – pure 
API, b – pure coformer, c – respective physical mixture in the same molar proportion, d – cocrystal 
obtained by spray congealing, e – cocrystal data obtained from CSD (1:1 CAF:SAL – XOBCAT and 
1:1 CBZ:NIC (form I) – UNEZES). CAF and CBZ are considered the APIs and SAL and NIC the 
coformers. 
 
In relation to particle size and morphology Figure 5.5, A and B, shows the SEM 
micrographs correspondent to the 1:1 CAF:SAL and 1:1 CBZ:NIC cocrystals, respectively. For 
both systems, compact and spherical particles were obtained, with a mean circular diameter of 
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13.59 ± 7.85 μm for the 1:1 CAF:SAL cocrystal system, and 31.56 ± 8.08 μm for the 1:1 
CBZ:NIC. The observation of particles’ surface under high magnification (Figure 5.5, A.2 and 
B.2) revealed that the particles were aggregates of individual cocrystals entangled with or 
adhered to each other. Both crystalline systems presented a needle-shaped habit, however the 
1:1 CAF:SAL cocrystals were more elongated when compared with the 1:1 CBZ:NIC 
cocrystals.  
In order to evaluate the influence of particle morphology on the dissolution kinetics, a 
simple dissolution test was carried out in acidic medium with the 1:1 CBZ:NIC cocrystal and 
pure CBZ (data not shown). It was observed that particle morphology did not influence CBZ 
release into the medium, and similarly to the results obtained by other groups [20,21], the 
cocrystal showed an enhanced resistance to hydrate formation when compared with pure CBZ, 
which is an advantage in terms of stability. 
 
 
            
 
Figure 5.5. Micrographs correspondent of 1:1 CAF:SAL (A) and 1:1 CBZ:NIC (B). 
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5.3.2 22+1 Experimental design: particle engineering of 1:1 CAF:GLU cocrystals 
 
Critical process variables associated with SCG include the congealing gas flow rate 
(F_gas), the feed flow rate (F_feed), the inlet and outlet temperatures of the congealing gas 
(T_in and T_out, respectively) and atomization parameters, such as the nozzle type and orifice 
diameter and gas flow rate (F_atom). In this work the F_gas, F_feed, nozzle type and orifice 
diameter were maintained constant, while F_atom and the T_in of the congealing gas, 
represented as ΔT, were varied according to the ranges shown in Table 5.1. The F_atom and 
the T_in of the congealing gas are two of the most important critical process variables. The 
former influences the droplet size/particle size, while the latter has direct impact of the cooling 
stage.   
 
5.3.2.1 Effect of process variables on cocrystal formation and cocrystal purity  
Figure 5.6 shows the total heat flow profiles of the 1:1 CAF:GLU physical mixture and 
the different tests performed. 
 
 
 
Figure 5.6. Total heat flow profiles correspondent of 1:1 CAF:GLU: a – 1:1 CAF:GLU physical 
mixture, #1 to #5 –experimental design. 
 
 
The total heat flow profiles of pure CAF and GLU are represented in Figure 5.3A (curve 
a) and Supplementary Information D (Figure D.1), respectively. While the thermal analysis 
correspondent to the pure CAF presented two endothermic peaks, one at 139ºC and the other at 
233ºC (see Section 5.3.1), the endothermic peaks correspondent to pure GLU were observed at 
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lower temperatures, i.e. 70ºC and 95ºC, which, according to the literature, corresponded to a 
solid-solid phase transformation followed by melting, respectively [22]. Analyzing the thermal 
profile of the 1:1 CAF:GLU physical mixture (Figure 5.6, curve a) this showed a first peak at 
70ºC, most likely correspondent to the phase transformation of pure GLU, the second at 82ºC 
corresponded to the melting of the CAF:GLU eutectic, and the third peak at 94ºC to the melting 
of the cocrystal formed, which agrees with the data reported by Lu et al. [6]. 
Now, when analyzing the thermal analysis of the different spray-congealed materials 
produced (Figure 5.6, curves #1 to #5) these showed a set of minor endothermic events within 
the temperature range of 81-93º, followed by a major endothermic peak observed at 98.0 ± 0.3 
ºC and with an average enthalpy value of 115.0 ± 12.5 J/g. The agreement between the onset 
temperatures of these major peaks and the onset temperature of the cocrystal melting obtained 
from the physical mixture, was a first good indicator that cocrystals were formed, and varying 
the F_atom or ΔT during the SCG process had no impact on the formation of 1:1 CAF:GLU 
cocrystals. The minor endothermic events observed in the thermograms are related with a 
polymorphic phase transformation characteristic of this cocrystal, as previously mentioned in 
the Introduction section. The thermal analysis of both polymorphic forms of the 1:1 CAF:GLU 
cocrystal was recently reported by Vangala et al. [23]. They observed that form I of the cocrystal 
only exhibited a single endothermic peak correspondent to its melting at 99ºC, while form II 
presented two endothermic events – the first around 79-94ºC correspondent to the phase 
transformation of form II to form I, and the second at 99ºC correspondent to the melting of form 
I. Thus, according to the results obtained, one concluded that form II of the 1:1 CAF:GLU 
cocrystal was consistently produced among tests. The existence of polymorphic cocrystals has 
increased in the last few years, and the results obtained raised another potential advantage of 
the SCG process, which is the capacity of achieving polymorphic selectivity from the cooled 
melt by controlling the kinetics of crystallization.   
In what regards the purity of these cocrystals, from the DSC analysis, one believe that 
high conversion percentages were obtained, since the characteristic peaks of pure CAF were 
absent in all thermograms. This suggested that most of the CAF was combined with the GLU, 
forming the cocrystal. 
In order to complement the thermal analysis results, Figure 5.7 shows the XRPD 
diffractograms obtained for the different tests performed (Test 1 to 5) together with the 
diffractograms of the two polymorphic forms of the 1:1 CAF:GLU cocrystal obtained from the 
CSD. The XRPD diffractograms of pure CAF and GLU are represented in Figure 5.4A 
(spectrum a) and Supplementary Information D (Figure D.2), respectively. As can be observed, 
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the reflections of the different spray-congealed products matched with those already reported 
for polymorph form II of the 1:1 CAF:GLU cocrystal. These results were aligned with the 
thermal analysis not only further confirming that cocrystals were formed, but also that the 
endothermic peaks observed before the cocrystal melting were related to the phase 
transformation of form II to form I. However, when going into detail in the analysis of the 
spectra, it was also observed a small reflection at ~11.8 2θ in all patterns, with exception of 
Test 5. When comparing with the diffractograms of the pure components and physical mixture, 
it was concluded that this reflection corresponded to pure CAF, as its most intense reflection 
appears at 11.8 2θ. These results were indicative that, in fact, traces of unconverted pure 
components that were not detected from the thermal analysis existed in the final cocrystal 
particles obtained from Tests 1 to 4. 
 
 
 
Figure 5.7. XRPD diffractograms correspondent of 1:1 CAF:GLU: a– 1:1 CAF:GLU cocrystal data 
obtained from CSD, EXUQUJ01 (form I), b– EXUQUJ (form II), #1 to #5 – different tests performed 
according to the experimental design. The stars in the insert indicate the impurity peaks. 
 
 
In order to estimate cocrystal purity, a limit test for the CAF “impurity” was developed 
using XRPD. This method consisted in the comparison of the reflection area at 11.8 2θ either 
present in (1) a pure cocrystal sample spiked with a known and low concentration of CAF, and 
(2) the spray-congealed cocrystal samples. The pure form II of 1:1 CAF:GLU cocrystal was 
obtained from cooling crystallization according to the method reported by Yu et al. [17] (see 
Supplementary Information D), and the limit of quantification of CAF considered was 5 wt.%. 
The development of this limit test is further explained in detail in the Supplementary 
Information D (Figure D.5 to D.7).  
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Table 5.3 summarizes the reflection areas at 11.8 2θ measured for the 5 wt.% 
CAF:standard cocrystal physical mixture, considered as the reference, and for Test 1 to 5, using 
a slow scan over the 2θ interval from 10º to 14º, in order to improve peak detection. According 
to the results obtained, the following ranking by descending order of reflection area can be set: 
Reference>Test 3>Test 1>Test 4>Test 2>Test 5. Taking into account that the reflection area of 
the reference sample corresponded to 5 wt.% CAF, the results indicated that all the spray-
congealed cocrystals showed an amount of unconverted CAF below 5 wt.%., with Tests 3 and 
5 presenting the highest and the lowest level of unconverted CAF, respectively. Test 3 presented 
approximately 5 wt.% of unconverted CAF, while Test 5 was a pure cocrystal comparable with 
the standard produced by cooling crystallization. 
 
Table 5.3. Reflection areas measured at 11.8 2θ for the 5 wt.% CAF:standard cocrystal physical mixture 
and for the different tests performed. 
 
 Reference Test 1 Test 2 Test 3 Test 4 Test 5 
Reflection area (counts) 14986.1 7914.9 2501.6 14932.9 4238.2 N.D. 
wt.% CAF 5 < 5 < 5 < 5 < 5 N.D. 
             
 N.D. – not detected 
 
In order to understand the causes behind the different cocrystal purity levels observed, 
the process variables applied in each test were compared. In this respect, while the ΔT suggested 
to be a parameter with a positive influence on cocrystal purity, the F_atom appears to have had 
a negative effect. In what regards the effect of ΔT, the results were aligned with our 
expectations. In Tests 1 and 3, ΔT was set to 0ºC, while in Tests 2, 4 and 5, ΔT was set from 
25ºC to 50ºC. At ΔT=0ºC the molten droplets are cooled and solidified only by means of the 
decreasing temperature gradient observed inside the congealing chamber, thus slowing down 
the cooling kinetics. Delayed solidification and/or insufficient cooling may have contributed to 
the incomplete conversion of pure components in cocrystal, leading to the detection of an 
“impurity” peak with a higher area in the diffractograms of Tests 1 and 3, when compared with 
those detected in Tests 2 and 4 or even Test 5. The conversion of the cocrystal into its pure 
components, due to the loss of residual heat upon storage may also be a possibility as pointed 
out by Qiyun G [24]. Regarding the possible negative effect of F_atom on cocrystal purity, the 
results did not agree with the expected. The F_atom correlates with cocrystal purity since it 
determines the particle size, and said particle size consequently impacts the droplet/particle 
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cooling kinetics. In theory, the smaller the particle size of the molten droplet, the higher the 
cooling efficiency due to the enhanced surface area, and higher the purity of the cocrystal 
produced. However, when comparing the “impurity” peak areas observed for Tests 3 and 4, run 
at F_atom=20 L/min, with Tests 1 and 2 or even Test 5, run at F_atom= 11 and 16 L/min, 
respectively, the former were indicative of lower cocrystal purity levels. Further discussion 
regarding the particle size of the cocrystals will be presented in the following section. The 
generation of a pure cocrystal from Test 5, the central point, was another unexpected result that 
warrants further study. Nevertheless, this is a good example that pure cocrystals can be obtained 
by using spray congealing, and cocrystal purity can be optimized by tuning the process 
variables. 
 
5.3.2.2 Effect of process variables on cocrystal particle size, shape and flowability 
Figure 5.8 shows the SEM micrographs correspondent to the different 1:1 CAF:GLU 
cocrystals produced. To complement, Table 5.4 summarizes the number-based circular 
equivalent diameter (CED) distributions for the different tests performed, as well as, the 
compressibility and permeability results. 
As can be observed, solid particles were obtained among the different tests performed 
with Dn, 50 values for CED ranging between 3.8 μm for Test 2 and 6.6 μm for Test 4. Being the 
particle size mostly determined by the atomization conditions, it was expected to be inversely 
proportional to F_atom, for the same ΔT conditions. However, this was not observed when 
comparing the CED (Dn, 50) values of Tests 1 - 2 with Tests 3 - 4. In turn, these results may 
explain the negative correlation obtained between F_atom and cocrystal purity as mentioned in 
Section 5.3.2.1. The cocrystals obtained from Tests 3 - 4 were apparently less pure than the 
ones obtained from Tests 1 - 2 due to their larger particle size associated with a less efficient 
cooling. 
In terms of circularity all 1:1 CAF:GLU cocrystals produced were identical, however a 
certain degree of agglomeration between particles was also observed among tests. When 
evaluating the surface of the particles under higher magnification plate-shaped individual 
cocrystals, adhered with each other, were observed. The standard 1:1 CAF:GLU cocrystals 
produced by cooling crystallization were similar in terms of shape (see Figure D.4). Cocrystal 
particles obtained from Test 3 were an exception in this respect, presenting a spikier surface, 
with sharp-needle form individual cocrystals.  
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Figure 5.8. SEM micrographs correspondent to the 1:1 CAF:GLU cocrystals obtained. 
 
 
A possible explanation for the unexpected particle size results obtained may be related 
with the insufficient cooling power for this specific 1:1 CAF:GLU cocrystal system. 
Insufficient cooling of the droplets during the spray congealing process itself may have 
promoted the observed agglomeration between particles, which consequently increased the 
particle size. Each API-coformer system it is unique, and presents its own physicochemical 
properties while in the molten (e.g. viscosity, solidification behavior) and solid states (e.g. level 
of crystallinity, crystal shape). For example, when comparing these results with the ones 
obtained for the system 1:1 CAF:SAL - same API, but different coformer - a ΔT equal to 50ºC 
showed to be sufficient to cool and solidify single and perfectly spherical particles with a high 
purity level. Probably the minimum cooling requirements for the 1:1 CAF:GLU system should 
be above ΔT=50ºC.  
The compressibility and permeability tests provided information on the powder’s level 
of cohesiveness and flowability behavior, with relevance e.g. in processes of gravity feeding in 
tableting machines. The powder from Test 5 stands out for being the less compressible and also 
appears to have the lowest pressure drop. Powders presenting low compressibility and low-
pressure drop are generally non-cohesive or free flowing, due to the large particle size, and are 
linked to good tableting performance. Thus, when compared with the powders from Test 1 and 
Tests 2, 3 and 4, the powder from Test 5 was suggested to have superior downstream processing 
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properties, namely in tableting, thus presenting less potential for weight variability issues 
during filling, but also potentially lower probability of capping and lamination during 
compression. 
 
Table 5.4. Number-based circular equivalent diameter distribution (Dn, 50), compressibility and pressure 
drop across the powder bed for Test 1 to Test 5. 
 
 Test 1 Test 2 Test 3 Test 4 Test 5 
Circular equivalent diameter, Dn, 50 (μm) 4.10 3.82 4.66 6.61 5.93 
Compressibility @ 15 kPa (%) * 19.60 28.94 25.94 31.37 6.53 
Pressure drop across the powder bed  
@ 15 kPa and 2 mm/s (mbar) ** 
0.17 0.42 0.37 0.34 0.04 
 
* The compressibility percentage represents the increase in bulk density at a specified normal stress, in this case at 15 
kPa; ** The pressure drop across the powder bed is a measure of how easily a powder can transmit air through its bulk at 
a specified normal stress, in this case at 15 kPa. 
 
 
5.4 Conclusions 
 
The results obtained with 1:1 CAF:SAL and 1:1 CBZ:NIC successfully demonstrated 
the feasibility of spray congealing to produce pharmaceutical cocrystals. The DSC and XRPD 
results of the spray-congealed products were different from the pure components or physical 
mixtures and were aligned with those reported for the same cocrystals systems produced by 
other techniques. Cocrystal particles were compact and spherical consisting of aggregates of 
individual cocrystals entangled or adhered with each other. From the DoE study, it was 
concluded that cocrystal formation was independent from ΔT and F_atom, but varying both 
parameters suggested to influence cocrystal purity. Moreover, it was demonstrated that 
cocrystal particle properties (i.e. purity, size, shape, flow properties) can be adjusted, in situ, by 
varying ΔT and F_atom.  
When compared with typical solvent- or mechanochemical-based processes (e.g. 
reaction crystallization, neat or liquid-assisted grinding, spray drying) to produce cocrystals, 
spray congealing is a “green” and cost-effective method, easy scalable, compatible with 
continuous pharmaceutical processes and, most importantly, it allows particle engineering of 
pharmaceutical cocrystals in a single stage operation without the need for any downstream 
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processing. Particle properties can be fine-tuned, allowing for optimization of powder 
properties, which in turn results in more efficient pharmaceutical processes. 
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6 Conclusions and future work 
 
On the development of ASDs, both the drug’s chemical/physical stability and the in vivo 
performance are among the most important critical quality attributes (CQAs). Critical 
formulation variables that may impact these parameters include the selection of the right 
polymeric carrier and the definition of the drug load in formulation. This is reason why the early 
selection of critical formulation and process variables is of utmost importance to prevent late-
stage development failures due to drug-polymer incompatibility or drug recrystallization.  
In this work, two computational screening tools, one to predict amorphous physical 
stability and the other to predict in vivo performance were developed. The computational tool 
for predicting drug-polymer physical stability was reported to support the development of 
spray-dried dispersions and considers drug-polymer miscibility thermodynamics, solid-liquid 
and solid-solid diffusion and solvent evaporation. The model allowed to challenge both 
formulation and drying process variables simultaneously - an advantage over commonly 
applied approaches that allow an evaluation of drug-polymer miscibility thermodynamics as a 
function of temperature. The model showed to be useful for obtaining a preliminary physical 
stability or drug-polymer miscibility assessment, indicating the lower/higher propensity for 
amorphous phase separation of a drug with different stabilizing carriers at different drug 
loadings. Still, the predictions obtained should be evaluated in the light of the limitations of the 
model. In order to improve the predictive capacity of this tool, advanced (sub) models to 
describe the drug-polymer thermodynamics of mixing, the component’s diffusion and the 
evaporation rate during particle formation should be considered. For example, the Flory-
Huggins (F-H) thermodynamic lattice model does not account for important specific molecular 
interactions, such as hydrogen bonding or ionic interactions that are known for having a 
significant impact on the thermodynamics of mixing and miscibility. The F-H interaction 
parameter (χ) itself, apart from depending on the structure of the molecular components, also 
depends on temperature, component’s composition, and polymer molecular weight. The 
implementation of more advanced models to describe the thermodynamics of mixing [e.g. 
Perturbed-chain statistical associating fluid theory (PS-SAFT)] should also be evaluated. In the 
case of the kinetics of diffusion, a more complex formalism should be implemented to account 
for component’s precipitation, particle’s external shell formation, and the increasing viscosity 
of the solution/solid as this is being dried. The diffusivity of the drug-polymer-solvent system 
is a relevant physical attribute for controlling phase homogeneity. Finally, and in what accounts 
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the evaporation model, an upgrade should be made in order to consider the use of binary solvent 
mixtures and the relative evaporation rate of the solvents with different vapor pressures. By 
combining such complex (sub) models, the computational processing capacity and simulation 
time can significantly increase. The benefit-cost ratio should be evaluated according to the stage 
of process development, as e.g. during the screening phase quick estimates are preferred.  
Regarding the computational tool to guide polymer selection aiming the optimization of 
the in vivo performance of an ASD, this consisted on the development of a statistical model 
using multivariate data analysis tools, and based on ASDs past history. The input variables were 
general molecular descriptors of the drugs, polymers and drug-polymer interactions. These 
simple molecular descriptors can be simply computed based on the molecular structure of the 
components and have been used/identified in the literature as important variables for describing 
e.g. drug’s bioavailability and polymer precipitation inhibition capacity. As output variables, 
typical in vivo pharmacokinetic parameters obtained from the literature were considered. The 
model allowed to identify some interesting correlations between the molecular descriptors of 
the formulation components and performance related output variables. Polymers presenting 
higher hydrogen bonding capacity and higher solubility parameters seem to contribute for 
higher in vivo performances. Moreover, cellulose-based polymers seem to provide better 
precipitation inhibition across different classes of APIs, when compared with other polymer 
families. Correlations obtained between the molecular descriptors of the drug and the output 
variables were more difficult to interpret. Among the drug-polymer interaction variables 
considered, the ones that appeared as having most influence on the model, were similarly 
difficult to interpret. Indeed, the accuracy of the correlations obtained from a statistical model 
is highly dependent on the quality, size and diversity of the input dataset and the complexity of 
the molecular descriptors selected. The fact that the model was developed based on data 
obtained from the literature, adds a certain degree of uncontrolled variability into the system 
that may impact the accuracy of the model developed.  
All in all, and despite the identified limitations of the screening methodologies 
developed, combining the information obtained from both models, it is possible to successfully 
rank the best polymers for amorphous drug stabilization, both in the solid-state and in solution, 
as well as to narrow down the drug load range for an optimal concentration window to be tested 
in the following stages of formulation development, using e.g. miniaturized/bench screening 
methodologies. 
Another objective of this thesis, was the development of alternative preparation methods 
for the production of amorphous solid dispersions and pharmaceutical cocrystals with unique 
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particle properties. A solvent controlled precipitation technology based on microfluidization 
with potential to produce amorphous dispersions in the nano-range was assessed. The feasibility 
study was successfully demonstrated and nano-solid dispersions (both amorphous and 
crystalline) showed to be an advantage for drugs presenting dissolution-rate limited absorption, 
when compared with spray dried dispersions. Additionally, an evaluation focused on the impact 
of certain formulation variables on the final ASD was performed. For example, it was observed 
that level of aggregation between nanoparticles, after the isolation step, was dependent on the 
drug load in formulation, while the feed solids’ concentration in solution influenced the particle 
size of the nanocomposite aggregates. However, there are other formulation and process 
variables that are also known to affect the final product. Thus, as future work, other formulation 
variables such as the type of solvent and anti-solvent and the solvent-anti-solvent ratio, as well 
as process variables such as working pressure and mixing conditions should be evaluated in 
order to get an improved understanding of the factors affecting the final critical quality 
attributes of co-precipitated ASDs. The possibility of extending the co-precipitation process to 
non-ionic or immediate release polymers should also be evaluated, as in this work only enteric 
polymers were evaluated. This would also enable to reduce the constraints of solubility 
compatibility between the drug and the polymer in the same solvent system and the possibility 
to increase the solid’s concentration in the feed solution. 
On the solubility enhancement field, the use of pharmaceutical cocrystals has been 
drawing the attention of formulators in the last years. In this work, spray congealing was 
assessed as an alternative preparation method to produce cocrystals. Spherical cocorystals 
particles with high purity were obtained, and by varying the process conditions, particle 
properties can be fine-tuned in order to facilitate their incorporation into the final-dosage forms. 
Still, the improved understanding of the thermodynamics and kinetics of crystallization from 
the undercooled melt would be beneficial to extend the applicability of the technology for any 
drug compound. For example, there are APIs with a greater tendency to turn amorphous during 
the cooling step. Difficult to crystallize APIs are more easily cocrystallized via solution-based 
methods due to the presence of solvents/moisture that may enhance chemical reactivity and 
promote cocrystallization. The manipulation of the spray congealing process variables in order 
to produce cocrystals from difficult to crystallize molecules should be further explored. 
Similarly, the capacity of achieving polymorphic selectivity from the undercooled melt via 
spray congealing is another potential advantage of the process that should be further evaluated. 
In conclusion, it can be said that all the objectives proposed were successfully achieved, 
namely on contributing for the development of novel screening methodologies and alternative 
Chapter 6 
 
152 
production methods for the production of ASDs and pharmaceutical cocrystals, thus 
demonstrating the Thesis Hypothesis formulated at the beginning of the work. 
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Supplementary Information 
 
A. Chapter 2 
 
 Melting point depression studies to determine χdp at TM of ITZ: 
 
Crystalline ITZ and the polymers were dried in a tray dryer oven at 40ºC under vacuum 
during 24h before use. Physical mixtures of ITZ and each polymer were prepared by co-
grinding via mortar pestle, during 5 min to obtain a fine and homogenous powder. The 
concentration range of the physical mixtures produced varied from 15% to 35% (w/w) of 
polymer (total weight of 0.2 g). Physical mixtures with a concentration of polymer below 15% 
(w/w) were not tested, because it is usually observed a nonlinear relationship between 𝜒 and 
1/T in such range [1, 2]. Triplicates were prepared at each concentration. Powders were sieved 
using a 220 μm mesh screen and solids collected analyzed through conventional differential 
scanning calorimetry (DSC Q1000, TA Instruments, New Castle, Delaware, USA) for ITZ 
melting temperature measurement. The scan rate used was 1ºC/min and the end points of 
melting were obtained from the DSC thermograms [1, 2]. Figure A.1, Figure A.2 and Figure 
A.3 show the melting temperature of ITZ as a function of decreasing ITZ composition for the 
different physical mixtures prepared.  
 
 
 
Figure A.1. Offset of the melting point temperature of ITZ and PVP/VA 64 physical mixture. Bars 
represent the standard deviation (n=3). 
 
Supplementary Information 
155 
 
 
 
Figure A.2. Offset of the melting point temperature of ITZ and HPMCAS-MG physical mixture. Bars 
represent the standard deviation (n=3). 
 
 
 
Figure A.3. Offset of the melting point temperature of ITZ and Eudragit® EPO physical mixture. Bars 
represent the standard deviation (n=3). 
 
 Analytical characterization of ITZ-based cast films:  
 
Cast films were analyzed by modulated differential scanning calorimetry (mDSC), using 
a heating ramp from -10°C to 250°C at a heating rate of 5°C/min using a period of 60s and 
amplitude of 1.592°C. 
The results given by thermal analysis of the cast films are presented in Table A.1. 
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Table A.1. Glass transition temperature values (Tg) and indicators of phase-separation observed after 
analysis of the solvent casted films. 
 
s.d: standard deviation (n=3); N.D: not detected 
a n=2;  
 
 Analytical characterization of ITZ-based spray dried dispersions: 
 
Spray dried amorphous dispersions were also analyzed by mDSC, using a heating ramp 
from -10°C to 250°C at a heating rate of 5°C/min using a period of 60s and amplitude of 0.8°C. 
In addition, PLM was used to infer about the presence of starting crystalline material in the 
freshly prepared powders. The absence of interference colors is indicative of an amorphous 
material. The results given by thermal analysis and microscopy of the spray-dried powders are 
summarized in Table A.2 and Table A.3. 
 
 
 
 
 Key Indicators of Miscibility/Phase-separation 
Composition/ 
% ITZ (w/w) 
Tg ± s.d (°C) Mesophase? Crystallization ± s.d (°C) Melting ± s.d (°C) 
ITZ:HPMCAS-MG     
10 91.0±8.0 No - - 
15 95.1±5.5 No - - 
35 57.9±7.5 No - - 
45 56.0±5.3 No - - 
65 N.D. No - 151.6±1.2 
85 62.1±3.2 No 111.2±8.4 156.2±1.5 
ITZ:PVP/VA 64     
10 N.D. N.D. N.D. N.D. 
15 N.D. N.D. N.D. N.D. 
35 N.D. N.D. N.D. N.D. 
45 82.3±5.4 No - - 
65 69.8±0.5 No 119.1±10.2 152.4±2.0 
85 62.5±0.7 No 120.6±2.4 159.1±0.2 
ITZ:Eudragit® EPO     
10 47.0±1.2 No - - 
15 48.6±2.6 No - - 
35 51.1±1.5/60.7±0.5 Yes - - 
45 54.5±5.8/63.4±5.0 Yes 122.2±3.0a 161.8±5.5 
65 59.2±2.2 Yes 118.5±2.8 160.2±0.8 
85 61.8±0.7 Yes 112.0±3.5 161.1±0.7 
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Table A.2. Glass transition temperature values (Tg), indicators of phase-separation and indication of 
birefringence between crossed polarizers after analytical characterization of the spray-dried powders. 
 
s.d: standard deviation (n=3);  
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 Key Indicators of Miscibility/Phase-separation 
Composition/ 
% ITZ (w/w) 
Tg ± s.d 
(°C) 
Mesophase? 
Crystallization ± s.d 
(°C) 
Melting ± s.d 
(°C) 
Birefringence? 
ITZ:HPMCAS-MG      
No 
No 
45 80.9±1.8 No - - 
65 72.1±0.2 No 123.5±1.4 155.4±0.3 
ITZ:PVP/VA 64      
No 
No 
Yes 
45 87.1±1.7 No - - 
65 75.4±1.1 No - - 
85 64.7±0.7 No 113.4±0.2 163.1±2.8 
ITZ:Eudragit® EPO      
No 
No 
15 52.1±0.7 No - - 
35 52.5±0.7 Yes 117.7±1.1 154.6±0.3 
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Table A.3. Pure ITZ and respective spray-dried powders analyzed through PLM. 
Composition wt.% ITZ Bright Field (10x) Polarized Light Comment 
Pure ITZ 100 - 
 
Crystalline 
ITZ:HPMCAS-MG 45 
 
 
Completely Dark Field 
 
Amorphous 
ITZ:HPMCAS-MG 65 
 
 
Completely Dark Field 
 
Amorphous 
ITZ:PVP/VA 64 45 
 
 
Completely Dark Field 
 
Amorphous 
ITZ:PVP/VA 64 65 
 
 
Completely Dark Field 
 
Amorphous 
ITZ:PVP/VA 64 85 
  
Crystalline 
ITZ:Eudragit® EPO 15 
 
 
Completely Dark Field 
 
Amorphous 
ITZ:Eudragit® EPO 35 
 
 
Completely Dark Field 
 
Amorphous 
 
 
 
Supplementary Information 
159 
B. Chapter 3 
 
 Score plot of the 1st PCA - outliers identification:  
 
 
 
Figure B.1. Score plot of the first PCA performed. 
 
 Contribution Plot – Observation 6: 
 
 
Figure B.2. Contribution plot: API – Tacrolimus. 
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C. Chapter 4 
 
 Thermal analysis of the CBZ-based co-precipitated products (Tests 1 to 6): 
 
Regarding the thermal analysis of the CBZ-based co-precipitated products, Table C.1 
summarizes the results obtained.  
 
Table C.1. Thermal analysis of the different co-precipitated products (Tests 1 to 6): glass transition 
temperature (Tg) and change in heat capacity (ΔCp) during glass transition, temperature (T) and enthalpy 
(ΔH) of other endothermic events detected. 
Exp. 
Number 
Glass Transition Other Endo. Peaks 
Tg (°C) ΔCp (J/g °C) T (°C) ΔH (J/g) 
1 101,73 0,11 144,98 25,43 
2 N.D. N.D. 
167,31 69,96 
187,59 132,80 
3 N.D. N.D. 
148,60 38,31 
187,39 53,99 
4 166,80 0,20 198,20 0,54 
5 136,44 0,21 
150,45 1,25 
164,10 60,03 
6 N.D. N.D. 
139,76 24,20 
182,02 50,49 
          
     N.D. – not detected. 
 
Starting with the 20% (w/w) drug load formulations, both CBZ:HPMCAS and 
CBZ:Eudragit® L100 systems presented a single Tg value which was consistent with the 
averaged mixed Tg obtained using the Gordon-Taylor equation ( ~106 and ~167 ºC for Test 1 
and 4, respectively). These results suggested that amorphous dispersions or amorphous 
solutions were formed. No signs of phase-separation or drug recrystallization were detected 
during heating, but different endothermic events were observed. For example, in the thermal 
profile of 20% CBZ: HPMCAS, an endothermic peak at 145ºC was observed. The existence of 
an endothermic event without the observation of a prior exothermic recrystallization may 
indicate the presence of starting crystalline material in the sample.  
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For the 20% CBZ:Eudragit® L100 an endothermic peak around 190ºC was also detected, 
but this was most probably related with the cyclic anhydride formation between Eudragit® L100 
polymer chains [1]. 
Moving forward with the thermal analysis of the 40% CBZ:HPMCAS and 
CBZ:Eudragit® L100 systems, while for the former any glass transition events were detected, 
the latter presented a Tg value at 136,44°C, which by comparison with the value obtained by 
the Gordon-Taylor equation (~141ºC), it may correspond to a mixed Tg. 
The endothermic peaks that appeared in both thermal profiles and within the 
temperature ranges ~150-167ºC and ~164 to 188ºC were coincident with two endothermic 
peaks characteristic of pure CBZ. Pure CBZ first presents a polymorphic transformation at 
150ºC, followed by the melting of the new phase formed at 186ºC [2]. Temperature fluctuations 
are normal to happen due to the presence of the polymers. These results were indicative that 
both Tests 2 and 5 resulted in crystalline suspensions of CBZ within the respective polymers, 
still with the possibility of Test 5 to present a certain percentage of amorphous CBZ.  
When the drug load of both CBZ-based formulations was increased to up 60%, no glass 
transition events were observed. Moreover, the endothermic events associated with the phase 
transformation and/or melting of crystalline CBZ were still presented in the respective non-
reversible heat flow curves. Similarly to the results obtained for Test 2 and 5, Test 3 and 6 also 
corresponded to crystalline suspensions. 
 
 Spray-dried amorphous dispersion, equivalent to Test 4: 
 
Figure C.1 shows the XRPD results obtained for the co-precipitated product and 
respective spray-dried formulation. 
As can be observed, both diffractograms were equivalent. The spray-dried formulation 
also exhibited the typical halo characteristic of the amorphous state, and no signs of crystalline 
material were detected. In terms of drug molecular distribution within the polymeric matrix, the 
thermal analysis of the spray-dried product only revealed a single glass transition at 160ºC, 
which also agreed with the thermal behavior of its co-precipitated counterpart. These results 
indicated that the 20% CBZ:Eudragit® L100 spray-dried product was also an amorphous solid 
solution.  
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Figure C.1. Powder diffractograms correspondent to the 20% CBZ:Eudragit® L100 co-precipitated 
product (Test 4) and the 20% CBZ:Eudragit® L100 spray-dried product, at C_feed 8% (w/w). 
 
 NanoCrystalline solid dispersion by solvent controlled precipitation: 
 
Figure C.2 shows the XRPD result for the 60% CBZ:Eudragit® L100 at 8% C_feed, 
produced by co-precipitation. The XRPD correspondent to Test 6 (60% CBZ:Eudragit® L100, 
at 2% C_feed) is also represented for comparison purposes. 
As can be observed, the XRPD diffractogram of the NanoCrystalline formulation was 
equivalent to Test 6. The characteristic peaks of crystalline CBZ were detected, indicating the 
formation of a crystalline solid dispersion. 
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Figure C.2. Powder diffractograms correspondent to the 60% CBZ:Eudragit® L100 at 2% C_feed 
(Test 6) and the 60% CBZ:Eudragit® L100 at 8% C_feed (NanoCrystalline). 
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D. Chapter 5 
 
 mDSC thermal analysis and XRPD profile of pure glutaric acid (GLU): 
 
 
Figure D.1. Total heat flow thermogram correspondent to pure GLU. The onset temperatures and 
enthalpy values associated to the endothermic events are also indicated. 
 
 
 
Figure D.2. XRPD diffractogram correspondent to pure GLU. 
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 Production of standard 1:1 CAF:GU cocrystal using cooling recrystallization: 
 
The cooling crystallization method employed to produce form II of the 1:1 CAF:GLU 
cocrystal was based on the work of Yu et al. [1]. According to the phase diagram of the CAF-
GLU-acetonitrile (ACN) system reported and the crystallization method described, the critical 
step was to find the composition of the starting solution correspondent to “Run 1”, which led 
to the formation of form II of the cocrystal.  
18.9 g of pure GLU (purity 99%, Sigma-Aldrich Quimica SA) and 12.6 g of pure CAF 
(β-caffeine anhydrous, purity 99%, Sigma-Aldrich Quimica SA) were dissolved in 250 mL of 
ACN, at 40ºC. A 250 mL jacketed glass reactor with mechanical stirring at 410 rpm was used. 
The temperature in the reactor was controlled using a Huber thermostat. A silicone-based heat 
transfer fluid (SYLTHERM XLT, Dow Chemical Co.) circulated inside the jacket of the 
reactor. Temperature was cooled down from 40ºC to 34ºC quickly. No cocrystal seeds were 
added. Precipitation onset was observed. The suspension was cooled further down to 10 ºC at 
0.1 ºC/min. The solid was isolated by filtration.  
Figure D.3 shows the XRPD diffractogram obtained for the cocrystal obtained from 
cooling crystallization together with the diffractogram of the polymorphic form II of the 1:1 
CAF:GLU cocrystal obtained from the Cambridge Software Database (CSD). 
 
 
 
Figure D.3. XRPD diffractograms correspondent to the 1:1 CAF:GLU system: a - cocrystal data 
obtained from CSD, code EXUQUJ (form II), b - cocrystal obtained by cooling crystallization. 
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Figure D.4 shows the SEM images obtained for the cocrystal. Plate-shaped individual 
cocrystals were observed. 
 
 
 
Figure D.4. Micrographs correspondent to the 1:1 CAF:GLU cocrystal produced by cooling 
crystallization. 
 
 Development of a XRPD limit test for the evaluation of cocrystals purity: 
 
The development of the XRPD limit test as regards to the CAF “impurity” involved two 
different stages: first, a peak selectivity and preferred orientation analysis was conducted, 
followed by a second stage that involved the optimization of the XRPD method, preparation of 
physical mixture and peak area analysis. 
 
1. Peak selectivity and preferred orientation analysis: 
 
Peak selectivity consisted of identifying one or more peaks, preferably with high 
intensity, in the diffractogram of pure CAF that were absent in the diffractogram of the standard 
cocrystal, and pure GLU. After this identification stage, an analysis of preferred orientation of 
the samples was conducted. Pure CAF was gently grinded with mortar and pestle one and two 
times, during approximately 1 min. After grinding, if the samples reveal preferred orientations, 
it means that the distribution of the crystallites in the holder is non-random, and the area and 
the intensity of the peaks will change [2]. The peak at 11.8 2θ in the diffractogram of pure CAF 
was the one selected for being selective against the standard cocrystal and for not revealing 
preferred orientations, as can be seen in Figure D.5. 
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Figure D.5. XRPD diffractograms correspondent to pure CAF: a - as is, b – grinded once, c– grinded 
twice. The arrows indicate the high intensity 11.8 2θ peak. 
 
2. Optimization of the XRPD method, preparation of the physical mixture and peak 
area analysis: 
 
The optimization of the XRPD method involved the fine tune of XRPD parameters in 
order to improve the detection of the peaks in the 2θ range of interest, in this case around the 
position of the CAF peak selected. The samples were measured over a 2θ interval from 10 to 
14º with a step size of 0.017º and step time of 1500 s. 
A physical mixture of 1:1 CAF:GLU standard cocrystal (produced using cooling 
crystallization) and 5 wt.% CAF was prepared. The physical mixture was analyzed using the 
optimized XRPD method, and the area of the peak at 11.8 2θ was used as the reference. The 
reflection integration interval considered was from 11.7 to 12.1 2θ.  
Figure D.6 shows the XRPD diffractograms of the pure standard cocrystal and 5 wt.% 
CAF:standard cocrystal physical mixture. 
In order to estimate cocrystal purity of the spray-congealed samples, the powders 
correspondent to Test 1 to 5 were also analyzed using the optimized XRPD method, and the 
peaks integrated likewise. Figure D.7  shows the XRPD diffractograms at slow scan of Tests 1 
to 5. 
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Figure D.6. XRPD diffractograms, at slow scan, correspondent to a - 1:1 CAF:GLU standard cocrystal 
produced by cooling crystallization and b - 5 wt.% CAF:standard cocrystal physical mixture. The dashed 
lines represent the integration interval (i.e. 11.7 to 12.1 2θ). 
 
Figure D.7. XRPD diffractograms, at slow scan, correspondent to the spray-congealed 1:1 CAF:GLU 
cocrystals: #1 to #5 – different tests performed according to the experimental design. The dashed lines 
represent the integration interval (i.e. 11.7 to 12.1 2θ). 
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